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The inflammatory bowel diseases (IBD) ulcerative colitis (UC) and Crohn’s 
disease (CD) are chronic relapsing inflammatory disorders which have a rising 
incidence and cause significant morbidity. There are currently several 
treatment options with many more in the drug pipeline, but there are a lack of 
accurate biomarkers for decisions on treatment choice, assessment of disease 
activity and prognostication. There is a growing interest and desire for 
personalised or ‘precision’ medicine in IBD where novel biomarkers may help 
individualise IBD care in terms of diagnosis, choice of therapy, monitoring of 
response and detection of relapse. One class of functionally active biomarkers 
which have yet to be thoroughly investigated in IBD is damage-associated 
molecular patterns (DAMPs) including mitochondrial DNA (mtDNA). It has 
been recently shown that gut mitochondrial dysfunction can result in loss of 
epithelial barrier function and the development of colitis. Mitochondrial DAMPs 
have recently been described as elevated in several inflammatory diseases.  
 
Hypothesis  
The primary hypothesis of this thesis is that circulating levels of mtDNA is 
elevated in IBD. Secondary hypotheses are: (a) levels of other mitochondrial 
DAMPs are elevated in IBD, (b) circulating mtDNA can be used as a novel 






Plasma and serum were collected prospectively from recruited IBD patients 
and non-IBD controls. Faeces and colonic tissue were collected from a subset 
of these patients. mtDNA in serum, plasma and faeces was measured using 
qPCR (amplifying COXIII/ND2 genes). Mass spectrometry was used to detect 
mitochondrial formylated peptides in the plasma of a subset of patients. IBD 
tissue was assessed for (a) mitochondrial damage using transmission electron 
microscopy (TEM) and (b) TLR9 expression, the target for mtDNA. 
 
Results 
97 patients with IBD (67 UC and 30 CD), and 40 non-IBD controls were 
recruited. Plasma mtDNA levels were increased in UC and CD (both p<0.0001) 
compared to non-IBD controls; with significant correlations with blood (CRP, 
albumin, white cell count), clinical and endoscopic markers of severity; and 
disease activity. In active UC, we detected significantly higher circulating 
mitochondrial formylated peptides and faecal mtDNA levels (vs. non-IBD 
controls [p<0.01 and <0.0001 respectively]) with demonstrable TEM evidence 
of intestinal mucosal mitochondrial damage. In active IBD, TLR9+ lamina 
propria inflammatory cells were significantly higher in UC/CD compared to 
controls (both p<0.05). 
 
Conclusions 
Taken together, the findings suggest mtDNA is released during active 






The mitochondria (‘batteries’ for the living cells) provide energy and regulate 
many key biological processes that maintain cellular health and function. The 
mitochondria within the lining of the large bowel are particularly exposed to a 
number of detrimental factors, which can damage the mitochondria. In health, 
damaged mitochondria (‘faulty batteries’) are effectively re-cycled or packaged 
away for safe disposal.  
 
In the inflammatory bowel diseases (IBD) Crohn’s disease and ulcerative 
colitis, it has been shown that these protective processes do not work properly 
or are overwhelmed. The unhealthy colon therefore leaks damaged 
mitochondria and their products (including their genetic ‘code’: DNA) into the 
internal environment of the cells and importantly into the blood circulation. Of 
interest, the mitochondria, which reside in all cells, are evolutionarily derived 
from helpful bacteria maintaining a mutually beneficial relationship with the 
host cells. The mitochondria share many similar properties with bacteria – 
including their ability to activate the inflammatory and immune system. It has 
already been shown that in many human inflammatory diseases, levels of 
mitochondrial DNA and other products have been found to be elevated in the 
blood circulation. 
 
In this thesis, a well-characterised patient population was recruited and 
compared to healthy people. Mitochondrial product levels were found to be 
xii 
 
significantly higher in patients with IBD compared to healthy people, and higher 
levels were found within the IBD cohort for those with active inflammation. This 
information may be useful as a ‘biomarker’ to assess for disease activity, 
predict how patients will do, or how they may respond to therapy.  
 
High levels of mitochondrial products were also found in the faeces, and cells 
expressing the receptor that is activated by these products were also found to 
be higher in the lining of the gut. These findings suggest that the inflamed gut 
may be the primary source of these mitochondrial products.  
 
Importantly, this data adds to the growing evidence suggesting blockade of the 
inflammatory effects arising from damaged mitochondria within the lining of the 
gut may benefit some patients with IBD. This requires further investigation.  
 
In summary, this work has identified a highly novel, specific and measurable 
factor in inflammatory bowel disease. This sets the platform for further 
research into this area to investigate how mitochondrial DNA may be used as 
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1.1 Inflammatory Bowel Disease 
 
1.1.1 Background to Crohn’s disease & ulcerative 
colitis 
 
The inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn’s 
disease (CD) are chronic, relapsing and remitting diseases of the 
gastrointestinal tract. The incidence and prevalence of IBD is increasing, and 
will affect an estimated 20 million people worldwide by 2025 (Molodecky et al., 
2012; Kaplan, 2015). Both conditions are incurable, often diagnosed at a 
young age and are associated with significant socio-economic costs and 
morbidity (Baumgart and Sandborn, 2012; Ordás et al., 2012). IBD can 
severely affect social functioning and cause significant disruption to 
employment, education, relationships and family life. 
 
There are clear differences between UC and CD (Table 1.1). However, failure 
to resolve mucosal inflammation (which commonly re-activates upon 
withdrawal of anti-inflammatory treatments such as glucocorticoids) is a 
notable shared clinical feature.  UC invariably affects the rectum and extends 
proximally to a variable distance, with characteristically confluent inflammation 
limited to the mucosal layer of the colon. In contrast, CD can affect any part of 
the gastrointestinal tract and inflammation is characteristically non-continuous 
and transmural.  
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Due to its transmural nature, CD often requires surgery due to fistulas 
(abnormal connection between two epithelial surfaces) or strictures (narrowing 
of the intestine that may cause obstruction). Perianal disease (inflammation 
around the anus) is a particularly disabling manifestation of CD and occurs in 
up to a third of patients (Schwartz, Loftus and Tremaine, 2002). 
 
 Crohn’s Disease Ulcerative Colitis 
Anatomical 
Distribution 
May affect anywhere from 
mouth to anus; commonly 
affects terminal ileum and 
colon 
Limited to the large intestine; 
extends from rectum proximally 
to a variable distance 
Type of gut 
inflammation 
Non-continuous, patchy 
inflammation with skip lesions 
Continuous, superficial  
Histology Deep, transmural, focal 
inflammatory infiltrate. 
Markedly focal cryptitis, non-
necrotizing granulomas, 
epithelioid granulomas.  
Superficial (affecting the 
mucosa and submucosa) 
inflammatory infiltrate with loss 
of crypt architecture, basal 




Diarrhoea, abdominal pain, 
fatigue, weight loss 
Rectal bleeding, tenesmus, 




20.2 per 100,000 person-
years 
19.2 per 100,000 person-years 
Peak incidence Between 20-40 years Between 20-40 years 
Environmental 
associations 
Smoking, western diet, stress, 
appendectomy 
Milder disease with smoking, 
lower risk with appendectomy 
Genetics Themes involving defective 
intracellular bacterial killing 
and innate immunity  
and de-regulated 
adaptive immune responses. 
Themes involving epithelial 
integrity, innate immune 
function, immune regulatory 
function, and cellular 
homeostasis in response to 
endoplasmic reticulum stress. 
Table 1.1: Features of Crohn’s disease and ulcerative colitis 
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1.1.2 Pathogenesis of IBD 
 
The last decade has seen remarkable progress in understanding the 
pathogenesis of IBD. Although the aetiology is complex, the most widely 
accepted hypothesis purports IBD as an immune mediated condition in 
genetically susceptible individuals, where disease onset is triggered by 
environmental factors that perturb the mucosal barrier, alter the healthy 
balance of the gut microbiota, and abnormally stimulate gut immune responses 
(Boyapati, Satsangi and Ho, 2015; Colombel and Mahadevan, 2017). IBD is 
thought to arise from a complex and incompletely understood interplay 
between these factors (Figure 1.1).  Advances in these fields have catalysed 
a decade of spectacular progress in our understanding of IBD.  
 
The importance of genetic predisposition is clear: first degree relatives of a 
patient with CD or UC have a 10-fold increased risk of developing the same 
condition, whilst there is also a significant but less pronounced increased risk 
of developing the other of the two diseases (Orholm et al., 1991). Meta-
analysis now involving 50,000 IBD individuals implicates more than 200 
susceptibility loci (Jostins et al., 2012; J. Z. Liu et al., 2015) . This information 
provided new hitherto unknown insights into disease mechanisms and 
biological pathways. An aberrant immune response is a key feature of IBD; 
genetic studies have most strongly and consistently implicated themes 
involving epithelial integrity, innate immune function, endoplasmic reticulum 
(ER) stress, defective intracellular bacterial killing and de-regulated adaptive 
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immune responses (Boyapati, Satsangi and Ho, 2015; G-T. Ho, Boyapati and 
Satsangi, 2015).  
 
Figure 1.1: Complex interplay of various factors in IBD pathogenesis. IBD 
pathogenesis involves a complex interplay over time between genetic, 
epigenetic, immunological, and microbiological mechanisms affected by 
exposure to triggering factors. Individual patients with IBD have a unique 
pathogenic signature comprised of different contributions from each of these 
factors. Stratification of patients based on these signatures may lead to more 
focused, personalized, and successful therapies. Therapeutic translation is 
grounded on a greater understanding of these genetic and molecular 
pathways. Furthermore, correcting and avoiding triggering factors related to 
the exposome are areas of considerable interest. ‘Smart’ clinical trials with 
simultaneous mechanistic studies may allow improved understanding even in 
the case of therapeutic failures (Boyapati, Satsangi and Ho, 2015). 
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Beyond genetics, epigenetics is emerging as a further tier of information that 
could complement genome wide association studies (GWAS) (Ventham et al., 
2013). Several epigenome wide studies have been published in IBD and other 
diseases (Nimmo et al., 2012; Adams et al., 2014; Dick et al., 2014; Yuan et 
al., 2014; McDermott et al., 2016). These studies identify epigenetic 
mechanisms as a potential interface between genetics and disease. The 
microbiome or ‘other genome’ – the collective genome of the gut microbiota –  
represents a further giant dimension in big data in IBD and other complex 
multifactorial conditions such as diabetes and obesity (Jostins et al., 2012; Qin 
et al., 2012; Le Chatelier et al., 2013; Zeevi et al., 2015) enabled by advances 
in culture independent sequencing technologies.  
 
Although some environmental factors have been established (e.gs smoking, 
stress and appendectomy), it is likely that many more environmental ‘triggers’ 
are relevant but unidentified (e.g. diet). These are particularly difficult research 
areas and most available evidence relies on case-control studies which suffer 
from important limitations such as recall bias. There are current efforts 
recruiting into large prospective cohorts investigating how the environment 
may contribute to the onset of IBD (e.g. http://www.gemproject.ca) and trigger 
flares in patients who have IBD (e.g. http://www.predicct.co.uk). 
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1.1.3 Clinical overview of IBD 
 
1.1.3.1 Diagnosis 
The diagnosis of IBD can be difficult, as there is currently no accurate, quick 
and non-invasive diagnostic test. Furthermore, several other conditions are 
symptomatically similar including gastrointestinal infection and irritable bowel 
syndrome (IBS) (Table 1.2). Some patients are symptomatic for many years 
before a diagnosis is made (Pimentel et al., 2000). Diagnosis usually 
encompasses clinical, laboratory, radiological, endoscopic and histological 
findings to establish the disease type, extent and severity. 
 
Differential diagnosis Features 
Bacterial dysentery Shigellosis; salmonellosis; Campylobacter infection 
Amoebic dysentery Watery bloody diarrhoea, recent travel to endemic 
area 
Cytomegalovirus Immunocompromised patients (e.g. HIV) 
Clostridium difficile Co-exists with UC in ∼5–10% of refractory cases 
Ischaemic colitis ‘Watershed’ areas (e.g. deep ulceration at distal 




Abdominal pain / cramping, bloating and alternating 
constipation / diarrhoea in the absence of 
inflammation on investigation 
Table 1.2: Differential diagnosis of IBD 
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1.1.3.2 Clinical features 
IBD is a relapsing and remitting condition that follows an unpredictable pattern. 
Although broadly classified into CD and UC, the disease is highly individual in 
terms of symptomatology, prognosis and response to treatment. Clinical 
features may include diarrhoea, colicky abdominal pain, rectal bleeding, 
urgency and systemic manifestations such as anorexia, malaise, weight loss 
and fever. Patients may also have extra-intestinal manifestations (EIM) of IBD 
such as axial or peripheral arthropathy, erythema nodosum, pyoderma 
gangrenosum, episcleritis, uveitis, primary sclerosing cholangitis and Sweet’s 
syndrome (Vavricka et al., 2015). Although specific therapies are sometimes 
required, treatment of the underlying intestinal inflammation often leads to 
resolution of EIMs. 
 
1.1.3.3 Treatment 
Disease flares require rapid diagnosis and institution of active management to 
minimise the impact of relapse on the patients’ wellbeing and to avoid 
hospitalisation. Complete mucosal healing, the strongest predictive factor for 
long lasting remission, is difficult to achieve. A summary of the medical 
therapies used in IBD and indications for surgery are provided in Table 1.3. 
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 Crohn’s Disease Ulcerative colitis 
Medical therapy   
Induction of      
remission 
Corticosteroids  5-aminosalicylates (topical 
and/or oral) 
 Anti-TNF therapy Corticosteroids (topical and/or 
oral) 
 Anti-integrin therapy 
(vedolizumab) 
Ciclosporin (acute severe UC) 
 Anti-IL-12/23 therapy 
(ustekinumab) 
Anti-TNF therapy 
  Anti-integrin therapy 
(vedolizumab) 







 Methotrexate Azathioprine/6-mercaptopurine 
 Anti-TNF therapy Methotrexate (evidence less 
strong) 
 Anti-integrin therapy 
(vedolizumab) 
Anti-TNF therapy 








Failed medical therapy 
(commonest) 
Failed medical therapy 
(commonest)  
 Perforation Massive haemorrhage 
 Corticosteroid dependency Toxic dilatation 
  Perforation 
  Corticosteroid dependency 
  Malignancy/dysplasia 
Table 1.3: Summary of medical therapy and surgical indications for IBD 
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1.1.3.4 Clinical assessment of disease severity 
There are many IBD clinical disease activity assessment tools used in 
research and clinical practice. For UC, the main clinical indices are the Simple 
Clinical Colitis Activity Index (SCCAI), the Partial Mayo Index and the Truelove 
and Witts’ Severity Index (for acute severe UC). For CD, the main clinical 
indices are the Crohn’s Disease Activity Index (CDAI), Harvey-Bradshaw Index 
(HBI) and the Perianal Crohn’s Disease Activity Index (PDAI).  
 
A summary of the main strengths and weaknesses of the respective scoring 
systems for UC (Table 1.4) and CD (Table 1.5) is provided.  
 
Ulcerative colitis    
Index name Strengths Weaknesses Reference 
SCCAI - Can be completed by 
patient 
- Reliable, valid, 
responsive and 
feasible 




- Widely used 
- Discriminates 
remission from active 
disease 












- Objective criteria for 
ASUC 
- Provides prognostic 
information 
- Only for ASUC (Truelove, 1955) 
Table 1.4: Disease activity assessment indices used in clinical practice for UC 
(adapted from Walsh et al. 2016) 
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Crohn’s Disease    
Index name Strengths Weaknesses Reference 
CDAI - Widely used  - Complex calculation including 
a 7-day diary 
- High variability 
- Low contribution to total 
score for perianal disease 
(Best et 
al., 1976) 
HBI - Simpler, less 
cumbersome 
- Correlates well 
with CDAI 
- Low contribution to total 





PDAI - Easy to use - Only for perianal disease 
- Fistula severity not included 
(Irvine, 
1995) 
Table 1.5: Disease activity assessment indices used in clinical practice for CD 
(adapted from Walsh et al. 2016) 
 
The scoring for indices used in this thesis are provided in Appendix A (HBI for 
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1.1.3.5 Severe disease 
In CD, most patients will encounter a disabling disease course and 
approximately half will require surgery within 10 years of diagnosis (Beaugerie 
et al., 2006; Peyrin-Biroulet et al., 2010). In UC, 15% will develop acute severe 
UC (ASUC) where there is significant colonic epithelial damage and treatment 
is with intravenous steroids (Gwo-Tzer Ho, Boyapati and Satsangi, 2015). 
ASUC is defined by the modified Truelove & Witts’ criteria (Appendix A). For 
patients with ASUC who do not respond to intravenous steroids, rescue 
therapy with either infliximab or ciclosporin is standard of care but the failure 
rate of medical therapy is high (~30% requiring surgical removal of the colon) 
(Turner et al., 2007) (Figure 1.2).  
 
 
Figure 1.2: (L to R) Endoscopic appearance of mild, moderate and severe UC. 
Far right image is colonic resection specimen of severe UC. 
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1.1.4 IBD biomarkers in current practice 
 
There are a handful of biomarkers that have established roles in current clinical 
practice: C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), 
albumin, faecal calprotectin, anti-TNF antibodies and thiopurine 
methyltransferase (TPMT) activity measurements. In addition, general blood 
parameters such as white cell count (WCC) and platelet count may provide 
information about general inflammation.  
 
CRP 
Blood based disease activity assessment in IBD has been dominated by CRP 
which is induced by IL-6, TNFα and IL-1β. CRP is a hepatocyte derived acute 
phase reactant protein and detected in the blood. CRP has a short half-life, 
and serum levels of CRP correlate with disease activity in CD (Vermeire, Van 
Assche and Rutgeerts, 2004). However, CRP is not specific to gut 
inflammation, and a subgroup of IBD patients will not mount a CRP response 
despite having significant inflammation (Boirivant et al., 1988).  
 
Erythrocyte sedimentation rate 
ESR measures the vertical distance that erythrocytes fall in one hour. A 
number of factors influence ESR including erythrocyte characteristics (size, 
shape, number) and patient factors (age, gender, pregnancy, presence of 
blood dyscrasias). Elevated levels are included as one of the criteria in the 
Truelove & Witts’ criteria for ASUC. In clinical practice, CRP is used more 
frequently as it is a better indicator early in the acute phase response. 
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Albumin 
Albumin is a negative acute phase reactant protein and low albumin levels is 
associated with inflammation. However, hypoalbuminaemia is also associated 
with non-inflammatory disease states such as malnutrition and malabsorption.  
 
Faecal calprotectin 
Faecal calprotectin is a screening tool for gut inflammation (van Rheenen, van 
de Vijver and Fidler, 2010) and to measure disease activity in IBD (Lin et al., 
2014). More recently, the potential to use faecal calprotectin in innovative ways 
has been explored including as a predictive tool e.g. to identify disease 
recurrence in post-operative CD (Wright et al., 2014) and as a secondary end-
point in IBD clinical trials.  
 
Anti-TNF antibodies 
Detection of anti-TNF antibodies allows for expedient switching to an 
alternative drug (Nanda, Cheifetz and Moss, 2013) and avoids conventional 
dose escalation which is often futile, expensive and potentially hazardous 
(Steenholdt et al., 2014). A randomised controlled trial (RCT) in the setting of 
secondary loss of response to infliximab compared conventional dose 
intensification with an algorithm based approach based on serum infliximab 
levels and antibodies (Steenholdt et al., 2014). Here, management dictated by 
drug levels and antibodies was found to be cost effective with no reduction in 
clinical efficacy. The current case of anti-TNF however, is instructive and 
highlights the difficulties ahead in developing a biomarker based decision-
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making model. Although therapeutic drug monitoring and antibody testing has 
been an important recent advance, there is currently no clinically useful 
predictor of anti-TNF response prior to initiation.  
 
Thiopurine methyltransferase (TPMT) 
TPMT measurement can screen for those who are likely to experience life 
threatening leukopenia from thiopurines (Lennard, 2002) and those who would 
benefit from a reduced initial dose. Although the routine use of TPMT 
measurement has been questioned based on cost-effectiveness, this test has 
been incorporated into standard clinical practice.  
 
Although of some clinical benefit, these current examples demonstrate the lack 
of accurate biomarkers in clinical practice for help in precise diagnosis, 
prognostication, monitoring of disease activity and monitoring of response to 
therapies for individuals with IBD.  
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1.1.5 Towards personalised biomarkers in IBD 
 
Given the highly individual nature of IBD, clinicians long for a future where a 
newly diagnosed patient can have his/her genetic, microbiome and immune 
profile measured at the outset; then matched to the most appropriate biologic 
or immunosuppressive treatment based on the likelihood of response/adverse 
effects. IBD individuals will be given information of what ‘exposome’ to modify 
and report on their disease activity using the set of optimal biomarkers. At all 
levels, one can expect a continuous feedback of new data from respective 
patients, which will further improve the dataset for biomarker discovery in this 
context. This future may seem farfetched, and many challenges remain, but 
multiple lines of evidence show progress towards ‘precision medicine’ in IBD 
(Boyapati, Kalla, et al., 2016). Key to progress in this area is the ability of 
researchers to identify novel biomarkers to help personalise therapy. 
 
DAMPs represent underexplored but potentially important pathogenic stimuli 
that may contribute to maintaining the state of abnormal mucosal inflammation 
in IBD (Boyapati, Rossi, et al., 2016). Although relatively underexplored in IBD, 
it is salutary to note that the most useful clinical biomarker used in IBD currently 
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1.2 Damage-associated molecular patterns 
 
1.2.1 Recognising danger and promoting 
inflammation 
 
The inflammatory response is essential to host defence, promoting microbial 
containment and clearance. This sentinel function of the innate immune 
system rapidly and precisely distinguishes between ‘self’ and ‘non-self’ by 
recognizing microbial invariant molecular patterns (pattern associated 
molecular patterns, PAMPs) through a system of germline encoded pattern 
recognition receptors (PRRs) (Akira, Uematsu and Takeuchi, 2006). PRR 
activation leads to intracellular signalling cascades, transcriptional 
upregulation of inflammatory genes, production of proinflammatory cytokines, 
chemokines and type I interferons (IFN), and recruitment of inflammatory cells 
such as neutrophils.  
 
Similar strong immune responses are seen in the absence of invasive 
pathogens (‘sterile inflammation’) such as in autoimmunity, trauma and 
ischemia. This phenomenon is explained by Matzinger’s ‘danger hypothesis’ 
in which immune responses are geared towards recognizing danger whether 
these signals arise endogenously or exogenously  (Matzinger, 1994) (Figure 
1.3). Endogenous damage-associated molecular patterns (DAMPs) are 
‘danger signals’ or ‘alarmins’ released during host cellular stress or injury. 
Along with exogenous PAMPs of microbial origins, DAMPs can initiate and 
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perpetuate an inflammatory response typically via germline encoded pattern 
recognition receptors (PRR). 
 
1.2.2 PAMPs, DAMPs and PRRs 
 
In this context, PRRs are activated by both non-self (PAMPs) as well as 
endogenous molecules released at times of danger to the host (DAMPs) 
(Matzinger, 2002). The major classes of PRRs are cell surface or endosomal 
toll-like receptors (TLRs), cytoplasmic nucleotide binding and oligomerisation 
domain (NOD) like receptors (NLRs) and inflammasomes, C-type leptin 
receptors, RIG-1 like receptors and absence in melanoma 2 (AIM2)-like 
receptors (Takeuchi and Akira, 2010)(Blander and Sander, 2012). In addition, 
the more DAMP-specific receptor for advanced glycation end-products 
(RAGE) is also a categorized as a PRR (Xie et al., 2008).  
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Figure 1.3: Danger recognition by the innate immune system. PRRs such as 
TLR, NLR, and RAGE sense danger associated with infection via recognition 
of evolutionarily conserved PAMPs on pathogens or sterile injury via 
recognition of DAMPs. Activation of cell surface or intracellular PRRs leads to 
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1.2.3 DAMP cellular mechanisms 
 
DAMPs comprise of structurally diverse non-pathogen derived molecules that 
share a number of characteristics: (1) they bind to and activate PRRs; (2) are 
passively leaked after plasma membrane rupture following various forms of 
cell death including necrosis, necroptosis and secondary necrosis; (3) may be 
actively secreted by stressed cells via non-classical pathways independent of 
the ER/Golgi apparatus; and (4) may change from a physiological to a 
proinflammatory function when released into the extracellular milieu (Rock et 
al., 2008) (Figure 1.4).  
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Figure 1.4: DAMP cellular mechanisms. Cellular stress may also lead to 
damaged cellular components such as reactive oxygen species (ROS) 
generating mitochondria. Increased ROS production and oxidative stress may 
have multiple effects including increased translocation and active release of 
DAMPs and further cellular stress, leading to a vicious cycle. Defects in 
homeostatic pathways such as autophagy leads to escape of DAMPs such as 
mtDNA. Intranuclear DAMPs require translocation into the cytosol before 
active release. Active release (‘‘secretion’’) occurs through nonclassical 
pathways and cellular membrane rupture after necrosis or necroptosis results 
in passive release of DAMPs. ER stress contributes to the functional activity of 
DAMPs e.g. through increased translocation and contributing to its role as an 
adjuvant; DAMPs can directly lead to increased ER stress. (Boyapati, Rossi, 
et al., 2016) 
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Extracellular DAMPs may activate cell surface PRRs or intracellular PRRs 
after phagocytosis, endocytosis or other mechanisms of internalisation 
(Schaefer, 2014). DAMPs may originate from any compartment of stressed 
cells and include intracellular proteins, extracellular matrix (ECM) derived 
proteins and purinergic molecules. The list of recognized DAMPs is growing 
rapidly—a list of putative DAMPs and their receptors is provided in Table 1.6. 
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DAMP Receptor 
HMGB1 TLR2, TLR4, TLR9, RAGE  
S100 proteins TLR4, RAGE, surface heparin sulfate 
proteoglycan and carboxylated N-glycans 
IL-1α IL-1R 
IL-33 ST2 (IL1RL1) 
Heat Shock Proteins (HSPs) TLR2, TLR4, CD91, CD40, CD14 
ATP P2Y, P2X, NLRP3 
Lactoferrin TLR4  
Mitochondrial DAMPs mtDNA: TLR9 
TFAM: RAGE and TLR9 
N-formyl peptides: formyl peptide receptor 1 
(FPR1) and FPR2 
NLRP3 inflammasome 
Histones TLR2, TLR4, NLRP3, TLR9 
Galectins TLR2 
Uric Acid TLR2, TLR4, NLRP3, CD14 
Thioredoxin Unknown 
Cathelicidins FPR2 
Adenosine A1, A2A, A2B, A3 
Defensins CCR6 and TLR4, TLR1, TLR2 
Calreticulin CD91 
RNA TLR3 
Genomic DNA TLR9, AIM2, NLRP3  
Small nuclear RNA TLR7, TLR8 
SAP130 CLEC4E 
Extra cellular matrix (ECM) components 
Hyaluronan TLR2 and TLR4 
Biglycan TLR2, TLR4, P2X4, P2X7, NLRP3 
Versican TLR2, TLR6, CD14 
Heparan sulfate TLR4 
Fibronectin (extra domain A) TLR2, TLR4 
Fibrinogen TLR4 
Tenascin C TLR4 
Other ECM components e.g. 
laminin, elastin and collagen 
derived peptides 
Integrins 
Table 1.6: Putative list of DAMPs & receptors (Boyapati, Rossi, et al., 2016) 
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Under physiological conditions, DAMPs reside intracellularly or are 
sequestered in the ECM and are thus hidden from recognition by innate 
immune cells bearing PRRs. In response to perceived danger such as tissue 
damage, DAMPs are liberated extracellularly serving to signal danger to the 
host, promoting inflammation and repair processes that are initially beneficial 
and protective (Schaefer, 2014). However, in the setting of significant and 
persistent DAMP release, ongoing PRR activation with resultant cytokine and 
chemokine production may result in deleterious ‘collateral damage’ and 
therefore have a central role in pathogenesis. The clearest example is in acute 
gout, where uric acid crystals directly trigger the NLRP3 inflammasome leading 
to overwhelming inflammation (Martinon et al., 2006).  
 
The role of DAMPs has been explored in disease models using direct 
administration of purified or recombinant DAMPs and/or depletion via 
antagonists or antibodies (Kono and Rock, 2008). DAMP genetic knockout 
(KO) studies have limitations as they are unable to discriminate between the 
physiological intracellular and proinflammatory extracellular functions of 
DAMPs. In the first study to demonstrate how DAMP administration can cause 
inflammation in vivo, Johnson et al. observed a systemic inflammatory 
response syndrome (SIRS)-like response after administration of the DAMP 
soluble heparin sulfate (Johnson, Brunn and Platt, 2004). Systemic 
administration of a recombinant form of the DAMP high-mobility group box 1 
protein (HMGB1) in mice is lethal (Wang et al., 1999), with gut epithelial barrier 
dysfunction a notable feature (Sappington et al., 2002).  
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In sepsis, initial PAMP mediated activation of PRRs may be followed by cellular 
damage, DAMP release and subsequent DAMP-PRR inflammatory signalling. 
In a study illustrating this concept, lethal anthrax challenge in baboons was 
associated with only transiently elevated bacterial DNA whilst mitochondrial 
DAMP levels remained elevated until death (Lindberg et al., 2013). The 
authors used activated protein C treatment as an approach to suppress innate 
immunity which led to animal survival and no such persistent DAMP elevation. 
This suggests that endogenous DAMPs may have critical pathogenic roles 
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1.3 Mitochondria & mitochondrial DAMPs 
 
1.3.1 Introduction to mitochondria 
 
Mitochondria are intracellular double-membrane bound organelles (‘cellular 
powerhouses’) with many essential physiological roles in energy production, 
programmed cell death, calcium homeostasis and the synthesis of lipids, 
amino acids and haem. In addition, they are involved in antibacterial, antiviral, 
and stress responses to hypoxia and tissue injury (West, Shadel and Ghosh, 
2011; Nunnari and Suomalainen, 2012). Each nucleated cell has a varying 
number of mitochondria depending on the metabolic requirements of the cell 
(up to thousands per cell). 
 
Mitochondria are evolutionarily derived from energy producing alpha-bacteria, 
engulfed by archezoan cells approximately 2 billion years ago leading to a 
symbiotic relationship that forms the basis of the eukaryotic cells (Dyall, Brown 
and Johnson, 2004). The mitochondria share several features with their 
bacterial ancestors, including the double-membrane structure, an 
independently replicating circular genome rich in hypomethylated CpG motifs 
and the synthesis of N-formylated proteins (Galluzzi et al., 2012).  
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1.3.2 Mitochondrial DAMPs  
 
As the innate immune system recognizes conserved bacterial molecules, 
mitochondrial constituents are similarly immunogenic acting as DAMPs when 
released into the cytosol and extracellular environment, triggering innate 
immune responses and promoting inflammation (Boyapati, Rossi, et al., 2016). 
 
Cellular stress and necrosis leads to extracellular release of intramitochondrial 
components such as mitochondrial DNA (mtDNA), N-formyl peptides, 
transcription factor A mitochondrial (TFAM), ATP and mitochondrial lipids as 
DAMPs. In addition to roles in activating PRRs (Table 1.7), mitochondrial 
DAMPs have additional roles such as with chemotaxis – for example, 
mitochondrial formylated peptides can recruit and activate neutrophils 
(Dorward et al., 2015).  
 
Mitochondrial DAMPs Receptor(s) 
mtDNA TLR9, NLRP3 inflammasome 
TFAM RAGE and TLR9 
N-formyl peptides FPR1 and FPR2 
Table 1.7: Mitochondrial DAMPs and their receptors 
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1.3.3 Mitochondrial DNA 
 
The mitochondrial DAMP which has thus far attracted the most attention is 
mtDNA. MtDNA is present in multiple copies within each nucleated cell (each 
mitochondrion is estimated to contain between 2-10 mtDNA copies (Wiesner 
et al., 1992)). It is a relatively small, circular, double stranded DNA molecule 
consisting of 16,569 base pairs (Figure 1.5) enriched with inflammatogenic 
unmethylated CpG motifs resembling bacterial DNA.  
 
mtDNA comprises of 13 protein coding genes encoding for proteins of the 
electron transport train within the inner mitochondrial membrane (Figure 1.5) 
as well as 22 transfer ribonucleic acids (RNAs) coding genes and 2 ribosomal 
RNAs (12S and 16S rRNAs) which are vital for the processes of translation 
and peptide synthesis (Taanman, 1999).  
 
Genetic defects in mtDNA may be inherited through maternal transmission and 
may lead to a wide range of rare debilitating multi-organ system diseases and 
syndromes (Taylor and Turnbull, 2005).  
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Figure 1.5: Structure of mtDNA. The mitochondrial genome contains 13 
protein-coding genes, two rRNA genes (12S and 16S) and 22 tRNA genes 
(denoted by black circles) alongside a D-loop from where the initiation of 
replication and transcription occurs. Adapted from Taanman et al. 1999 with 
permission from Dr David Dorward. 
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1.3.4 Detecting and measuring circulating mtDNA 
 
I performed a review of the literature around sampling, processing and 
quantification protocols for mtDNA to inform the study design. Quantification 
of mtDNA from a sample varies considerably depending on various factors, 
discussed in full in Section 2.4.1. In brief, variation occurs based on the type 
of blood fraction used (serum vs. plasma), time to sample processing, 
consistency in sample processing, centrifugation protocol (whether a second-
high speed spin is used) and qPCR (quantitative polymerase chain reaction) 
protocol.  
 
Therefore, to ensure a robust and accurate assessment of the differences in 
the levels of circulating mtDNA between IBD and non-IBD cohorts, the 
following was implemented as part of this thesis:  
• A prospective design 
• Strict sampling methodology including minimal delays in processing 
samples. 
• Second, high speed centrifugation step employed to remove mtDNA-
plasma. 
• Both plasma and serum obtained 
• qPCR protocols based on sentinel reports (Chiu et al., 2001; Zhang et 
al., 2010) and then developed and optimised at QMRI, Edinburgh 
(Dorward et al., 2017). 
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1.3.5 Circulating mtDNA in inflammatory diseases 
 
Freely circulating mtDNA can be detected, with over 60 studies quantifying 
mtDNA by qPCR in plasma and serum in human diseases (listed in Table 1.8), 
with many studies suggesting circulating mtDNA may be a potential biomarker.  
 
Uncontrolled mtDNA release is evident during conditions associated with acute 
tissue injury such as systemic inflammatory response syndrome (SIRS), 
fulminant liver failure, trauma, acute myocardial infarction, and sepsis; and in 
chronic inflammatory states such as systemic lupus erythematosus (SLE) 
(Boyapati et al., 2017) . This implicates major cellular stress and uncontrolled 
cell death as key factors in the release of mtDNA (Figure 1.6). In cancer, where 
its role as ‘liquid biopsies’ is a topic of considerable interest, the pattern is less 
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Figure 1.6: The contribution of mtDNA to disease pathogenesis. Medical 
conditions are in italics. Where and how mitochondria are released are 
indicated in red. Box in dotted line frames mtDNA sensor target (Boyapati et 
al., 2017).  
 
 
Given the significant tissue injury burden typically observed in active IBD, we 
hypothesised that such pathogenic release is present and that mtDNA can act 
as a pro-inflammatory DAMP potentiating and perpetuating the abnormal 
inflammatory response.  
1. Introduction                34 
 






Trauma     
 Trauma Plasma High mtDNA levels in trauma compared to healthy controls, and 
correlated with injury severity  
(Lam et al., 2004) 
 Trauma Plasma High mtDNA levels in trauma (Zhang et al., 2010; 
Zhang, Itagaki and 
Hauser, 2010) 
 Trauma with MODS Plasma Higher levels of mtDNA had higher relative risk for mortality 
Higher levels of mtDNA in those with SIRS / MODS compared to 
those without 
(Simmons et al., 2013) 
 Trauma and severe 
sepsis 
Plasma mtDNA higher in patients with trauma compared to healthy controls 
on day 1 
mtDNA correlates with injury severity scores in trauma patients 
mtDNA higher on day 1 in non-survivors compared to survivors  
(Hsu et al., 2013) 
 Post-Traumatic SIRS Plasma mtDNA is an independent predictor for post-traumatic SIRS (Gu et al., 2013) 
 Trauma Plasma mtDNA higher in trauma patients with correlation with injury severity (Nicole Y.L. Lam, 
Timothy H. Rainer, 
Rossa W.K. Chiu and 
Lo, 2004) 
 Trauma (femur 
fracture) 
Plasma mtDNA higher in trauma patients than healthy controls (Hauser et al., 2010) 
 Trauma Plasma mtDNA higher in trauma patients compared to healthy controls at 
two-time points (pre-hospital and day 1) 
(Timmermans et al., 
2016) 
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 Trauma Plasma mtDNA higher in trauma patients than healthy controls 
mtDNA higher in non-survivors compared to survivors 
(Prikhodko et al., 2015) 
 Hip fracture Plasma mtDNA levels were higher in hip fracture patients compared to 
healthy controls, and even higher in the lung injury subgroup 
compared to lung injury absent subgroup 
(Zhang et al., 2017) 
Sepsis     
 Severe sepsis Plasma mtDNA higher in patients with severe sepsis compared to healthy 
controls 
No significant difference in mtDNA between non-survivors and 
survivors in severe sepsis 
(Hsu et al., 2013) 
 Severe sepsis in the 
ED 
Plasma mtDNA higher on admission in severe septic patients than healthy 
controls; mtDNA higher in non-survivors than survivors, increased 
initially then gradual decrease after antimicrobial therapy, 
independent predictor of fatality. 
(Kung et al., 2012) 
 Sepsis Plasma mtDNA higher in septic patients compared to healthy controls (Bhagirath, Dwivedi 
and Liaw, 2015) 





Plasma mtDNA levels were higher in patients with aseptic and in bacterial 
meningitis compared to healthy controls mtDNA levels fall during 
course of admission  
High mtDNA levels associated with poorer outcome in adult 
community-acquired bacterial meningitis 
(Lu et al., 2010) 
 Infectious SIRS Plasma mtDNA higher in septic patients compared to healthy controls (Garrabou et al., 2012) 
 Paediatric sepsis Plasma mtDNA higher in septic patients compared to critically ill non-septic 
and healthy control patients 
(Di Caro et al., 2015) 
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 Severe sepsis in the 
ED 
Plasma No significant difference in mtDNA between sepsis and healthy 
control cohorts 
(Puskarich et al., 2012) 
Critically unwell patients 
 ICU patients Plasma Increased mtDNA levels associated with ICU mortality (Nakahira et al., 
2013) 
 Critically Ill Patients 
(in ICU) 
Plasma  Patients with highest quartile of mtDNA in plasma had higher risk of 
dying.  
When stratified by TLR9 expression, only patients with high 
expression of TLR9 had an association between with mortality and 
mtDNA level. 
(Krychtiuk et al., 
2015) 
 Out of Hospital 
Cardiac Arrest 
Plasma Significantly higher levels in non-survivors than survivors (Arnalich et al., 2012) 
% 
Liver Failure     
 Acetaminophen 
induced acute liver 
failure 
Serum mtDNA higher in acetaminophen induced acute liver failure patients 
compared to healthy controls 
mtDNA higher in in non-survivors compared to survivors 
(McGill et al., 2014) 
 Acetaminophen 
induced acute liver 
injury 
Plasma mtDNA higher in patients with acetaminophen overdose with abnormal 
liver function tests compared to healthy controls and those with 
acetaminophen overdose but normal liver function tests 
(McGill et al., 2012) 
 Fulminant liver failure Serum Higher during acute liver injury (Marques et al., 2012) 
Heart disease     
 AMI Plasma Significantly higher mtDNA in STEMI patients than stable angina 
pectoris patients (reducing rapidly to similar levels 3 days after PCI) 
 
(Bliksøen et al., 2012) 
 AMI Plasma Significantly higher levels in AMI patients compared to healthy 
controls.  
(L. L. L. Wang et al., 
2015) 
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Levels dropped to normal immediately post PCI. 
 AMI Plasma Significantly higher levels in acute AMI compared to healthy controls 
on admission 
(Qin et al., 2016) 
 T2DM with CAD Plasma Significantly elevated levels in T2DM compared to healthy controls. 
Higher levels in those with DM & CAD compared to those without CAD. 
mtDNA levels correlated with CRP in patients with CAD. 
(J. Liu et al., 2015) 
 Heart failure Plasma Higher levels of mtDNA in heart failure patients compared to age and 
sex matched healthy controls; no association with disease severity 
(Dhondup et al., no 
date) 
 Heart failure Plasma Higher levels of mtDNA in acute vs. chronic heart failure; in acute heart 
failure, mtDNA predicted mortality 
(Krychtiuk et al., 
2017) 
Stroke     
 Acute ischaemic 
stroke 
Plasma mtDNA levels higher in acute cerebral infarction than healthy controls 
No significant difference in mtDNA between good vs poor outcome 
cohorts 
(Lakra et al., 2011) 
 Subarachnoid 
haemorrhage 
Plasma No significant difference in mtDNA between subarachnoid 
haemorrhage and healthy control groups 
(Wang et al., 2013) 
 Intracerebral 
haemorrhage 
Plasma No significant difference in mtDNA between intracerebral 
haemorrhage and healthy control groups 
No correlation between mtDNA and disease severity 
(Wang et al., 2012) 
Malignancy     
 Breast Cancer Plasma Reduced levels of mtDNA in benign or malignant breast cancer 
compared to healthy controls 
(Kohler et al., 2009) 
 Ovarian Cancer Plasma & 
Serum 
Plasma: Significantly higher levels of mtDNA in ovarian cancer group 
compared to healthy controls and ovarian benign tumour group 
Serum: No significant difference between groups above 
(Zachariah, Schmid 
and Buerki, 2008) 
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 Testicular Germ Cell 
Cancer 
Serum mtDNA levels were significantly higher in patients with testicular 
cancer than healthy controls although it did not correlate with any 
clinicopathological variable of disease status 
(Ellinger et al., 2009) 
 Urological 
malignancies 
Serum mtDNA were significantly higher in ‘urological malignancies’ (bladder 
cell, renal cell and prostate cancer) 
(Ellinger et al., 2012) 
 Prostate Cancer Serum mtDNA could not distinguish between benign prostatic hypertrophy 
and prostate cancer. 
Patients with early biochemical recurrence post radical prostatectomy 
have higher mtDNA levels 
(Ellinger et al., 2008)  
 Ewing’s Sarcoma Serum mtDNA significantly lower in patients with Ewing’s sarcoma compared 
to healthy controls 
(Yu et al., 2012) 
 Lung Cancer Serum mtDNA significantly higher in lung cancer patients compared to those 
with benign lung diseases and healthy individuals and closely 
associated with TNM stage 
(Hou et al., 2013) 
 Advanced Prostate 
Cancer 
Plasma mtDNA levels are elevated in advanced prostate cancer patients and 
is associated with decreased survival.  
(Mehra et al., 2007) 
 Adenocarcinoma of 
the lung in patients 
receiving erlotinib 
Plasma Rise in mtDNA levels in patients with partial response; drop in mtDNA 
levels in those with progressive disease or no response. No correlation 
with progression free survival. 
(Huang et al., 2014) 




Serum Exposure to these carcinogens was significantly associated with 
elevated serum levels of circulating mtDNA (case control study) 
(Budnik et al., 2013) 
 Renal Cell Carcinoma Plasma Higher levels in metastatic compared to non-metastatic patients and 
controls. 
(Lu et al., 2016) 
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HIV     
 HIV Plasma Higher levels in acute HIV infection, late presenters compared to long 
term non-progressors and healthy controls. Also correlated with viral 
load. 
(Cossarizza et al., 
2011) 
 Lipodystrophy in HIV 
patients treated with 
HAART 
Plasma Significantly higher levels in HIV infected vs non-infected individuals.  
Significantly higher levels in those with lipodystrophy compared to 
those without lipodystrophy at month 24. 
(Dai et al., 2015) 
 HIV 
 
Plasma No significant association between HIV disease status and mtDNA (Lauring et al., 2012) 
 
Inflammatory autoimmune conditions 
 Rheumatoid Arthritis Plasma 
 
Higher percentage of detectable levels in rheumatoid arthritis 
compared to controls 
(Hajizadeh et al., 
2003) $ 
 Granulomatosis with 
polyangiitis 
Serum Significantly higher levels in granulomatosis with polyangiitis 
compared to controls 
(Surmiak et al., 2015) 
Age & Exercise 
 Age Plasma mtDNA levels increased gradually after the fifth decade of life 
 
(Pinti et al., 2014) 
 Age Plasma No association with age but mtDNA associated with HLA-DR (Verschoor et al., 
2015) 
 Aging and ‘frailty’ Plasma Aging: no difference in mtDNA between younger and older subjects 
Frailty: mtDNA copy number directly correlated with frailty score 
(Jylhävä et al., 2013) 
 Exercise Plasma Reduced mtDNA in response to exercise (Shockett et al., 2016) 
 Male Volleyball 
Players 
Plasma Lower levels in participants in professional volleyball players 
compared to healthy nonathlete controls 
(Nasi et al., 2015) 
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Psychiatric disorders    
 Bipolar Disorder Serum No difference between bipolar disorder & healthy control groups 
Higher levels in bipolar disorder group compared to sepsis 
(Stertz et al., 2015) 
 Suicide attempters Plasma Higher plasma levels of mtDNA in suicide attempters compared with 
healthy controls 
(Lindqvist et al., 2016) 
 Major depressive 
disorder 
Plasma Higher plasma levels of mtDNA in major depressive disorder 
compared to controls 
(Lindqvist et al., 2018) 
 Major depressive 
disorder and biopolar 
disorder 
Plasma Lower plasma mtDNA levels in major depressive disorder and bipolar 
disorder compared to healthy controls 
(Kageyama et al., 
2018) 
Miscellaneous     
 Corrosive injury 
(gastrointestinal 
ingestion) 
Plasma Significantly higher mtDNA in mortality group vs survival group at 
presentation and after 12 hours 
(Chou et al., 2008) 
 Pulmonary Embolism Plasma Predictor of 15-day mortality (Arnalich et al., 2013) 
* 
 Autism Serum Significantly higher mtDNA in young autistic children compared to 
healthy controls 
(van Rossum et al., 
2010) 
 Haemodialysis Plasma Significantly higher levels in maintenance haemodialysis patients 
compared to healthy controls  
(Cao et al., 2014) 
 End-stage renal 
failure in Han 
population 
Plasma End-stage renal failure patients had higher mtDNA copy number (Zhang et al., 2016) 
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 Low levels of ionising 
radiation 
Serum Higher levels in interventional cardiologists exposed to low levels of 
ionizing radiation compared to controls 
(Borghini et al., 2015) 
 Friedreich’s ataxia Plasma Significantly reduced mtDNA in Friedreich’s ataxia patients compared 
to healthy controls 






Higher mtDNA copy number in non-haemolytic transfusion reaction 
platelet concentrate vs normal platelet concentrate 
(Yasui et al., 2016) 
 Cardiopulmonary 
bypass surgery 
Plasma Higher mtDNA post cardiopulmonary bypass; patients with post-
operative atrial fibrillation had greater increases in mtDNA post-
surgery 
(Sandler et al., 2018) 
 
 
Note: this table lists studies reporting mtDNA analysed by PCR on serum or plasma (i.e. circulating as a DAMP) in human diseases 
* earlier study in 2010 not included 
% letter 
# conference abstract only 
$ PCR rather than qPCR used  
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1.4 Hypothesis and aim 
 
Aim 
The aim of this thesis is to investigate the role of mtDNA in IBD.  
 
Hypotheses 
Primary hypothesis: Circulating mtDNA is elevated in IBD. (Chapter 2) 
 
Secondary hypotheses: 
• Other circulating mitochondrial DAMPs are elevated in IBD (Chapter 2) 
• Circulating mtDNA can be used as a novel biomarker in IBD (Chapter 3) 
• mtDNA is released locally at sites of inflammation in IBD (Chapter 4) 
 














DAMPS IN IBD 
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The pathogenesis of IBD is complex and remains to be fully elucidated. One 
area of limited exploration thus far has been the role of DAMPs in instigating 
and/or propagating sterile inflammation which has been found to be relevant 
in several other inflammatory diseases. Mitochondrial DAMPs are of particular 
interest given their high inflammatory potential.  
 
The mitochondrial DAMP that has attracted the most interest thus far is 
mtDNA, which is highly enriched with hypomethylated CpG repeats resembling 
bacterial DNA. A further shared feature of the mitochondria with bacteria is the 
production of short N-formylated peptides. Bacterial and mitochondrial proteins 
are the only source of N-formylated peptides in nature and mitochondrial 
formylated peptides (also released as mitochondrial DAMPs post cellular 
rupture) have been found to have important roles in sterile inflammation 
especially as chemoattractants.  
 
Mitochondrial DAMPs can be detected in the circulation and have been found 
to be raised in a number of inflammatory diseases. These include diseases of 
acute and chronic inflammation such as trauma, sepsis, AMI, T2DM and 
stroke. Although many DAMPs are elevated in IBD, there has been no data to 
date demonstrating elevated levels of mitochondrial DAMPs in IBD. 
Mitochondrial DAMPs are of particular interest in IBD given the recent findings 
by our group of gut mitochondrial dysfunction leading to loss of epithelial 
barrier function and development of colitis (Ho et al., 2018).  
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This chapter deals with the primary aim of this thesis which is to test the 
hypothesis that patients with active inflammatory bowel disease have higher 
levels of circulating mitochondrial DAMPs compared to non-IBD controls. For 
the reasons previously outlined, it was determined that a well characterised, 
prospectively recruited cohort of IBD patients was required. The recruitment 
inclusion criteria were kept deliberately broad given the role of mitochondrial 
DAMPs in IBD has yet to be defined. 
 
mtDNA was chosen as the primary mitochondrial DAMP for investigation for 
several reasons. A paper published in Nature in 2010 (Zhang et al., 2010) 
observed elevated levels of mtDNA in patients with SIRS and sparked 
significant interest and further research in this area as a potentially functional 
and clinically useful biomarker (Boyapati et al., 2017). Furthermore, colleagues 
at the Centre for Inflammation Research (Edinburgh) had recently developed 
and optimised the qPCR protocol for quantification of mtDNA (Dorward, 2014) 
based on the method initially described years previously (Chiu et al., 2003) 
and subsequently used by Zhang et al. 
 
To show corroborative evidence of mitochondrial DAMPs being released into 
the circulation, a second mitochondrial DAMP (N-formylated peptides) was 
also measured in some patients. 
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2.2 Materials & Methods 
 
2.2.1 Study design 
 
This was a single centre, prospective cohort study. 
 
2.2.2 Funding and ethics 
 
This work was supported by MRC grant G0701898, Crohn’s and Colitis United 
Kingdom (UK) M16-1 to Gwo-tzer Ho; Edinburgh Gastrointestinal Trustees 
Grant (2014) to Ray Boyapati and Wellcome Trust grant WT096497 to David 
Dorward and Adriano Rossi. 
 
All clinical and biological material/data acquisition were carried out under 
Lothian Bioresource ethics approval 15/ES/0094. 
 
2.2.3 Recruitment of study participants 
 
Individuals were recruited from outpatient and inpatient settings from the 
Gastrointestinal Unit, Western General Hospital, Edinburgh between April 
2014 and November 2015. Patients with IBD of either major type (CD or UC) 
and with a range of severity (from quiescent disease in the outpatient clinic 
through to severe disease requiring intravenous steroids on the inpatient 
wards) were considered eligible for inclusion. In addition, individuals with IBS 
or with no history of IBD and no gastrointestinal symptoms were recruited as 
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non-IBD symptomatic controls. A call was made for healthy control volunteers 
at the Queens Medical Research Institute, Edinburgh (those with no history of 
gastrointestinal illness/diagnosis or other known chronic health conditions). 
Given the prospective design of our study, we set out to carry out sex- and 
age-matching. Healthy controls were recruited between January 2015 and 
June 2015. Individuals were excluded if they were younger than 18 or were 
unable to give written consent. 
 
For the IBD cohort, recruited patients fulfilled the criteria of CD or UC based 
on clinical, endoscopic and histological criteria (Lennard-Jones, 1989). IBS 
individuals (non-IBD symptomatic controls) had altered bowel habit and were 
defined following normal ileo-colonoscopy, stool calprotectin and blood 
parameters.  
 
2.2.4 Information/samples collected 
 
At initial contact, patients were provided with a patient information sheet and 
provided time to consider participation in the study. If the patient agreed to 
participate, two consent forms (one for use of questionnaire data and one for 
use of samples) and a comprehensive IBD questionnaire (Appendix B) was 
completed at first recruitment. The comprehensive IBD questionnaire included 
information on ethnic origin, country of birth, social history, smoking/alcohol 
history, childhood exposures, family and medical history, IBD history, 
medication history and pregnancy status.  
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An additional clinical activity form (Appendix C) was completed with the 
assistance of the researcher at the time of each sample. This form included 
information on weight, temperature, heart rate, current medications, and 
information on clinical assessment of disease activity as per two validated 
scoring indices: the Simple Clinical Colitis Activity Index (SCCAI) for UC 
(Walmsley et al., 1998) and Harvey Bradshaw Index (HBI) for CD (Harvey and 
Bradshaw, 1980) (Appendix A). Completed forms were stored securely for 
entry into a database. 
 
Where appropriate, clinical bloods (full blood examination, albumin and CRP) 
were collected at the time of recruitment and blood sampling. Where multiple 
samples were taken for a single patient, the mean values were used in any 
per-patient analysis. 
 
Overall, the aim was to collect clinical and biochemical data to measure 
disease type, activity, severity and extent. A further aim was to collect some 
longitudinal data to assess for variation in mtDNA over short and long time 
frames and thus, for some patients, multiple sample points were taken.  
 
2.2.5 Clinical disease activity stratification 
 
For UC and CD, disease activity was classified using the SCCAI and HBI 
respectively (Appendix A). Clinical remission was defined as SCCAI of less 
than or equal to 2 for UC patients, and HBI of less than 5 for patients with CD.  
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Patients with clinical active disease (i.e. not in clinical remission) were further 
classified into severe disease if they required intravenous steroids for CD or 
fulfilling the modified Truelove & Witts’ criteria for ASUC (Appendix A).  
 
2.2.6 Plasma and serum sampling & processing 
 
Venepuncture was performed by a trained clinician with a 21-gauge butterfly 
needle. 12-18mL of blood including at least 9mL in an 
ethylenediaminetetraacetic (EDTA) acid tube (Vacuette ®) for plasma and 1 x 
serum tube (Vacuette ®) was collected and processed within 2 hours of 
collection.  
 
EDTA blood was centrifuged at 1000g for 10 minutes at 4oC and the plasma 
fraction was transferred to a 15mL Falcon ® tube; this was then centrifuged at 
5000g for 10 minutes at 4oC to remove platelets and microparticles in order to 
achieve ‘cell free plasma’. 
 
Serum was stored for 1-hour storage at 4oC for clotting and then centrifuged 
at 2,500g for 10 minutes at 4oC. Both serum and plasma fractions were divided 
into 0.5mL aliquots and stored at -80oC until further use. 
 
At the same venepuncture, bloods requested by clinicians caring for the patient 
(in the IBD or IBS cohorts) were taken and sent to the Western General 
Hospital (Edinburgh) clinical laboratory for full blood examination, albumin and 
CRP.   
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2.2.7 Mitochondrial DNA 
 
The methods described below were largely developed and optimised by Dr 
David Dorward at the MRC Centre of Inflammation Research (Edinburgh) as 
part of his research into the contribution of mitochondrial formylated peptides 
to the pathogenesis of acute lung injury (Dorward, 2014; Dorward et al., 2017). 
The methods with amendments are reproduced here with permission.  
 
2.2.7.1 Isolation of DNA from serum & plasma  
DNA was isolated from serum and plasma using an automated robotics 
platform (QIAcube, Qiagen Qiagen, Valencia CA, USA) at the same time to 
ensure uniformity. QIAamp DNA Blood mini kits were used as per 
manufacturer’s instructions (blood and body fluids protocol, Qiagen) as 
described previously (Chiu et al., 2003; Zhang, Itagaki and Hauser, 2010).   
 
Plasma and serum samples were initially centrifuged at 9,500g for 10 minutes 
and 200µL of sample added to 20µL QIAGEN protease in a 1.5mL Eppendorf 
tube.  After the addition of 200µL of Buffer AL samples were vortexed for 15 
seconds and incubated at 56°C for 10 min.  Ethanol was then added (200µL), 
samples vortexed, transferred to a QIAamp mini spin column and centrifuged 
at 6,000g for 1 min.  The collection tube and elute were discarded and the 
column placed in a clean tube.  500µL of Buffer AW1 was then added, samples 
centrifuged again at 6,000g for 1 minute and flow through discarded.  Following 
the addition of 500µL Buffer AW2 columns were centrifuged at 16,000g for 3 
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minutes and then again for a further 1 minute to ensure removal of any ethanol 
carry-over.  Spin columns were transferred to clean 1.5mL Eppendorf tubes 
and 50µL of Buffer AE added to each filter. Following 5 minutes incubation at 
room temperature samples were centrifuged at 6,000g for 1 minute and the 
elute stored at -20°C until analysed. 
 
2.2.7.2 Developing standard curves for qPCR 
 
Isolation of mitochondria 
Whole mitochondria were extracted from cultured HepG2 cells selected due to 
their high metabolic capacity and abundant mitochondria. Mitochondria were 
extracted from cultured HepG2 cells using the Mitochondrial Isolation kit for 
cultured cells (Sigma) using the manufacturer’s instructions.  
 
Adherent HepG2 cells were detached from their cell culture flasks with trypsin-
EDTA and RPMI with 10% FCS was added. Cells were pelleted at 600g for 5 
minutes at 2°C and then washed (cells were resuspended in ice cold PBS and 
counted using a haemocytometer, then pelleted at 600g for 5 minutes). 2x107 
cells were used for each mitochondrial preparation. The wash step was then 
repeated without counting the cells. 2mL of the prepared Extraction Buffer A 
was added and incubated on ice for 15 minutes. Cells were then homogenised 
using a Dounce homogenizer. Homogenisation was performed gradually and 
followed by staining an aliquot with trypan blue and counting the cells under a 
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microscope, diluting if necessary to count the cells. An additional 5 strokes 
were performed until at least 50% of cells were damaged.  
 
The homogenate was then centrifuged at 600g for 10 minutes at 2°C. The 
supernatant was then transferred to a fresh tube and centrifuged at 11,000g 
for 10 minutes at 2°C. The supernatant was removed, and the pellet was 
resuspended in 200 µL of CelLytic M Cell Lysis Reagent with Protease Inhibitor 
Cocktail (1:100 [v/v]). Isolated mitochondria were stored at -20oC until further 
use. 
 
Extraction of DNA from isolated mitochondria  
DNA was extracted from isolated mitochondria using the QIAamp DNA Micro 
Kit (Qiagen, Valencia CA, USA) as per the manufacturer’s instructions.  
 
50µL of media containing isolated mitochondria was added to 50µL of Buffer 
ATL in a 1.5mL Eppendorf tube.  10µL of proteinase K and 100µL of Buffer AL 
was then added, and mixed by pulse-vortexing for 15 seconds and incubated 
at 56°C for 10 min.  50µL of ethanol (96-100%) was then added, vortexed, and 
incubated at room temperature (15-25°C) for 3 minutes. The entire lysate was 
then transferred to a QIAamp mini spin column and centrifuged at 6,000g for 
1 minute. The collection tube and elute were discarded and the column placed 
in a clean tube.  500µL of Buffer AW1 was then added, centrifuged again at 
6,000g for 1 minute and column placed in a clean tube. Following the addition 
of 500µL Buffer AW2 columns were centrifuged at 6,000g for 1 minute and 
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then the column was placed in a clean tube. This was then centrifuged at 
20,000g for 3 minutes to dry the membrane completely. Spin columns were 
transferred to clean 1.5mL Eppendorf tubes and 50µL of Buffer AE added to 
each filter. Following 5 minutes incubation at room temperature, samples were 
centrifuged at 20,000g for 1 minute and the elute stored at -20°C until 
analysed. 
 
Purity of the DNA was determined using Nanodrop 2000 spectrophotometer 
(ThermoScientific, Wilmington, DE, USA) and all DNA samples had 
OD260/OD280 values of 1.7-2.0.   
 
Amplification of mtDNA primer products 
Conventional PCR was performed using primers against mtDNA coding for 
nicotinamide adenine dinucleotide dehydrogenase (ND2) and cytochrome C 
oxidase subunit III (COXIII). COXIII and ND2 primers were selected as primer 
sequences (Appendix D) as they have been previously described for 
quantification of mtDNA (Lu et al., 2010; Zhang et al., 2010) and are specific 
for human mtDNA. Primers were blasted against human genome as well as 
known bacteria to ensure selectivity for human mtDNA 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/).  
 
mtDNA primer products were amplified from isolated mtDNA by conventional 
PCR.  
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The reaction mix contained: 
• 2x PCR master mix    50μl 
• 100μM forward primer  1μl 
• 100μM reverse primer  1μl 
• DNA      10μg  
• ddH2O    Added for final volume of 100μl 
 
PCR conditions were  
• Stage 1   95oC for 2 minutes 
• Stage 2    40 cycles of 95oC for 30 seconds,  
   58oC for 30 seconds  
   72oC for 30 seconds 
• Stage 3   72oC for 5 minutes 
 
Primer validation 
To confirm the PCR product size was as expected, the PCR product was run 
on a 4% agarose gel (2g of agarose resuspended in 50mL 1x TBE with 5μl Gel 
Red added to the solution once the agarose dissolved). 10μl of PCR product 
was used and samples run next to a 100bp DNA ladder. The gel was run at 
120V for 55-60 minutes until the leading edge reached the distal gel edge with 
products subsequently visualised using an ultraviolet illuminator (UV 
Transilluminator, UVP Inc). PCR product size was as expected (103bp for 
COXIII, 90bp for ND2) (Figure 2.1). 
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Figure 2.1: Gel confirming amplified PCR primer products 
 
In addition, ND2 and COXIII mtDNA primer specificity has been previously 
demonstrated within biological systems by demonstrating minimal PCR 
products seen in mitochondrial depleted cells (Dorward, 2014). In brief, A549 
and Beas 2B cells were cultured with ethidium bromide for 6 weeks to deplete 
mitochondria as described (King and Attardi, 1989; Crouser et al., 2009) after 
which DNA and protein were extracted. Primer specificity was demonstrated 
with minimal PCR products seen in mitochondrial depleted (Ro) cells following 
agarose gel electrophoresis relative to untreated control cells cultured for the 
same duration.  Furthermore, there was no observable loss of nuclear DNA 
content as assessed by qPCR. 
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Generation of Standard Curves 
Standard curves for absolute quantification of circulating free mtDNA were 
generated using the initial method described for quantification of plasma 
mtDNA (Chiu et al., 2003). The QIAgen PCR Purification kit (Qiagen) was used 
on amplified primer products (as described above) in accordance with 
manufacturer’s instructions. In brief, 500µL of Buffer PB was added to 100µL 
PCR product, transferred to a spin column and centrifuged at 6,000g for 1 
minute before 750µL Buffer PE was added and the column centrifuged. The 
DNA was then eluted with 50µL Buffer EB into a sterile 1.5mL Eppendorf and 
stored at -20°C until use. Isolated DNA was quantified by nanodrop 
(ThermoScientific) and serially diluted. mtDNA concentration in copies/µL was 
determined using the formulae described below in Material and Methods 
section 2.2.7.3. 
 
2.2.7.3 qPCR protocols for absolute quantification  
Primers (MWG Eurofins) were suspended at 100μM stock solution with DEPC-
treated water and stored at -20°C prior to use.  Subsequently, 20x primer 
solution (1.8μM) was made (3.6μL forward, 3.6μL reverse, 192.8μL DEPC-
H2O).  In MicroAmp® Optical 384-Well Reaction Plates (Applied Biosystems) 
7μl of master mix containing 5μL 2x SYBR Green Fast mix (Applied 
Biosystems), 0.5μL 20x primer mix and 1.5μl DEPC-treated water was mixed 
with 3μl of isolated DNA sample or standard.  All reactions were carried out in 
duplicate, and discordant results retested. All plates contained wells with no 
DNA as a negative, no template control.   
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qPCR reactions were conducted in an ABI7900 Fast Real-Time PCR System 
(Applied Biosystems) with the following settings:  
 
• Stage 1   95°C for 20 seconds 
• Stage 2   40 cycles of 95°C for 3 seconds & 60°C for 30   
  seconds 
• Melt curve   95°C for 15 seconds, 60°C for 1 minute, 95°C for  
   15 seconds, 60°C for 15 seconds 
 
Absolute quantification of mtDNA was determined relative to the standard 
curve based on the following equation (as described by Chiu et al. (Chiu et al., 
2003)): C = Q x VDNA/VPCR x 1/Vext 
 
• C  target concentration in plasma or serum (copies per millilitre)  
• Q  target quantity (copies) determined by sequence detector in PCR  
• VDNA  total volume of DNA obtained after extraction, typically 50μl per  
extraction 
• VPCR  volume of DNA solution used for PCR, typically 3μl  
• Vext  volume of plasma, typically 200μl 
 
Amplification efficiency of between 90 and 110% was taken as acceptable 
where slope refers to the gradient of the standard curve: (Efficiency = 10(-1/slope) 
– 1). The coefficient of determination value was also calculated with r2>0.985.  
SYBR green analysis meltcurves were run to identify the presence of any 
primer dimer peaks. 
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2.2.8 Mitochondrial formylated peptides 
 
Mitochondrial N-formylated peptides are functionally similar to their bacterial 
counterparts acting as primarily as neutrophil chemoattractants (Carp, 1982). 
To provide further corroborative evidence to our mtDNA data, we employed a 
mass spectrometric approach to identify and quantify N-mitochondrial 
formylated peptides in a subset of 5 acute severe UC vs. 5 non-IBD controls. 
The 10 patient samples for analysis were picked at random from the recruited 
patient population of ASUC (5 samples) and non-IBD (5 samples).   
 
Mass spectrometry was performed by Dr Mary Doherty and Professor Phil 
Whitfield at the University of the Highland and Islands using their previously 
optimised protocol as outlined in (Dorward et al., 2017). The methods are 
reproduced here with permission. 
 
Synthetic peptides  
N-formylated hexapeptides were identified on the basis of their accurate mass, 
retention times and characteristic fragmentation patterns compared to custom 
synthesised standards (Peptide Protein Research Ltd, Fareham, UK). The 
hexapeptide standards of the N-terminal fragments of each of the 13 
mitochondrial formylated peptides were based on sequences previously 
described (Rabiet, Huet and Boulay, 2005) (Appendix E).  They were 
resuspended in methanol:H2O (1:1) to a 1mg/mL stock solution, serial dilutions 
using 0.5% acetic acid made and analysed by LC MS/MS. 
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Mass Spectrometry analysis of standard peptides 
The standards were first infused into the mass spectrometer to determine the 
molecular ion and then each fragmented using both collision induced 
dissociation (CID) and higher collision dissociation (HCD). A 5µL aliquot of 
each sample was analysed by LC-MS/MS using a Thermo LTQ-Orbitrap XL 
LC-MSn mass spectrometer equipped with a nanospray source and coupled to 
a nanoUPLC (Waters nanoAcquity) The peptides were loaded onto a 
Symmetry C18 trap column (5µm particle size, 180µm x 20mm, Waters) and 
then were separated using a BEH130 C18 analytical column (1.7µM particle 
size, 75µm x 250mm) with an acetonitrile/water gradient and MS spectra 
collected using data-dependent acquisition in the range m/z 400-1300. 
Peptides were fragmented using both CID and HCD. A mixture of the standard 
peptides was also prepared and analysed in the same way. The analyses were 
repeated at a range of concentrations and standard curves plotted for the 
peptides analysed individually (500fg-500pg) and as the combined samples 
(250fg-250pg on column).  
 
Separation of protein and peptide containing fractions from patient 
plasma 
Plasma samples were each centrifuged at 13,000rpm for 1 minute to remove 
any residual cellular debris.  To precipitate proteins 100µL sample was added 
to 1000µL acetone and incubated at -20°C for 1 hr.  Following centrifugation 
at 13,000 rpm for 1 minute the peptide-rich acetone layer was aspirated and 
acetone then evaporated at 40°C in a Speed Vac for 1 hr until approximately 
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50µL of acetone remained.  Peptide samples were diluted either 10- or 100-
fold in 0.5% acetic acid then centrifuged at 13,000rpm for 4 minutes prior to 
analysis as described for the standard peptides.  
 
Analysis of protein-derived peptides by LC-MS/MS  
Plasma samples (100µL) were acetone precipitated, dried down under vacuum 
and reconstituted in 0.5% acetic acid. Peptides were then analysed by LC-
MS/MS in positive ion mode using a Thermo LTQ-Orbitrap XL mass 
spectrometer (Hemel Hempstead, UK) coupled to a Waters nanoAcquity 
UPLC system (Manchester, UK) with a linear gradient over 39 minutes (mobile 
phase A: 0.5% acetic acid in water; mobile phase B: 0.5% acetic acid in 
acetonitrile). Quantification was achieved using a corresponding stable isotope 
labelled internal standard and calibration curve for each N-formylated 
hexapeptide. 
  
The peptides were separated using BEH130 C18 trapping and analytical 
columns with an acetonitrile/water gradient and MS spectra collected using 
data-dependent acquisition in the range m/z 400-1300. Peptides were 
fragmented using both CID and HCD and the data analysed using 
ProteomeDiscoverer for identification MaxQUANT for relative quantification. 
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2.2.9 Statistical Analysis 
 
Data are presented as numbers, percentages, means ± standard error of the 
mean (SEM) and medians ± interquartile range (IQR) for parametric and non-
parametric data respectively. Student t- and Mann-Whitney statistics were 
used for parametric and non-parametric data respectively. The sensitivity, 
specificity, and likelihood ratio for mtDNA, CRP and albumin levels to predict 
the need for colectomy in ASUC were calculated using receiver operator 
characteristic (ROC) curve analysis. Area under ROCs curves (AUROCs) 
were calculated for each biomarker, and differences between AUROCs 
compared using the DeLong method. Kaplan – Meier survival analysis was 
used to compare the course of disease between patients with high and low 
mtDNA levels. 
 
Multivariate logistic regression was performed to assess variables predictive 
of high mtDNA. Wilcoxon matched-pairs signed rank test was used to 
determine the difference in matched pre- and post-colectomy mtDNA levels 
and matched faecal mtDNA levels using two protocols. The Delong method 
was used to compare AUROCs for ability to predict colectomy. Spearman’s 
correlations were calculated to evaluate the relationship between mtDNA level 
and other biochemistry, and between COXIII and ND2 qPCR results.  
 
Statistical analyses were performed using Graphpad Prism version 7 
(Graphpad Software, San Diego, California, USA) and SPSS version 22 (IBM 
Corp., Chicago, USA). Two-sided p values of <0.05 were considered 
statistically significant. 




2.3.1 Study recruitment  
 
97 IBD patients (67 UC and 30 CD patients), and 40 non-IBD controls (20 
healthy [HC] and 20 IBS controls) were prospectively recruited to the study. 
The first participant was recruited in August 2014 and the final participant in 
June 2015 (Figure 2.2) 
 
 
Figure 2.2: Recruitment of IBD, non-IBD and HC cohorts over time 
 
In total, there were 160 sample points for the 97 IBD patients. 58 patients had 
one sample point, 27 patients had two sample points, 5 patients had three 
samples points, 2 patients had four sample points and 5 patients had five 
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2.3.2 Baseline characteristics 
 
The baseline characteristics of the IBD (CD and UC) and Control (HC and IBS) 
cohorts are summarised in Table 2.1. There were no statistically significant 
differences between the cohorts based on age, sex or smoking status. 
 
 IBD Controls p 
value 
 
CD UC HC IBS  
n 30 67 20 20  
Age 37 (27-44) 36 (28-51) 36 (32-46) 33 (27-42) NS 
M / F 17 / 13 44 / 23 10 / 10 13 / 7 NS 
Current smoker 26% 21% 15% 25% NS 
Table 2.1: Demographic details of CD, UC, HC and IBS cohorts; all p > 0.05 
(one-way ANOVA). NS: not significant 
 
Ambulatory (outpatients) were divided into remission and active disease based 
on the HBI for CD and the SCCAI for UC (Appendix A). Patients were further 
categorised into those with severely active disease (hospitalised and receiving 
intravenous steroids for CD; and hospitalised, receiving intravenous steroids 
and meeting modified Truelove and Witts’ criteria [Appendix A] for UC). The 
baseline biochemistry and HBI/SCCAI of the IBD cohort based on IBD type 
and activity is presented in Table 2.2.  
 
  












Hb (g/dl) 145 (137-151) 156 (138-158) 130 (125-137) 
WCC (x109/L) 7.4 (5.4-15.1) 10.9 (7.7-11.9) 8.75 (7.4-11.6) 
Platelets (x109/L) 253 (218-295) 509 (300-414) 334 (279-378) 
CRP 3.5 (1-7.5) 5 (3.5-8) 26 (12-62) 
Albumin 38 (33-40) 38 (37-38) 29 (27-34) 












Hb (g/dl) 136 (128-151) 131 (123-146) 114 (104-130) 
WCC (x109/L) 6.3 (4.7-7.5) 7.7 (6.3-8.8) 11.3 (8.3-14.6) 
Platelets (x109/L) 292 (252-303) 305 (256-335) 414 (288-501) 
CRP 2 (2-5) 3 (2-17) 21 (10-54) 
Albumin 39 (38-40) 38 (35-40) 30 (25-34) 
SCCAI 0 (0-0) 6 (4-8) 7 (4-10) 
Table 2.2: Baseline characteristics of IBD cohorts by IBD type & activity. Data 
presented as median (±IQR).   
 
As expected, values for biochemistry and clinical activity indices differed 
between various cohorts as stratified by clinical activity (using Mann-Whitney 
tests for comparison of non-parametric data). Groups are referred to as ‘clinical 
remission’, ‘clinically active’ and ‘severely active’ below. 
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Haemoglobin was significantly lower in severely active CD patients compared 
to those in clinical remission (p = 0.04). For UC patients, haemoglobin was 
significantly lower in severely active patients compared to clinical remission 
(p=0.0007) and clinically active disease (p=0.0006). WCC was significantly 
higher in severely active UC patients compared to clinical remission 
(p=0.0006) and clinically active disease (p=0.0006).  
 
CRP levels in severely active CD disease was significantly higher than those 
in clinical remission (p=0.0029). Severely active UC patients had significantly 
higher CRP values than those in clinical remission (p=0.039) and active 
disease (p<0.0001). CD and UC patients with severely active disease had 
significantly lower albumin levels than those in clinical remission (CD p=0.017, 
UC p<0.0001) and active disease (CD p=0.0029; UC p<0.0001). Platelets 
were higher in the UC severely active disease group compared to clinical 
remission (p=0.0057) and active ambulatory disease (0.0022)  
 
As per stratification, HBI was lower in CD patients with remission compared to 
clinically active disease ambulatory (p=0.0003) and severely active disease 
(p<0.0001) but not different between clinically active and severely active 
(hospitalised) groups. SCCAI was lower in UC patients with remission 
compared to clinically active disease ambulatory (p<0.0001) and severely 
active disease (p<0.0001) but not different between clinically active and 
severely active (hospitalised) groups. 
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2.3.3 Reproducibility of the mtDNA assay 
 
Duplicates measurement of mtDNA from plasma using COXIII primers were 
analysed on the same PCR plate. The coefficient of variation was calculated 
to be 7.7% (95% CI, 6.9%-8.6%). 
 
2.3.4 Plasma and serum mtDNA correlation 
 
mtDNA levels from paired serum and plasma samples (i.e. from the same 
patient at the same time) were compared in a subset of samples (n=114). 
There was a moderate correlation between plasma and serum mtDNA data for 
COXIII (Figure 2.3, Spearman’s r=0.46) and ND2 genes (Figure 2.4, 
Spearman’s r=0.52). 
 
Figure 2.3: Correlation between serum and plasma mtDNA levels for analysed 
samples using COXIII primers (r=0.46, p<0.0001). 




Figure 2.4: Correlation between serum and plasma mtDNA levels for analysed 
samples using ND2 primers (r=0.52, p<0.0001). 
 
Plasma was chosen as the sample for main analysis due to reasons discussed 
in detail in Section 2.4.1.1. In brief, most published studies (including the major 
studies in this area) examining the role of mtDNA in circulation use plasma, 
and there is a risk of post-sampling liberation of DAMPs with leukocyte rupture 
in serum processing.  
 
Herein, unless otherwise specified, mtDNA relates to levels detected in 
plasma. 
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2.3.5 Correlation between mtDNA genes in plasma 
 
qPCR was performed using 2 sets of primers flanking COXIII and ND2 genes 
of the mitochondrial genome. COXIII and ND2 data were highly correlated in 
















Figure 2.5:  Correlation between plasma mtDNA (copy/µL) for all samples 
using 2 different primers COXIII and ND2 (r=0.84, p=<0.0001). 
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Figure 2.6:  Correlation between serum mtDNA (copy/µL) for all samples using 
2 different primers COXIII and ND2 (r=0.93, p=<0.0001). 
 
COXIII amplification efficiency as assessed by qPCR analysis of serial 
dilutions of DNA is slightly higher than ND2 (95% vs 96.4%)(Dorward, 2014). 
Given the strong correlation between COXIII and ND2 genes, COXIII data was 
chosen for further analysis and is presented herein. 
 
  
2. Circulating mitochondrial DAMPs in IBD 71 
 
2.3.6 Higher circulating mtDNA plasma levels in CD 
and UC 
 
Overall, we found significantly higher levels of circulating cell-free plasma 
mtDNA in IBD (167.8 copies/µL [IQR 78.06-387.2]) compared to HC (64.6 
copies/µL [IQR 51.6-104]) (p=0.0002) and IBS (44.6 copies/µL [IQR 27.9-
134.7]) (p<0.0001). There was no difference between HC and IBS, and these 














Figure 2.7: Plasma mtDNA (copy/µL) in IBD, HC and IBS (n= 97, 20 and 20 
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Plasma mtDNA levels were significantly higher in both UC (172.3 copies/µL 
[IQR 74.4-393.2]) (p<0.0001) and CD (136.7 copies/µL [IQR 88.0-370.9]) 
(p<0.0001) compared to non-IBD controls (61.5 copies/µL [IQR 32.8-104]) 















Figure 2.8: Plasma mtDNA (copy/µL) in CD, UC and non-IBD (n= 30, 67 and 
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2.3.7 Mitochondrial N-formylated peptides increased 
in ASUC 
 
A screen for the free N-terminal hexapeptides of the thirteen-known 
mitochondrial encoded proteins (Appendix E) confirmed the presence of five 
N-formylated termini (fMMYALF, fMTPMRK, fMNPLAQ, fMNFALI and 
fMTMHTT) in acute severe UC plasma samples which were not detected in 
non-IBD controls. When quantified with synthetic standards, we found that the 
concentrations of each of these formylated peptides was significantly elevated 
(p<0.01) in acute severe UC (Individual values: Figure 2.9; Summary data: 
Figure 2.10). 
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Figure 2.9: Individual values of mitochondrial formylated peptide quantification 
in 5 UC (white bars) vs. 5 non-IBD controls (black bars) for fMMYALF, 
fMTPMRK, fMNPLAQ, fMNFALI and fMTMHTT). 
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Figure 2.10: Summary data of mitochondrial formylated peptide quantification 
in 5 UC vs. 5 non-IBD controls (*p=<0.01 for fMMYALF, fMTPMRK, fMNPLAQ, 
fMNFALI and fMTMHTT). Mean ± SEM. 
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2.3.8 Summary of results 
 
• The study prospectively recruited 97 IBD patients (67 UC and 30 CD) 
and 40 non-IBD controls (20 HC and 20 IBS).  
 
• We have for the first time shown that:  
 
o mtDNA is elevated in the circulation of patients with IBD (in both 
CD and UC) when compared to non-IBD controls.  
 
o N-formylated peptides (a second mitochondrial DAMP) is 
elevated in patients with ASUC compared to controls.  
 
• We found a strong correlation between two mitochondrial specific genes 
(ND2 and COXIII) in mtDNA quantification 
 









2.4.1 Sample type, processing and quantification of 
mtDNA  
 
2.4.1.1 Plasma or serum 
Most published studies in inflammatory diseases have used plasma for 
quantification of circulating mtDNA. In 2003, a sentinel report suggested a 
standardised quantification method of circulating mtDNA using plasma (Chiu 
et al., 2003). Serum DNA concentration has been reported as 3 to 24 fold 
higher compared to plasma (Lo et al., 1998; Lee et al., 2001; Lui et al., 2002; 
Zhong et al., 2007). One study reported circulating cell free nuclear DNA as 
being even up to 45 times as high in serum than in plasma (Xia et al., 2009), 
and mtDNA being 12 fold higher. The higher levels of DNA in serum compared 
to plasma is likely due to the release of intracellular DNA in the process of 
fragile cell lysis from clotting (Lee et al., 2001; Thijssen et al., 2002). For this 
reason, many have suggested that plasma better reflects in vivo levels of 
circulating cell free DNA.  
 
Serum samples appear to produce more variable DNA quantification results 
compared to plasma (Boddy et al., 2005). One contributing factor is likely to 
be that plasma is less affected by delays in processing than serum. DNA 
concentrations in serum samples were 2.3 fold higher than plasma when 
processed immediately compared to between 3.8 to 4.8 fold higher when 
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stored for 2-8 hours at room temperature and 3 fold higher when stored for 24 
hours at 4oC (Jung and Klotzek, 2003). 
 
Umetani et al. examined this issue in more detail with a study comparing serum 
and plasma DNA levels in patients with various cancers (Umetani, Hiramatsu 
and Hoon, 2006). The authors found serum had six-fold higher circulating DNA 
levels compared to plasma in the same patients and the amount of DNA in 
paired serum and plasma specimens was positively correlated (r=0.72, 
p=0.0002). It seems likely that both leukocyte cell lysis during serum 
separation and the unequal distribution of DNA during separation from whole 
blood contribute to the higher levels of DNA detected in serum compared to 
plasma although the precise relative contributions remain unclear (Umetani, 
Hiramatsu and Hoon, 2006). Furthermore, it is possible that different patient 
populations and diseases may influence how well circulating DNA correlates 
between serum and plasma.  
 
Given the large differences in size and structure of nuclear DNA to mtDNA (3 
billion base pairs compared to 16,569 base pairs; lack of introns and long 
noncoding sequences in mtDNA), it may be problematic assuming that the 
data presented above would apply to mtDNA. However, there is limited direct 
evidence relating to the differences in detected levels of mtDNA in serum and 
plasma. Lauring et al. noticed that in their healthy blood donors, mtDNA levels 
as determined by qPCR in the serum and plasma was similar, although this 
data was not presented (Lauring et al., 2012). Conversely, Zachariah et al. 
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performed an analysis of serum and plasma mtDNA levels in patients with 
ovarian cancer and found that although there was a difference between 
mtDNA in healthy controls / benign tumours compared to the ovarian cancer 
group in plasma, this difference was not evident in serum (Zachariah, Schmid 
and Buerki, 2008). The serum levels of mtDNA were significantly higher 
compared to plasma possibly due to release of cellular DNA during clotting.  
 
2.4.1.2 Delays in processing of plasma/serum samples  
Specific studies assessing the effect of delays in processing of samples on 
quantification of circulating mtDNA levels are lacking. Jung et al. found no 
effect in the concentration of DNA in plasma samples for up to 24 hours (Jung 
and Klotzek, 2003). However, DNA detected in serum samples were 
significantly higher (approximately double) if centrifugation was delayed for two 
hours at room temperature compared to if processing occurred immediately. 
Xue et al. more recently found that if processing was delayed by more than 
two hours post venipuncture, significantly higher levels of DNA were detected 
in plasma (4-25 hours) irrespective of whether samples were kept on ice or at 
room temperature prior to centrifugation (Xue et al., 2009). 
 
Irrespective of sample type, it is likely that extensive delays between 
venipuncture and centrifugation is associated with significant increases in the 
total DNA copy number detected. This effect is presumably due to leukocyte 
lysis and this effect appears to be more pronounced the longer the delay until 
centrifugation.  
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2.4.1.3 Centrifugation protocols for plasma 
The concentration of circulating nucleic acids in plasma varies based on the 
blood processing protocol used. mtDNA copy number after centrifugation at 
1,600g as detected by qPCR was found to be significantly higher compared to 
centrifugation at 1,600g followed by a further 16,000g spin (Chiu et al., 2003). 
MtDNA exists in plasma in both particle and non-particle associated forms 
(Chiu et al., 2003). After separation of plasma from whole blood using a slow 
speed spin, subsequent filtration or a high speed spin is required to remove 
particles, cell fragments and platelets to achieve ‘cell free plasma’ (Chiu et al., 
2001). The centrifugal force required for the high speed spin is unclear but 
common protocols in the literature include 5,000g, 9,600g and 16,000g (Chiu 
et al., 2001)(Zhang et al., 2010). 
 
Of the particles removed in high speed centrifugation, platelet associated 
mtDNA seem particularly important. Lauring et al. attempted to determine 
whether residual platelets in processed samples would lead to spurious 
mtDNA results (Lauring et al., 2012). From stored plasma (previously spun 
twice at 1,000g/10min), platelets were separated with a subsequent 
centrifugation at 3,000g for 5 minutes. Although there was a correlation 
between the mtDNA calculated in each sample (r = 0.46), there was 
significantly less mtDNA detected in the sample with the platelet depleting 
extra centrifugation step.  
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Other groups have also examined the effect of platelets on mtDNA 
quantification but in the context of either whole blood, peripheral blood 
mononuclear cell (PBMC) or buffy coat preparations. Urata et al. measured 
mtDNA before and after platelet depletion in PBMCs, concluding that platelet 
contamination indeed caused large overestimation of mtDNA (Urata et al., 
2008). In the same study, platelet depletion decreased variation of mtDNA 
copy number to about a half indicating that achieving platelet poor preparations 
is important for reproducible measurement. Similarly, other authors have also 
found platelets to be an important source of contamination (Banas, Kost and 
Goebel, 2004).  
 
2.4.1.4 DNA degradation 
There is evidence that DNA degrades over time even with storage at -80oC. 
One study estimated this at 30% per year (Sozzi et al., 2005) – both for plasma 
and extracted DNA samples – although this has not been specifically assessed 
in mtDNA. This impacts on comparison cohorts when using biobanks of patient 
samples that have been collected and processed for other purposes. 
 
2.4.1.5 Quantification method for mtDNA 
Review of the literature revealed significant discrepancies in the primer design 
and qPCR conditions. Work by Dr David Dorward at the MRC Centre of 
Inflammation Research (Edinburgh) in establishing optimised a mtDNA qPCR 
protocol was used as the basis of the qPCR methods in this thesis (Dorward, 
2014).  
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2.4.1.6 Recommendations for mtDNA quantification in DAMP 
research 
MtDNA acts as a DAMP after being liberated from cells during non-apoptotic 
cell death. The aim of quantifying mtDNA in the circulation in inflammatory 
disease is to quantify freely circulating levels at time of sampling. To achieve 
this, a rigorous protocol is necessary.  
 
Based on the literature review, I have formulated the following 
recommendations for any research aiming to quantify mtDNA in the circulation 
in the context of its role as a DAMP: 
• Process samples expediently (within two hours) of venepuncture. 
• Preferentially use plasma over serum due to variability in serum mtDNA; 
quantification and potential leucocyte lysis (which may erroneously 
increase the DAMPs detected); 
• Achieve ‘cell free plasma’ through a two-stage centrifugation process with 
a second, high speed spin to eliminate cellular debris and particulate 
associated mtDNA; 
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2.4.2 Prospective cohort  
 
2.4.2.1 Decision to recruit prospectively 
The initial plan for this thesis was to perform an analysis of previously 
biobanked serum to test the hypothesis that mtDNA was raised in the 
circulation of patients with IBD. I made initial enquiries as to the availability of 
such IBD ‘biobanked’ samples for this work, which revealed that a large 
number of (mainly) serum samples had been stored over the last decade and 
potentially available for such an analysis.  
 
However, as detailed in the previous section (Section 2.4.1), a literature review 
into this area strongly suggested that precise methodology was critical for 
accurate mtDNA analysis. Unfortunately, most stored patient samples in 
available IBD biobanks had large variations in sampling date, sample type and 
processing with variable documentation available. Furthermore, it became 
apparent that for any potential assessment of mtDNA as a biomarker of IBD 
disease activity or prognosis, a well characterised cohort would be required.  
 
Several challenges were identified in the use of biobanked samples. In brief: 
• Most biobank samples available were of serum, rather than plasma; 
• Most plasma sampled did not undergo a second, high speed centrifugation 
spin (see Section 2.4.1.3);  
• The timing (post-venepuncture) and method of centrifugation varied 
considerably between samples; 
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• There was a variable lack of documentation and paired clinical/ 
biochemical information; 
• Many available samples were collected many years previously (see 
Section 2.4.1.4) 
 
In summary, it appeared from initial investigation that use of biobanked 
samples were inadequate to accurately test the primary hypothesis of this 
thesis. Therefore, a prospective study was designed with consistent and 
validated sampling and processing methodology.  
 
2.4.2.2 Evolution of the prospective cohort 
Initially, patients were recruited from inpatient and outpatient services with a 
range of disease activity levels. However, early data suggested that higher 
mtDNA levels were present in patients with active disease compared to IBD in 
remission. This shifted the focus of the recruitment strategy to patients with 
active disease, to help with assessment of the potential role of mtDNA as a 
novel biomarker. 
 
2.4.2.3 Limitations of the recruited cohort 
Although prospectively recruited patients provided the study with significant 
strengths, including a strictly enforced and consistent protocol and a well 
characterised cohort, there are limitations that must be acknowledged.  
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The patients were recruited from a single-centre (Western General Hospital, 
Edinburgh). Inherent in a single-centre strategy is the potential for recruitment 
bias. After adjustment for sample size, single-centre studies tend to show 
larger treatment effects on survival than do multicenter trials (Dechartres et al., 
2011). This may be particularly relevant with the shift in focus in this study from 
IBD towards ‘active IBD’. Indeed, far more UC patients (and in particular 
ASUC) were recruited compared to CD. This was largely a result of 
accessibility of ward based hospitalised patients for recruitment. Notification of 
potential participants was generally from clinicians and nursing staff on the 
wards, which also contributed to significantly more patients with severe 
disease being recruited than initially anticipated.  
 
However, this bias towards more severely active disease may also have been 
influenced by the overwhelming inflammatory response seen in ASUC (i.e. 
these patients would be the lowest hanging fruits for high mtDNA levels). 
However, given the exploratory nature of this research and funding restrictions, 
this was felt to be an appropriate methodology. It is clear that any findings from 
this exploratory study will require validation in further cohorts.  
 
Although attempts were made to age and sex match controls with IBD patients, 
this was limited by the pool of controls available for recruitment. Despite this 
lack of strict age/sex matching, there was no significant differences between 
the recruited cohorts in terms of demographics. 
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Given the relatively small number of patients recruited, there is potential for 
type II error in some of the subgroup analysis performed. In particular, only 30 
patients were recruited to the CD cohort. This could lead to type II error 
especially with assessing mtDNA as a biomarker with subgroup disease 
activity analysis (Chapter 3).  
 
2.4.3 Reproducibility of the mtDNA assay 
 
There are various statistical methods that can be used to determine a test’s 
test-retest reliability (“reproducibility”). Correlation coefficients can provide an 
indication of relative reliability, and are a reflection of the way in which two sets 
of observations follow a straight line (of best fit). However, the main drawback 
of correlation tests in assessing for repeatability is that it does not provide any 
insight into systematic errors that may be present. In this way, a high level of 
correlation may have a marked divergence from the line of complete 
agreement. Correlation of variation also provides an assessment of relative 
reliability and assesses the extent of variability in relation to the mean. In the 
context of duplicate measurements, it provides an indication of the precision 
or repeatability of a test. 
 
In this study, intra assay coefficient of variation (CV) was 7.7% for mtDNA 
quantification. This intraassay CV compares favourably to some published 
studies for mitochondrial DNA quantification of 11.3% (Gahan et al., 2001) and 
13.0% (Bhat et al., 2004) and unfavourably with other studies of 1% (Gourlain 
et al., 2003) and 3.3% (Xia et al., 2009). The differences in the reported intra 
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assay CV rates could be partly explained by the different blood fractions and 
PCR primers used in the above studies. Collectively, the data suggests good 
reproducibility of qPCR for mitochondrial DNA quantification. 
 
Data for inter assay reproducibility was not available in this study. Reported 
inter assay CV rates in the literature for mitochondrial DNA quantification vary 
between 5.5% and 30% (Gourlain et al., 2003; Kavlik et al., 2011; Bhat et al., 
2004). 
 
There are numerous other statistical methods that may be used to assess 
agreement between two sets of data, including visualisation via a Bland-
Altman plot (Bland and Altman, 1986). A Bland-Altman plot is generally used 
to compare two measurement techniques and plots the absolute difference 
between the different tests on the vertical axis around the mean difference. It 
can help detect systemic bias and provide limits where 95% of the differences 
are expected to lie between limits (if the data points are normally distributed). 
 
2.4.4 Variability in healthy control mtDNA levels 
 
There was a notable variability in the mtDNA levels of healthy controls in this 
study (median 64.6 copies/µL, range 13.7 - 205.2, IQR 51.6 - 104). There are 
a number of possible explanations for this variability. Firstly, variation in 
measurable levels of biomarkers is expected in healthy individuals. For 
example, the 2.5th, 50th and 97.5th percentile values for CRP was found to be 
0.08, 0.64 and 3.11 in healthy donor population with a nongaussian distribution 
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(Macy et al., 1997).  In addition, ageing and exercise may influence circulating 
cell free mtDNA levels. MtDNA levels were found to be higher in levels of older 
(Pinti et al., 2014) and correlated with ‘frailty’ scores (Jylhävä et al., 2013). 
However, another study found no association between plasma mtDNA levels 
and age (Verschoor et al., 2015). Exercise has been associated with lower 
circulating mtDNA levels (Shockett et al., 2016), and lower levels have been 
found in professional sportspeople compared to nonathlete controls (Nasi et 
al., 2015). In addition, other conditions not classically associated with 
inflammation such as depression have been found to have been associated 
with higher mitochondrial DNA levels (Lindqvist et al., 2018) (Kageyama et al., 
2018). There was no association with age or gender and mtDNA in healthy 
controls in this study, although the numbers were small.  
 
Large, population-based studies are required to determine the distribution of 
mitochondrial DNA levels in the healthy population. This will help identify 
‘normal’ ranges and ‘abnormal’ levels as well as determine whether the 
distribution is gaussian. 
 
2.4.5 Correlation between serum and plasma mtDNA 
levels  
 
As discussed earlier (Section 2.4.1.1), the two main blood fractions used for 
circulating mtDNA quantification are plasma and serum. Most studies in 
inflammation research have used plasma, due to the theoretical risk for serum 
of intracellular DAMPs (including mtDNA) being released during clotting. 
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However, only a few studies have examined the correlation between plasma 
and serum in matched samples. In addition, I am not aware of any published 
data comparing matched plasma vs. serum for mtDNA quantification (as 
opposed to nuclear DNA). Given both plasma and serum were collected for 
participants, we performed comparative matched analysis. 
 
We found a modest positive correlation between paired plasma and serum 
samples for mtDNA genes COXIII (r = 0.46) and ND2 (r = 0.52). These findings 
are in keeping with the existing literature for quantification of nuclear DNA 
(Boddy et al., 2005; Umetani, Hiramatsu and Hoon, 2006; Zanetti-Dallenbach 
et al., 2008). Umateni et al. found a positive correlation between qPCR 
detected DNA in serum and plasma (n=24, r=0.72, p=0.0002) (Umetani, 
Hiramatsu and Hoon, 2006). Zanetti-Dallenbach et al. found a positive 
correlation (n=107, r=0.54, p=0.01) for DNA in serum and plasma in healthy 
control, and benign and malignant breast cancer participants. Boddy et al. 
found a positive correlation for DNA between two-spin plasma and serum 
samples in patients with malignant and benign prostatic disease (n=40, r = 
0.56, p < 0.001). 
 
The stronger correlation seen in Umetani et al. compared to results in this 
study could be due to various factors. Firstly, the number of paired samples 
assessed was larger in our sample (n=114). Secondly, processing protocols 
differed significantly with our protocol (and with those of the other two studies 
mentioned above) with no second high speed spin being performed for plasma 
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samples; instead, a 13mm filter for both serum and plasma was used. Thirdly, 
our data reflected mtDNA gene amplification whereas Umetani et al. amplified 
nuclear DNA using a primer set designed to produce an amplicon size of 
115bp.  
 
This is the largest correlative comparison (n=114) that I am aware of 
comparing DNA as quantified by qPCR in cell-free plasma vs. serum. 
Furthermore, this is the first comparative analysis of mtDNA as quantified by 
qPCR in cell-free plasma vs. serum. 
 
2.4.6 Mitochondrial DAMPs are elevated in IBD 
 
2.4.6.1 Major findings 
Recently, mtDNA as detected by qPCR was recently reported by our group to 
be higher in the plasma of mice with chemical induced colitis compared to 
those without colitis (Ho et al., 2018). In this thesis, I present data to show for 
the first time that significantly increased levels of mtDNA are found in active 
human IBD. This applies to both UC and CD when compared to non-IBD 
controls. 
 
I corroborated these findings with a second known mitochondrial DAMP, by 
demonstrating the presence of N-formylated peptides arising from the 
mitochondria in the plasma of patients with active UC. Of the mitochondrial N-
formylated peptides detected, fMMYALF was the most abundant. This is highly 
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relevant as fMMYALF is the most biological active mitochondrial N-formylated 
peptide (Rabiet, Huet and Boulay, 2005).  
 
2.4.6.2 Practical considerations 
The supportive N-formylated peptide data was exploratory in nature and 
performed in only a small subset of patients (n=5 ASUC and n=5 HC). Funding 
and time restrictions prevented further investigation of the role of N-formylated 
peptides in IBD. However, given the biological associations between N-
formylated peptides and mtDNA, this data provides valuable support to the 
hypothesis that mitochondrial DAMPs are released during inflammation in IBD. 
In the future, we seek to perform similar measurements in a larger cohort of 
IBD patients including CD and mild-moderate UC.  
 
An additional limitation to our data is that we have not studied mtDNA in non-
IBD intestinal inflammatory conditions such as infectious colitis or diverticulitis. 
It is conceivable that high mtDNA release is also present in these conditions, 
and further investigation is warranted.  
 
2.4.6.3 MtDNA levels in inflammatory disease 
Circulating mtDNA levels have been found to be elevated in several other 
inflammatory conditions (summarised in Section 1.3.5). Here, I put the findings 
of raised circulating mtDNA levels in IBD into the wider context of inflammatory 
disease.  
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Systemic inflammatory response syndrome (SIRS) 
SIRS is a serious condition associated with high mortality where affected 
individuals display progressive signs or symptoms of systemic upset reflecting 
widespread inflammation, often involving multiple organ dysfunction and 
failure (e.g. lungs, kidneys, brain). SIRS is often a result of major sepsis but 
also commonly occurs in the context of injury such as trauma. An early study 
by Lam et al. found that individuals admitted for blunt traumatic injury had 
increased plasma nuclear DNA and mtDNA levels (Lam et al., 2004). 
Subsequently, Hauser and colleagues made the seminal observation that it is 
the freely circulating mtDNA following traumatic injury which possess the 
distinct ability to trigger and drive the clinical manifestation of SIRS (Zhang et 
al., 2010). Several studies have now confirmed the observation of elevated 
plasma mtDNA in trauma and SIRS (Nicole Y.L. Lam, Timothy H. Rainer, 
Rossa W.K. Chiu and Lo, 2004; Hauser et al., 2010; Zhang, Itagaki and 
Hauser, 2010; Gu et al., 2013; Hsu et al., 2013; Simmons et al., 2013; 
Prikhodko et al., 2015; Timmermans et al., 2016).  
 
In sepsis, elevated levels of circulating mtDNA have also been found in 
multiple studies (Lu et al., 2010; Garrabou et al., 2012; Kung et al., 2012; Hsu 
et al., 2013; Bhagirath, Dwivedi and Liaw, 2015; Di Caro et al., 2015; 
Timmermans et al., 2015). The one negative study in sepsis may be explained 
by numerous factors including a relatively well patient cohort, only one ‘spot’ 
measurement being taken at presentation and the potentially confounding 
factor of cellular content/debris (Puskarich et al., 2012). 
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Acute single organ injury: Liver, heart and brain 
High levels of mtDNA are present in the serum and plasma of patients with 
acute injury to a variety of single organs. Acetaminophen overdose induces 
massive hepatocyte necrosis and in severe cases can lead to multi-organ 
failure and remains one of the commonest indications for liver transplantation. 
Drug induced acute liver failure patients had serum mtDNA levels of up to 
10,000 fold higher (Marques et al., 2012) than healthy controls. Serum mtDNA 
of acetaminophen overdose patients with derangement in the liver enzyme 
alanine aminotransferase (a marker of hepatocyte damage) is significantly 
higher than overdose patients who had normal liver enzymes (McGill et al., 
2012), suggesting the extent of mtDNA release into the circulation depends on 
the extent of hepatocyte necrosis.  
 
Similarly, extensive cardiomyocyte necrosis is found in acute myocardial 
infarction which is also associated with elevated mtDNA in multiple studies 
(Bliksøen et al., 2012; L. L. L. Wang et al., 2015; Qin et al., 2016) and fall after 
angioplasty or coronary stent insertion to restore blood flow to the damaged 
myocardium (Bliksøen et al., 2012; L. L. L. Wang et al., 2015). Patients with 
diabetes mellitus and coronary artery disease have higher mtDNA levels than 
those with diabetes but without coronary artery disease (J. Liu et al., 2015). 
MtDNA is also higher in acute cerebral ischaemia, caused by a reduction in 
cerebral blood flow by embolus or local thrombosis, and plasma levels 
gradually drop over time after the initial tissue injury (Lakra et al., 2011). 
Interestingly, studies by the same group relating to plasma mtDNA in 
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subarachnoid haemorrhage and spontaneous intracerebral haemorrhage 
found no significant difference compared to healthy controls, although both 
were small studies (Wang et al., 2012, 2013).  
 
Overall in these conditions, significant mtDNA release following massive tissue 
or cellular injury is evident and likely contributes to the uncontrolled 
inflammatory response.  
 
Chronic inflammatory and immune-mediated diseases 
Distinct to conditions relating to injury, the role for mtDNA in immune-mediated 
inflammatory diseases is now also emerging. In rheumatoid arthritis, a chronic 
relapsing autoimmune condition affecting the joints, mtDNA was present in the 
plasma and synovial fluid of most patients but undetectable in healthy controls 
(Hajizadeh et al., 2003). Similarly, higher plasma mtDNA is found in 
granulomatosis with polyangiitis, an autoimmune disease whose features 
include necrotizing granulomatous inflammation and vasculitis (Surmiak et al., 
2015).  
 
Systemic lupus erythematosus (SLE) is a multi-organ autoimmune disease in 
which hallmarks include excessive type I interferon (IFN) and antibodies 
against nucleic acids. Caielli et al. explored the potential pathogenic 
importance of oxidised mtDNA in SLE. They showed that there is a defect in 
mitochondrial clearance which leads to abnormal extrusion of oxidised mtDNA 
which triggers subsequent interferogenic response (Caielli et al., 2016).  
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Higher levels of mtDNA have been found in the chronic inflammatory states of 
HIV (although not in all studies), end-stage renal failure and diabetes mellitus 
(Table 1.8). In obese individuals with steatohepatitis, mitochondria enclosed in 
microparticles can also be detected in plasma (Garcia-Martinez et al., 2016). 
These findings suggest that mtDNA, otherwise a ‘self-signal’, may be an active 
component in the aberrant immune or inflammatory response in chronic 
diseases and in autoimmunity. 
 
2.4.6.4 Other DAMPs raised in IBD 
In IBD, the chronic non-resolving and extensively inflamed gut mucosa 
represents an enriched source of local and systemic DAMPs (Figure 2.8). 
Unsurprisingly, several other DAMPs are found in abundance during active 
disease in IBD including the S100A calgranulins (S100A8/9 complex or 
calgranulin A/B or MRP8/14 or calprotectin; and S100A12), HMGB1 and 
interleukin-1α/33 (IL-1α and IL-33). The latter group DAMPs are regarded as 
‘alarmins’ (Garlanda, Dinarello and Mantovani, 2013), molecules that possess 
cytokine-like functions which are stored in cells and released upon 
uncontrolled cell death.  
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Figure 2.11: Contribution of DAMPs to inflammatory response in IBD. In 
health, intestinal epithelial cells undergo constant shedding and apoptosis. 
Tissue damage releases danger signals which initiates a protective 
inflammatory response to restore tissue homeostasis. In IBD, non-apoptotic 
cell death, mucosal oxidative stress and deregulation of homeostatic pathways 
lead to overwhelming release of DAMPs creating a pro-inflammatory milieu. 
These DAMPs lead to an inflammatory response through a variety of pathways 
leading to further tissue damage and ongoing intestinal epithelial cell death. 
(Boyapati, Rossi, et al., 2016) 
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A comprehensive list of DAMPs implicated in IBD and experimental colitis is 
provided in Table 2.3 although it is noteworthy that many DAMPs have yet to 
be studied in the context of intestinal inflammation (for references, please see 
(Boyapati, Rossi, et al., 2016)).  
 
DAMP/Alarmin Main source 
S100A8/S100A9 Neutrophils, monocytes, epithelium 
S100A12 Neutrophils 
HMGB1 Predominantly macrophages and monocytes but 
also NK cells, DC, neutrophils, eosinophils and 
platelets 
IL-1α Neutrophils, macrophages, IECs  
IL-33 Initially via stressed IECs and later via lamina 
propria cells  
Lactoferrin Neutrophils, brush border cells, macrophages, 
monocytes, lymphocytes 
Heat shock proteins 
(HSPs) ** 
Wide variety of cell types 
Tenascin-C  Wide variety of cell types 
Hyaluronan Wide variety of cell types 
Galectins Wide variety of cell types 
ATP Wide variety of cell types 
** It is controversial as to whether heat shock proteins are DAMPs 
Table 2.3: DAMPs implicated in IBD and experimental models of colitis 
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The findings of this chapter support the idea that in addition to the DAMPs 
discussed above, mitochondrial DAMPs are also released into the circulation 
in IBD. The likely source of mitochondrial DAMPs in IBD is the inflamed gut 
mucosa where cellular stress and death occur. However, the mechanisms 
relating to DAMP release in IBD are complex and warrant further discussion. 
The next section deals with the mechanisms regulating DAMP activity and 
clearance that are relevant to IBD.  
 
2.4.7 Implications of findings 
 
In this chapter, I have provided the first evidence to show that mitochondrial 
DAMPs (in particular mtDNA) is released into the circulation in active IBD and 
that higher levels are associated with more severe disease. I hypothesise that 
mtDNA is an important pathogenic trigger that maintains the state of abnormal 
mucosal inflammation. IBD-specific factors which support this hypothesis 
related to DAMP activity and release are discussed below.  
 
2.4.7.1 The manner of cell death affects DAMP release 
Current evidence suggests the load and composition of DAMPs may 
determine whether their effects become pathogenic, hence re-emphasizing the 
delicate balance between the protective and pathologic roles of DAMPs. Here, 
I review the factors that may influence this balance in the context of IBD. 
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In health, the intestinal epithelium is replaced every 5-7 days; epithelial cells 
are either shed or die by apoptosis. In active IBD, non-apoptotic cell death (e.g. 
epithelial necrosis) occurs more commonly (Gunther et al., 2012).  More 
recently, necroptosis or programmed necrosis is increasingly appreciated as 
an alternative mechanism (Kaczmarek, Vandenabeele and Krysko, 2013) 
which appears to contribute to intestinal inflammation similar to that found in 
IBD (Günther et al., 2011; Welz et al., 2011).  
 
Of interest, relevant KO mouse models and some limited evidence in human 
studies suggest a role for necroptosis in IBD although it remains possible that 
these clinical phenotypes are primarily driven by loss of barrier and specialised 
enterocyte function (Paneth cells in this case) rather than mucosal DAMP 
release  (Boyapati, Rossi, et al., 2016). Necroptosis lacks the massive caspase 
activation seen in apoptosis and this leads to comparative DAMP activation. 
For example, the lack of caspase-activated deoxyribonuclease (DNase) 
means DNA is not cleaved, leading to higher molecular weight DNA with 
greater proinflammatory potential (Martin, Henry and Cullen, 2012).  
 
Similarly, full length IL-33 is released in necroptosis compared to the non-
immunological IL-33 in apoptosis which is due to caspase-dependent 
proteolysis (Lüthi et al., 2009). HMGB1 is oxidised into its non-immunological 
form during apoptosis by caspase mediated reactive oxygen species (ROS) 
with irreversible binding to chromatin, but this does not occur in necroptosis 
(Taylor, Cullen and Martin, 2008). The DAMP-necroptosis link has been 
2. Circulating mitochondrial DAMPs in IBD 100 
 
illustrated in several experimental models of necroptosis in skin, brain and 
systemic inflammation, which have shown higher levels of various DAMPs 
such as S100A9, IL-33, mtDNA and HMGB1 (Kaczmarek, Vandenabeele and 
Krysko, 2013).  
 
2.4.7.2 The influence of the mucosal milieu on the 
inflammatory pathogenicity of DAMPs 
Increased mucosal oxidative stress is another key feature of active IBD, which 
can enhance the pro-inflammatory effects of DAMPs. An oxidative milieu 
modifies various proteins and lipids such as cholesteryl ester hydroperoxides 
and oxidised phospholipids, activating their role as potent DAMPs causing 
further inflammation (Imai et al., 2008; Choi et al., 2009). Oxidised mtDNA also 
becomes significantly more inflammatogenic. Shimada et al. found that 
cytosolic oxidised mtDNA rather than its non-oxidised form, directly activates 
the NLRP3 inflammasome and IL-1β production (Shimada et al., 2012). 
Pazmandi et al. further showed the increased immunogenicity of oxidatively 
modified mtDNA on plasmacytoid dendritic cells compared to native mtDNA 
(Pazmandi et al., 2014).  
 
2.4.7.3 De-regulation of mucosal homeostatic pathways 
‘prime’ the inflammatory potential of DAMPs 
Defective autophagy and the unfolded protein response (UPR) regulating ER 
stress are important in the pathogenesis of IBD (Kaser et al., 2008). A meta-
analysis of GWAS has identified the autophagy genes ATG16L1 and IRGM as 
key susceptibility genes particularly in CD (Jostins et al., 2012). ER stress 
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related genes have been implicated in IBD by GWAS (ORMDL3) and 
candidate gene approaches (XBP1 and AGR2) (Zheng et al., 2006; Kaser et 
al., 2008). The importance of autophagy in endogenous DAMP-mediated 
inflammation is increasingly appreciated although its role in the clearance of 
intracellular pathogens (“xenophagy”) is established. 
 
From a DAMP perspective, failure to clear proinflammatory damaged 
mitochondria is a key consequence of defective autophagy and may contribute 
to enrichment of cells with DAMPs, priming them to be released into the 
circulation. Dysfunctional, ROS-generating mitochondria (Zhou et al., 2011) 
and specifically oxidised mtDNA (Shimada et al., 2012) can activate the 
NLRP3 inflammasome. Other DAMPs such as ECM components biglycan and 
hyaluronic acid can additionally prime inflammasome activation in this context 
(Iyer et al., 2009).  Nakahira et al. showed that defective autophagy promotes 
the accumulation of mitochondrial DAMPs and NLRP3 inflammasome 
activation (Nakahira et al., 2011). Indeed, in ATG16L1-deficiency there is an 
increased susceptibility to inflammasome mediated release of IL-1β and IL-18 
(Saitoh et al., 2008).   
 
A further study showed that defective autophagy can lead to the release of 
DAMPs and subsequently contribute directly to inflammatory pathology in vivo 
(Oka et al., 2012). Here, Oka et al. showed that mice deficient in DNase leaked 
mtDNA and developed a TLR9 mediated proinflammatory state, 
cardiomyopathy and heart failure (Oka et al., 2012). These studies point to a 
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failure in autophagy resulting in a higher load of inflammatory intracellular 
DAMPs. It is noteworthy that in vivo mouse models of ATG16L1 deficiency 
(chimeric, hypomorphic, human IBD ATG16L1 polymorphism T300A knock-in 
and epithelial specific ATG16L1-deficiency) do not develop spontaneous colitis 
but are very susceptible to gut inflammation when subjected additional 
injurious stimuli (dextran sulfate sodium [DSS], murine norovirus or genetic 
deficiency of ER-stress) (Boyapati, Rossi, et al., 2016) . Hence, a postulated 
potentiating rather than initiating role in gut inflammation.  
 
2.4.5.4  Summary 
In the setting of overwhelming DAMP release in IBD, the inflammatory milieu 
may tip the balance from a protective to pathological inflammatory state. 
Furthermore, the local mucosal inflammatory state may help prime DAMPs 
such as mtDNA to become more inflammatogenic.  
 
It is important to emphasise that the observation of elevated circulating mtDNA 
levels in patients with IBD does not in itself imply any mechanistic effects of 
mtDNA in IBD. Raised mitochondrial DAMPs may be a hallmark of 
inflammation associated with IBD or alternatively, it may be an important factor 
in perpetuating inflammation in IBD. The IBD-related factors associated with 
the higher potential inflammatory effect of DAMPs (as discussed above) 
supports mtDNA as an active player, but substantial further investigation 
(discussed in Chapter 5).  
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Many inflammatory conditions are associated with raised levels of mtDNA, 
suggesting that release is unlikely to be disease-specific. However, this lack of 
disease-specificity does not preclude a potentially important role for mtDNA in 
propagating inflammation associated with IBD. Separate from the mechanistic 
discussion is the potential role of mtDNA as a biomarker. It is notable that the 
main clinically useful biomarkers in IBD (faecal calprotectin, CRP and albumin) 
are not specific for IBD-related inflammation. The next chapter deals with the 
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Biomarkers (‘biological markers’) are substances, structures or processes that 
are able to be measured objectively, accurately and reproducibly influencing 
or predicting the incidence of outcomes or diseases (Strimbu and Tavel, 2010). 
Biomarkers have a particularly important role in IBD, where disease 
heterogeneity and complexity renders clinical markers limited in the ability to 
predict intestinal inflammation and long-term outcomes (Lichtenstein and 
McGovern, 2016). 
 
IBD clinicians currently rely on a few clinically useful biomarkers including 
ESR, CRP, albumin and faecal calprotectin (Section 1.1.4). However, definitive 
assessment of mucosal healing (the best predictor of long-term outcome) 
generally requires invasive and expensive investigations (including 
endoscopy, radiology and histology) to classify, assess disease activity, 
monitor response to therapy and provide prognostic information.  
 
Currently available IBD biomarkers suffer from many limitations. Blood-based 
biomarkers such as ESR, CRP and albumin are acute phase reactants which 
are raised in many inflammatory states; in contrast, faecal calprotectin is not 
affected by extra-intestinal inflammation and thus is more specific (Gisbert and 
McNicholl, 2009). However, faecal calprotectin is reflective of gut inflammation, 
is not disease-specific and is raised in several non-IBD gut inflammatory states 
such as nonsteroidal anti-inflammatory drug (NSAID) enteropathy and 
infectious gastroenteritis. Furthermore, there are issues with faecal 
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calprotectin around sampling difficulty and high intraday variability in some 
patients (Lasson et al., 2015). Therefore, there is a clear need for novel non-
invasive biomarkers in IBD to help in clinical decision making.  
 
Beyond this, IBD clinicians yearn for a time when biomarkers will allow for 
treatment decisions in a ‘personalised’ or ‘precision’ medicine approach 
(Boyapati, Kalla, et al., 2016). This will involve large scale prospective cohorts 
and patient inputted data leveraging big-data driven approaches. However, 
discovery-based approaches are currently burdened by significant challenges, 
and hypothesis/biology-based biomarkers have had the most success so far 
in IBD. Thus, there remains an important role in biomarker discovery for 
organic scientific thinking.  
 
After establishing that mtDNA was elevated in patients with IBD, we wanted to 
assess its potential as a biomarker. Specifically, we aimed to assess the value 








3.2.1 Prospective study & mtDNA quantification 
 
Methods are as described in Chapter 2 (Section 2.2) for the prospective study 
and mtDNA quantification. 
 
3.2.2 Endoscopic disease activity stratification 
 
Endoscopic disease severity was obtained from endoscopic reports generated 
by the gastroenterologist in charge of patients at time of sample collection. 
Endoscopy assessment was considered appropriate for inclusion if it was 
performed within 72 hours of a sample. 
 
Only patients with UC were considered for inclusion in this analysis. CD can 
affect any part of the gastrointestinal tract from mouth to anus, which means 
that areas of inflammation may not be reachable via colonoscope (e.g. in the 
proximal small bowel). Furthermore, a normal colonoscopy does not 
necessary imply the absence of gut inflammation in CD. In contrast, UC affects 
the colon in a distal-to-proximal distribution, leading to a more robust 
understanding of the current level of gut inflammation from colonoscopy.  
 
Disease activity was classified as ‘mild’, ‘moderate’ and ‘severe’ disease as 
per the endoscopic reports. In UC, ‘mild’, ‘moderate’ and ‘severe’ relate to the 
most widely used endoscopic scoring system in clinical practice (Mayo score, 
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Appendix F). Representative pictures of mild, moderate and severe 
endoscopic appearance are presented in Section 1.1.3.5 (Figure 1.2). If 
categorisation was unclear from the endoscopy report, the gastroenterologist 
who performed the procedure was consulted. 
 
3.2.3 Colectomy data 
 
Patients with ASUC were followed to determine whether they had undergone 
colectomy. If it was unclear from clinical notes whether a patient had 
undergone colectomy by the end of the study period, attempts were made to 
contact the patient for this information. 
 
For patients who underwent colectomy, attempts were made to repeat 
sampling to compare pre- and post-colectomy mtDNA levels. If multiple 
samples were taken during admission for these patients, the first sample was 
considered as the ‘pre-colectomy’ sample. Patients who were unable or 
declined to be resampled were considered lost to follow-up. 
 
3.2.4 Serum Calprotectin 
 
ELISA for quantification of calprotectin in the serum was performed by Dr 
Rahul Kalla using a protocol as previously outlined (Kalla et al., 2016). The 
methods are reproduced here with permission. 
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Samples were analysed in duplicate using the Calpro AS™ calprotectin ELISA. 
Prior to each 96 well run, 100µL of serum was first diluted (1:5) using a dilution 
buffer. 100µL of the diluted sample was then transferred onto 96 well plate 
coated with 3% bovine serum albumin (BSA).  
 
A total of 100µL of standards, positive and negative controls and samples were 
plated in duplicates and all plates contained wells with blanks (no template 
control).  This layout was then transferred onto the ELISA plate using a 
repetitive multichannel pipette and incubated for 45 minutes on a horizontal 
plate shaker. At the end of incubation, the liquid was discarded and 3 wash 
cycles (300µL per well) were performed using an automated plate washer. 
100µL of enzyme conjugate was then added to each well using a multichannel 
pipette and the samples were incubated for 45 minutes on a horizontal plate 
shaker. A further 3-cycle wash step was performed followed by an enzyme 
substrate step (100µL per well) and incubation at room temperature for 30 
minutes, protected from light. After incubation, 1M NaOH was added to 
standardise the incubation period and the plate was read at an optical density 
(OD) 405nm using an ELISA reader.  
 
A 4-parameter standard curve was generated for each run and all standards 
and control OD were matched to the manufacturer recommended range. Any 
plate with standards and/or controls that were out of range were repeated. 
Samples with a calprotectin result of >2500 ng/mL were diluted and retested. 
Coefficients of variation of <10% were included in the analysis. 




3.3.1 Steroid use during ASUC 
 
All patients with ASUC were on intravenous steroids at some point during their 
admission. There were 81 samples taken from patients with ASUC in the study. 
3 samples were taken from patients who had been changed to oral 
prednisolone (all 40mg daily) at the time of sampling. Table 3.1 lists the 
number of samples taken categorised by the number of doses of intravenous 
steroid they had received prior to sampling. Patients with ASUC received twice 
daily dosing of 30mg of intravenous methylprednisolone. 
Doses of IV 
steroids received 















Table 3.1: Number of samples from patients with ASUC categorised into the 
number of doses of intravenous steroids prior to the sample being taken  
3. MtDNA as a biomarker in IBD  112 
 
3.3.2 mtDNA over the course of 5 days in ASUC 
 
I sought to investigate the change in mtDNA level over the course of an 
admission for ASUC. I identified five patients with ASUC for mtDNA 
measurement over five consecutive days post admission. Daily mtDNA, CRP 
and albumin levels for each patient (1-5) is presented below. 
 
 
Figure 3.1: Patient 1 mtDNA, CRP and albumin over 5 days patient admission 
with ASUC. 39-year-old female who made initial good clinical response to IV 
steroids but required colectomy on day 7. 
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Figure 3.2: Patient 2 mtDNA, CRP and albumin over 5 days patient admission 
with ASUC. 29-year-old male, responded to IV steroids. 
 
 
Figure 3.3: Patient 3 mtDNA, CRP and albumin over 5 days patient admission 
with ASUC. 29-year-old male, responded to IV steroids initially but required 
colectomy day 70 after subsequent relapse. 
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Figure 3.4: Patient 4 mtDNA, CRP and albumin over 5 days patient admission 
with ASUC. 35-year-old female, responded to IV steroids. 
 
 
Figure 3.5: Patient 5 mtDNA, CRP and albumin over 5 days patient admission 
with ASUC. 81-year-old female, CRP peak 59, responded to IV steroids 
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3.3.3 MtDNA as a marker of disease activity 
 
3.3.3.1 MtDNA levels stratified by clinical activity 
Ulcerative colitis 
In UC, patients were stratified using the SCCAI (Appendix A) as being in 
‘clinical remission’ or with active disease and the latter group further classified 
into ‘mild-moderate’ or ‘severe’ activity based on whether they met Truelove 
and Witts’ criteria for severe disease (Appendix A). 
 
Those in with severe disease had significantly higher circulating plasma 
mtDNA levels (234.7 copies/µL [115.3 – 723.4]) compared to those in clinical 
remission (53.77 copies/µL [IQR 30.56 – 86.8]; p<0.0001) and mild-moderate 
disease (98.52 copies/µL [IQR 62.23 – 205.2]; p=0.002) (Figure 3.6). 
 
Patients with clinically mild-moderate disease had significantly higher 
circulating plasma mtDNA levels compared to those in clinical remission (98.52 
copies/µL [IQR 62.23 – 205.2] vs. 53.77 copies/µL [IQR 30.56 – 86.8]; 
p=0.002). 
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Figure 3.6: Plasma mtDNA (copies/µL) in UC in clinical remission, active and 
severe active (n= 13, 18 and 44 samples respectively; 8 UC individuals had 
samples taken more than 1 time point during active disease and in remission). 
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Crohn’s disease 
In the smaller cohort of CD, patients were stratified using the HBI (Appendix 
A) as being in ‘clinical remission’ or ‘active’ and the latter group further 
classified into severely active if they required hospitalisation and intravenous 
steroids. 
 
Higher mtDNA levels were observed in those with severely active CD (159.1 
copies/µL [IQR 90.17-421]) compared to those in remission (79.92 copies/µL 
[IQR 30.94 – 145.9] (p=0.04) (Figure 3.7).  
 
There was no difference in circulating mtDNA between those categorised as 
mild-moderately active CD compared to those in clinical remission (179.9 
copies/µL [IQR 110.8 – 551.1] vs. 79.92 copies/µL [IQR 30.94 – 145.9]; 
p=0.06). There was no difference in circulating mtDNA between those 
categorised as severely active compared to the mild-moderately active group 
(159.1 copies/µL [IQR 90.17-421] vs. 179.9 copies/µL [IQR 110.8 – 551.1] 
(p=0.72) (Figure 3.7).  
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Figure 3.7: Plasma mtDNA (copies/µL) in CD, clinical remission, active and 
severe disease (n= 10, 5 and 16 samples respectively. One CD individual had 
samples taken more than 1 time point during active disease and in remission). 
Median ± IQR.  
 
  
3. MtDNA as a biomarker in IBD  119 
 
3.3.3.2 MtDNA levels stratified by endoscopic activity 
A total of 68 samples had endoscopy reports suitable for inclusion in this 
analysis. Patients with endoscopically moderate (199.5 copies/µL [IQR 109 – 
427.4]) and severe disease (255.4 copies/µL [96.71 – 641.4]) had significantly 
higher circulating mtDNA plasma levels in comparison to those with 
endoscopically mild disease (33.11 copies/µL [IQR 28.71 – 44.9] (p<0.0001 
and p=0.0002 respectively) (Figure 3.8). Patients with moderate and severe 















Figure 3.8: Circulating plasma mtDNA by endoscopic appearances in UC 
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3.3.4 Correlation with existing biomarkers in IBD 
 
3.3.4.1 CRP 
For our IBD cohort samples, mtDNA levels was positively correlated with CRP 
when mtDNA was quantified using COXIII (r=0.35, p<0.0001; Figure 3.9) and 












Figure 3.9: Spearman correlation between paired mtDNA plasma (copy/µL) 
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Figure 3.10: Spearman correlation between paired mtDNA plasma (copy/µL) 




For our IBD cohort samples, mtDNA levels was negatively correlated with 
albumin when mtDNA was quantified using COXIII (r=-0. 38, p<0.0001) 
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Figure 3.11: Spearman correlation between paired mtDNA plasma (copy/µL) 
as quantified by COXIII gene primers and albumin.  
 
 
Figure 3.12: Spearman correlation between paired mtDNA plasma (copy/µL) 
as quantified by ND2 gene primers and albumin.  
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3.3.4.3 White cell count 
For our IBD cohort samples, mtDNA levels was positively correlated with CRP 
when mtDNA was quantified using COXIII (r=0.36, p<0.0001; Figure 3.13) and 
ND2 genes (r=0.39, p<0.0001) (Figure 3.14). 
 
 
Figure 3.13: Spearman correlation between paired mtDNA plasma (copy/µL) 
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Figure 3.14: Spearman correlation between paired mtDNA plasma (copy/µL) 
as quantified by ND2 gene primers and WCC.  
 
 
3.3.4.4 Serum calprotectin 
Serum calprotectin data was available for 29 ASUC plasma samples and 14 
serum samples paired with mtDNA data. 
 
There was no significant correlation between plasma mtDNA levels and serum 
calprotectin when mtDNA was quantified using COXIII (r=0.22, p=0.24; Figure 
3.15) or ND2 genes (r=0.35, p=0.06) (Figure 3.16). 
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Figure 3.15: Spearman correlation between paired mtDNA plasma (copy/µL) 
as quantified by COXIII gene primers and serum calprotectin.  
 
 
Figure 3.16: Spearman correlation between paired mtDNA plasma (copy/µL) 
as quantified by ND2 gene primers and serum calprotectin. 
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There was a significant positive correlation between serum mtDNA levels and 
serum calprotectin when mtDNA was quantified using COXIII (r=0.55, p=0.04; 
Figure 3.17) and ND2 genes (r=0.60, p=0.02) (Figure 3.18). 
 
Figure 3.17: Spearman correlation between paired mtDNA serum (copy/µL) 
as quantified by COXIII gene primers and serum calprotectin.  
 
Figure 3.18: Spearman correlation between paired mtDNA serum (copy/µL) 
as quantified by ND2 gene primers and serum calprotectin. 
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3.3.5 mtDNA as a prognostic biomarker 
 
 
The CD cohort had only one individual who underwent surgery during 
recruitment and follow up, precluding any further analysis. Of the 40 patients 
with ASUC, 12 (30%) underwent colectomy during follow-up after admission 
for ASUC. Follow up was for a median of 269 days (IQR 10-399). 
 
mtDNA levels on admission for patients with ASUC who went on to require 
subsequent emergency colectomy were higher than those who responded to 
medical therapy (colectomy: 302.5 copies/µL [IQR 139 – 1553] vs no 
colectomy group 165 copies/µL [66.75 – 253]; p=0.04) (Figure 3.19).  
 
 
Figure 3.19: Plasma mtDNA (copy/µL) on initial sample for patients with ASUC 
who required colectomy (n=12) vs. no colectomy (n=28). Median ± IQR. 
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Comparative ROC curve analysis of mtDNA, CRP and albumin demonstrated 
AUROCs of 0.71, 0.76 and 0.82 in predicting colectomy (p=0.04, 0.01 and 
0.002) respectively (Figure 3.20). There were no significant differences 























Figure 3.20: ROC curve analysis of (A) mtDNA, (B) CRP and (C) albumin in 
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To investigate the discriminant ability of mtDNA to predict subsequent 
colectomy, the cut off of maximum likelihood ratio was calculated from ROC 
curve data (1,545 copies/µL, likelihood ratio 7.0) and used to generate Kaplan-
Meier survival curves with censored data for subsequent colectomy during 
follow up (Figure 3.21). There was a significant separation between the two 
survival curves (p=0.006). 
 
 
Figure 3.21: Kaplan-Meier survival curves for ASUC patients (mtDNA >1,545 
vs. ≤ 1,545 copies/µL; log-rank Mantel-Cox; p = 0.006; ROC curve analysis of 
maximum likelihood ratio 7.0; n=40 (12 colectomy, 28 no colectomy)). 
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3.3.6 Characteristics of the ‘high mtDNA’ group 
 
We identified a group of individuals with very high mtDNA levels (n=18, >600 
copies/µL) and investigated if there were unique phenotypic characteristics 
that defined the group.  
 
Multivariate analysis showed that CRP was independently associated with 
very high mtDNA levels (p=0.007, Table 3.2).  
 
 p-value 95% confidence interval 
Hb 0.621 0.973-1.046 
WCC 0.083 0.984-1.310 
Platelets 0.343 0.998-1.007 
CRP 0.007* 1.084-1.672 
Albumin 0.861 0.360-2.346 
Age 0.630 0.974-1.045 
Smoking status 0.918 0.123-10.311 
Sex 0.645 0.416-4.126 
 
Table 3.2: Multivariate logistic regression to analyse parameters associated 
with high mtDNA levels in 160 samples with complete paired data with mtDNA 
levels (mtDNA >600 vs. ≤ 600 copies/µL).  
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3.3.7 Pre- and post-colectomy paired mtDNA levels 
 
12 out of 40 patients (30%) with ASUC in the study underwent colectomy. Of 
these 12 patients, post-colectomy plasma samples were obtained from 8 
patients (4 lost to follow up). This enabled pre- and post-colectomy matched 
mtDNA levels to be compared in these patients. 
 
In a longitudinal series of acute severe UC with paired samples pre- and post-
colectomy (median Δ107 days, IQR 89-189), plasma mtDNA fell following 













Figure 3.22: Longitudinal analysis of plasma mtDNA(copy/µL) in ASUC (n=8 
patients) during active disease and the same patient post colectomy in clinical 
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3.3.8 Summary of results 
 
• Higher circulating plasma mtDNA is associated with more severe 
disease in IBD as assessed by clinical indices. For ASUC, higher 
mtDNA levels are also associated with endoscopic severity.   
 
• mtDNA is positively correlated with known markers of disease severity 
including CRP, albumin and WCC. There was a significant correlation 
found between serum calprotectin and serum mtDNA but not with 
plasma mtDNA. 
 
• Patients with ASUC who did not respond to medical therapy and 
required colectomy had higher circulating mtDNA levels compared to 
those who responded to medical therapy. mtDNA performed similarly to 
CRP and albumin in predicting colectomy.  
 
• Multivariate analysis showed CRP to be independently associated with 
high mtDNA levels. 
 
• Sequential mtDNA samples on consecutive days during admission for 
ASUC demonstrated inter-day variability. 
 
• mtDNA levels significantly dropped between pre- and post-colectomy 
plasma samples for patients with ASUC 




3.4.1 Precision medicine & the future role of 
biomarkers in IBD 
 
3.4.1.1 Precision medicine 
The completion of the human genome project in 2003 represented a major 
scientific landmark, ushering in a new era with hopes and expectations of fresh 
insights into disease mechanisms and treatments. In IBD, many important 
discoveries soon followed, notably the identification of more than 200 genetic 
susceptibility loci and characterisation of the gut microbiome (Huttenhower et 
al., 2012). As ‘big data’, driven by advances in technology, becomes 
increasingly available and affordable, individuals with IBD and clinicians alike 
yearn for tangible outcomes from the promise of ‘precision medicine’ – precise 
diagnosis, monitoring and treatment.  
 
Precision medicine is a major priority in health care, now recognised by all 
major stakeholders including governments, the pharmaceutical industry, 
clinicians and patients. In January 2015, United States President Barack 
Obama announced the Precision Medicine Initiative® (PMI): a concerted effort 
by multiple government agencies and backed by $215 million in federal funds 
to help facilitate a greater understanding of individual disease variability and 
its clinical translation (Collins and Varmus, 2015). A major component is the 
PMI Cohort Program, an ambitious plan to build a national research cohort of 
more than one million participants in a participant-centred, data-driven manner 
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with integrated multi-omic profiling. The PMI working group’s report (Hudson, 
Lifton and Patrick-Lake, 2015) identified key scientific opportunities including 
a number relating to the importance of biomarkers (Table 3.3). Similarly, the 
Chinese government has plans to invest 20 billion yuan (around $3 billion) to 
support precision medicine research by 2030. In the UK, the 100,000 genomes 
project was launched in 2012 with the goal of large-scale integration of genetic 
information and health records from the National Health Service 
(http://www.genomicsengland.co.uk). In the same year, the National Phenome 
Centre was launched in UK, offering broad access to exploratory and targeted 
high-throughput metabolic phenotyping and computational biology facilities. 
These massive undertakings are potential game changers in the field of 
biomarker discovery and validation.  
 
• Translating already identified environmental and genetic risk factors 
into conclusions on disease causes and population impact with 
population-based cohort studies as well as identifying new 
associations. 
• Interrogation of the wide variation in therapeutic response and 
adverse reactions 
• Discovery of biomarkers for identification of individuals with higher 
risks of developing disease to help more rational prevention efforts 
• Novel classification systems which transcend the existing grouping 
based on symptoms, signs, lab results by using molecular 
characterisation 
• Using biomarkers to assign patients into a variety of clinical trials 
targeting subsets based on these biomarkers to help with 
development of novel therapies 
Table 3.3: Biomarker focussed scientific opportunities identified by the PMI 
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In IBD, the successful international partnerships in genetics and microbiome 
research already provide grounds for realistic optimism. A major concern 
remains the wide-ranging nature of the stochastic elements of IBD, which 
represent formidable hurdles with respect to study design and measurable 
outcomes. In our field, current creative research approaches are now 
beginning to integrate across molecular datasets (e.g. genetic + microbiome), 
override traditional boundaries of disease classifications (UC vs. CD) and most 
notably, increasingly rely on patient input using new technological applications 
to characterise the ‘exposome’ in IBD. Hence, a new theme of recombinant 
innovation is emerging with synergy arising from novel ideas within established 
and fresh datasets. 
 
3.4.1.2 Progress towards precision medicine in IBD 
 
Disease susceptibility, activity & behaviour  
Although genetic data has provided invaluable insights into disease 
pathogenesis, the role for genetic data in predicting susceptibility, activity and 
disease behaviour however is less strong. Genetic information allied with other 
biological data (e.g. pheno-genomic status), maybe more informative.  The 
strongest genetic signal, NOD2 status has been associated with ileal and 
fibrostenosing disease but the carriage of NOD2 mutant allele is uncommon. 
A combination of clinical, serological and genotypic data has been used to help 
predict the risks of surgery in CD (Dubinsky et al., 2013). Recently, a study of 
29,838 IBD patients tested for genetic-phenotype associations found that 
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predictive models based on generated genetic risk scores strongly 
distinguished colonic from ileal CD (Cleynen et al., 2015).  
 
Away from predicting susceptibility and behaviour in IBD, there is an unmet 
need for sensitive biomarkers to measure gut mucosal inflammation, which is 
necessary to provide objective data on disease activity and guide response to 
treatment. Presently, CRP and faecal calprotectin have better negative 
predictive values and are thus more useful in excluding significant 
inflammatory signals. Some progress can be expected in modalities to image 
inflammation (e.g. MRI) with or without the use of specific in-vivo labelling of 
inflammatory cells or targets. A recent study used confocal laser 
endomicroscopy to detect fluorescent antibody labelled membrane-bound 
TNF in intestinal immune cells of 25 CD patients and thus identify patients who 
are most likely to respond to anti-TNF therapy (Atreya et al., 2014). 
Furthermore, a re-thinking of ways to measure established biomarkers such 
as a measuring serum (rather than faecal) calprotectin may improve the 
performance and applicability of these tests (Kalla et al., 2016).  
 
In search of better disease activity prediction, current approaches such as 
those exemplified by the EMBARK study (Faubion et al., 2013) investigates 
panel of biomarkers by their correlations with endoscopy and radiological 
findings as the best reference measure. Such reference measure captures 
disease extent; location and burden well but are not specific enough to take in 
disease behaviour, complications and progression. As will be discussed later, 
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better biomarkers of activity may come from a refined approach measuring 
specific downstream effects of the biological pathway targeted. 
 
Prediction of drug response and adverse effects 
Exploiting the wealth of genetic data, the combination of phenotypic 
information with multiple susceptibility loci is shown to be predictive of primary 
non-response in anti-TNF therapy in paediatric IBD (Dubinsky et al., 2010). 
There have been some notable successes in transcriptomics (gene 
expression) in IBD. Lee et al. showed that CD8+ T-cell immune signatures are 
better at predicting disease course than traditional clinical or serological 
markers (Lee et al., 2011). Hence, this approach is useful to select individuals 
that might benefit from more aggressive medical treatment. At the mucosal 
level, one study of infliximab in UC used gene signatures to separate 
responders from non-responders with 95% sensitivity and 85% specificity 
(Arijs et al., 2009).  
 
In terms of predicting adverse effects, GWAS of azathioprine induced 
pancreatitis found increased susceptibility for HLA-DQA1-HLA-DRB1 variants 
with a 2.5 fold increased risk in heterozygotes and a 5 fold increased risk in 
homozygotes at rs2647087 (Heap et al., 2014). Although an important finding, 
this potential biomarker highlights some of the difficulties encountered in 
translation to the clinic. For example, the low pre-test probability of pancreatitis 
means that even in the highest risk homozygotes, there is an 83% chance of 
taking thiopurines without developing pancreatitis. Would this justify the 
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exclusion of thiopurines in these patients? It will however improve risk 
counselling and awareness. In a future of greater therapeutic options, this may 
be more feasible. In addition, the number needed to test was 76, making it an 
expensive option for screening. However, cheaper point of care testing in the 
future, and the possible combination with other biomarkers could change the 
economics of such a test.  
 
3.4.1.3 Biological basis of biomarker discovery 
 
IBD clinicians will have increasing number of drugs available with over 20 
currently in the developmental pipeline (D’Haens et al., 2014)(Danese, 2012). 
Rather than a sequential approach of trying one drug after another, one of the 
goals for Precision Medicine is to identify individuals or disease phenotypes 
that are better suited for a particular drug from the outset (e.g. anti-leukocyte 
migration vs. anti-TNF for example).  
 
This direction is appealing and cogent where recent advances in oncology and 
virology have shown the way. In breast cancer, HER2 (human epithelial growth 
factor) positivity provides prognostic information (more aggressive phenotype 
with higher recurrence rates) as well as therapeutic choice (response to 
monoclonal antibodies targeting HER2 such as trastuzumab) (Arteaga et al., 
2011). In non-small cell lung cancer, mutations in multiple oncogenes including 
ALK and EGFR can help direct tyrosine kinase therapy (Lindeman et al., 2013). 
In hepatitis C, prior to the direct acting antiviral revolution, IL28B genotype 
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helped predict the likelihood of sustained viral response to interferon and 
ribavirin therapy.  
 
In metastatic colorectal cancer, KRAS gene mutations predict response to anti-
epidermal growth factor receptor (anti-EGFR) monoclonal antibody therapy 
(Allegra et al., 2009). Notably, the early studies were performed based on a 
hypothesis developed from an understanding of EGFR biology (Lièvre et al., 
2006); subsequent retrospective subset analysis of randomised controlled 
trials provided strong evidence for clinical use.  
 
3.4.1.4 Hypothesis free vs hypothesis-based biomarker 
discovery  
 
The critical question is: are we on the cusp of a therapeutic revolution 
underpinned by the inexorable wave of ‘hypothesis free’ big data, or will we 
end up drowning in a sea of potential biomarkers that we cannot translate into 
clinical practice? A number of critical enablers allow for optimism (Figure 1.2) 
including developments of large-scale prospective cohorts, advances in high 
throughput technology, advances in computational power and increasing 
emphasis on patient inputted data. 
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Figure 3.23: Critical enablers in the flow of precision medicine in inflammatory bowel disease (IBD) (Boyapati, Kalla, et al., 2016) 
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Notwithstanding all these major interventions, there is a need for a dose of 
realism. In cancer research, where investment has been far greater, there has 
been a decrease in the number of Food and Drug Administration approved 
protein biomarkers over the last decade (Pavlou, Diamandis and Blasutig, 
2013). In IBD, it is notable that biomarkers in existing use such as faecal 
calprotectin were found through hypothesis based investigation (Roseth et al., 
1992) rather than high throughput methods or in silico database analysis.  
 
Discovery based approaches are currently burdened by several significant 
challenges (Table 3.4) although some potential solutions have been identified 
(Table 3.5). Selection bias from convenience sampling and data overfitting can 
result in over-interpretation of ‘significant’ p-values, potentially wasting 
valuable resources on random noise. For example, a host of studies have 
identified genetic polymorphisms as predictors of therapeutic response in IBD 
(Mosli et al., 2014) but these have not been consistently replicated. Therefore, 
there remains room for advancements based on discoveries in related 
inflammatory conditions, serendipity and organic scientific thinking although 
big data now forms the ground for the generation of new hypotheses. 
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Methodological challenges 
• Selection bias using convenience sampling 
• Increased flexibility and non-linearity in algorithms leading to overfitting 
• Potential confounders including interaction between the different ‘omes’ 
(e.g. microbiome studies with effect of host genome), disease activity, 
duration, location and effects of drug treatment, study design, 
heterogeneous cohorts  
• Standardisation of all steps in the process of biomarker discovery is 
optimal but in practice, difficult to achieve.  
Cost challenges 
• Lack of support from pharma companies not wanting to fragment markets 
• Large costs associated with biomarker validation for those biomarkers 
proposed by unbiased -omics testing 
Integration & Adoption Challenges 
• Electronic medical record integration – difficulties in standardisation, poor 
quality and granularity of inputted data. National approach easier in some 
countries (e.g. UK with NHS) than others e.g. USA 
• Adoption and acceptance by physicians and patients 
• Teamwork and large collaboration across institutions is particularly critical 
in relatively low incidence diseases such as IBD with creation of standard 
protocols and large cohort’s obvious benefits but more complex, difficult 
and costly coordination an important challenge. 
• Privacy and data security 
Table 3.4: Challenges with –omics research 
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There are many potential solutions to help resolve some of the earlier identified 
issues. For example, the importance of consistency in sample acquisition and 
processing and keeping patient cohorts as homogenous as possible cannot be 
overstated. We are approaching the stage where ‘big data’ will no longer be 
the rate-limiting step to progress; instead, it will be the clinician or researcher’s 
ingenuity in leveraging these assets into new knowledge which will be crucial. 
Increasingly, more targeted therapies will require more defined biomarkers to 
measure their effects on the respective biological pathways. This sets the 
scene for stratified clinical trials as seen in oncology for example. 
 
• Same method of sample acquisition 
• Homogenous patient subsets 
• Studies of subjects with no prior medical therapy 
• Data-driven approaches such as network interference 
• Require prospective studies with multiple time points 
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3.4.2 mtDNA as a biomarker in inflammatory diseases 
 
In addition to higher levels of mtDNA found in various inflammatory diseases 
(Section 1.3.5), many studies have additionally suggested its role as a 
potential biomarker. In trauma, studies have demonstrated correlation with 
injury severity (Lam et al., 2004; Nicole Y.L. Lam, Timothy H. Rainer, Rossa 
W.K. Chiu and Lo, 2004; Hsu et al., 2013) and found higher mtDNA levels in 
non-survivors compared to survivors (Hsu et al., 2013; Prikhodko et al., 2015). 
Further studies have found elevated plasma mtDNA is an independent 
predictor of SIRS in trauma patients (Gu et al., 2013) and correlates with SIRS 
score (Zhang et al., 2017).  
 
Di Caro et al. found higher mtDNA in the plasma of critically ill paediatric 
patients who were septic compared to similarly unwell but non-septic patients 
(Di Caro et al., 2015). Another study in severe sepsis demonstrated mtDNA to 
be more powerful as a prognostic indicator than either sequential organ failure 
assessment or lactate concentration (Kung et al., 2012). Similarly, some 
studies of patients in the intensive care setting have found that higher mtDNA 
levels are associated with poorer outcomes (Nakahira et al., 2013; Krychtiuk 
et al., 2015). In terms of chronic disease, a study found elevated anti-mtDNA 
antibodies in SLE, particularly in lupus nephritis where levels correlated with 
the lupus nephritis activity index better than did anti-dsDNA antibody levels (H. 
Wang et al., 2015). 
 
Collectively, these studies demonstrate the potential for mtDNA to be used as 
a biomarker in a variety of inflammatory diseases. 
3. MtDNA as a biomarker in IBD  145 
 
3.4.3 mtDNA as a potential novel biomarker in IBD 
 
3.4.3.1 Biomarker landscape in IBD 
Many dozens of potential genetic, blood-based, faecal, microbial and 
immunological biomarkers have been proposed in IBD (Dubinsky and Braun, 
2015; Sands, 2015). However, apart from a few notable exceptions, 
biomarkers have not yet found widespread clinical application in clinical 
practice for a variety reasons (Table 3.6).  
 
• Fails on the classic qualities of an ideal biomarker (simple, accurate, 
easy to perform, minimally invasive, cheap, rapid, reproducible) 
• Unclear or uncertain clinical utility: i.e. does not provide clinically 
useful information upon which to make decisions 
• low sensitivity/specificity 
• low prognostic/predictive values 
• Lack of validation: yet to be validated in independent cohorts or have 
had inconsistent results when validation has been attempted.  
• Some areas (such as microbiome-based biomarkers) are in their 
infancy 
Table 3.6: Problems with biomarkers that have not found widespread clinical 
application in IBD 
 
Most proposed biomarkers in IBD have failed to be implemented into clinical 
practice because they fail on the classic qualities of an ideal biomarker (simple, 
accurate, easy to perform, minimally invasive, cheap, rapid, reproducible) 
(Vermeire, Van Assche and Rutgeerts, 2006). 
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The use of DAMPs as biomarkers in IBD is established. The most relevant 
example is faecal calprotectin testing which has revolutionised IBD clinical 
practice with roles in differentiating IBD from functional gut disorders (Tibble et 
al., 2000); as a marker of disease activity (Lin et al., 2014) and to predict 
subsequent course of disease (Ho et al., 2009). Calprotectin is a major 
cytosolic protein found in neutrophils and other inflammatory cells and is 
released by stressed cells during intestinal inflammation. Faecal calprotectin 
is now also a measurable outcome in current clinical IBD therapeutic trials.  
 
The recent CALM study provides direct evidence for the benefit that 
biomarkers can play (Colombel et al., 2018). In this prospective, open-label, 
multicentre, active-controlled study in moderate-severe CD, treatment using 
an escalating therapy strategy based on symptoms alone was compared to 
symptoms and biomarker targets (CRP < 5 mg/L and faecal calprotectin level 
< 250 µg/g). The investigators found a significantly higher number of patients 
reached the primary endpoint of endoscopic remission as well as steroid free 
remission with the ‘treat-to-biomarker-target’ approach compared to the 
approach based on symptom management alone.  
 
As we move towards an era of ‘big-data’ (Section 3.4.1), hypothesis-free 
methods will propose many biomarkers going forward. However, a significant 
challenge remains to identify ‘functional’ biomarkers – i.e. those which have 
direct relevance to disease pathogenesis, which are more likely to help stratify 
patient populations that allow for yet further insights (Surinova et al., 2011; 
Boyapati, Kalla, et al., 2016).    
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3.4.3.2 Major findings 
The findings in this chapter are consistent with the potential role of mtDNA as 
a novel biomarker in IBD.  
 
mtDNA over a 5-day admission for ASUC 
Data from five randomly selected patients with ASUC who agreed to 
consecutive day sample collection during admission revealed day to day 
variability in mtDNA levels. Notably, all patients were on intravenous steroids 
during their admission. 
 
Some interesting observations may be made from this limited exploratory data. 
For example, mtDNA levels for patient 1 rose from day 2 to 3 whereas CRP 
consistently fell during the five days. Interestingly, this patient required a 
colectomy due to failure of medical therapy. Multiple samples from larger 
cohorts is required for both IBD patients and healthy controls to assess for 
inter-day and intra-day variability.  
 
It is interesting to note that mtDNA did not fluctuate in tandem with CRP for all 
patients. It is possible that mtDNA has a completely different acute phase 
response time compared to other biomarkers of inflammation. This would not 
be unexpected, given existing acute phase markers such as CRP and ESR 
temporally differ after an inflammatory insult.  
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Correlation with disease activity 
I found that mtDNA levels in UC correlated with disease severity as assessed 
by clinical indices. Patients with clinically mild-moderate UC had higher levels 
that those in clinical remission, and patients with severe disease had the 
highest levels. In CD, mtDNA levels in patients with clinical remission were 
significantly lower than those with severe disease but no different to those with 
mild-moderate disease.  
 
CD is a more heterogenous condition compared to UC with inflammation 
affecting anywhere from the mouth to the anus (vs. colon alone) and being 
transmural in nature often leading to fistulas, fibrostenotic strictures and 
abscesses (vs. confluent superficial inflammation). This heterogeneity in CD 
means that clinical indices may not correspond accurately to extent of 
inflammation. A recent study of over 500 IBD patients found a poor correlation 
between the HBI clinical index and endoscopic scores in CD, whereas there 
was a good correlation between the SCCAI and endoscopic scores in UC 
(Taleban et al., 2016). Given circulating mtDNA levels are likely a reflection of 
the extent of inflammation in IBD (and thus non-apoptotic cellular death and 
liberation of DAMPs), the more consistent finding between clinical indices and 
mtDNA in UC compared to CD is unsurprising.  
 
As expected in UC, patients with endoscopically mild disease compared to 
moderate or severe disease had significantly lower mtDNA levels. There was 
no significant difference found between the moderate and severe groups. It is 
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important to note that there are limitations to the endoscopy data: it was 
retrospective; classification was not blinded; and there was no central scoring 
of endoscopic severity. Endoscopists were, however, blinded to the mtDNA 
levels, and all endoscopists were senior IBD specialists capable of accurately 
reporting endoscopic severity in UC. 
 
A meta-analysis of the diagnostic accuracy of various biomarkers in IBD in 
predicting endoscopic activity found pooled area under the curve (AUC) for 
CRP and faecal calprotectin to be 0.49 (95% CI 0.34-0.64) and 0.88 (95% CI 
0.84-0.90) (Mosli et al., 2015). Based on the results presented here, 
prospective studies investigating the diagnostic utility of mtDNA in predicting 
endoscopic activity are warranted. 
 
Correlation with existing biomarkers of activity 
MtDNA correlated as expected with existing markers of severity including CRP 
(positive correlation), albumin (negative) and WCC (positive). This would be 
consistent with a recent publication of circulating DNA in elderly patients with 
venous thromboembolism which found strong correlations with CRP and WCC 
(Jiménez-Alcázar et al., 2018). A potential confounding factor was that most 
patients with severe disease were on corticosteroids at the time of sampling 
leading to elevated WCC. 
 
Serum calprotectin has recently been suggested as novel biomarker in IBD 
(Kalla et al., 2016). Kalla et al. found serum calprotectin significantly correlated 
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with CRP (r=0.41), WCC (r=0.37) and albumin (r=-0.39) in IBD patients and 
predicted colectomy with a AUC of 0.69 (similar to CRP in this cohort).  
 
Interestingly, I found that serum calprotectin had no significant correlation to 
either COXIII or ND2 mitochondrial genes in plasma, although there was a 
trend to significance for ND2 (r=0.35, p=0.06). This latter finding may be a 
result of multiple testing or a reflection of possible type II error. Notably, serum 
calprotectin did correlate positively and with COXIII (r=0.55, p=0.04) and ND2 
(r=0.60, p=0.02) when mtDNA was tested in serum. Matched serum samples 
tested for calprotectin and mtDNA were aliquots from the same processed 
sample; the stronger correlation found in serum vs. plasma may be a reflection 
of this (compared to plasma which was separately processed as per the 
plasma protocol).  
 
Prognostic indicator 
Colectomy was chosen as the ‘hard’ endpoint most commonly used in ASUC 
research. Of the 40 patients with ASUC, 12 (30.0%) underwent colectomy over 
the follow up period following admission for ASUC, similar to colectomy rates 
reported in the infliximab rescue therapy era (Jarnerot et al., 2005; Williams et 
al., 2016). 
 
I found that mtDNA performed similarly to CRP and albumin in predicting 
colectomy in ASUC (AUC 0.71, p=0.039). MtDNA compares favourably to 
other biomarkers reported in the literature including faecal calprotectin (AUC 
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0.65, p=0.04), serum calprotectin (AUC 0.69, 95% CI 0.53-0.81) and CRP 
(AUC 0.71. 95% CI 0.56-0.86) (Ho et al., 2009; Hare et al., 2014).  
 
Further studies might seek to validate this finding in another cohort. A larger 
cohort may also enable multivariable models to build a prognostic ‘score’ 
based on multiple biomarkers including mtDNA. In addition, its use as a 
prognostic marker for other outcomes in IBD such as predicting disease 
relapse, abdominal surgery and hospitalisation could be assessed. 
 
When a cutoff of 1,545 mtDNA copies/µL was used (guided by ROC curves 
for highest likelihood ratio), there was significant separation of the survival 
curves for colectomy on Kaplan-Meier analysis. This cut off requires validation 
other cohorts. However, in broad terms, this finding supports the idea that 
mtDNA levels may provide valuable prognostic information in some IBD 
patients.  
 
Characteristics of patients with high mtDNA levels 
The characteristics of patients with high mtDNA levels are of interest. An 
attempt was made to assess this through multivariable logistic regression 
analysis which found that only CRP was independently associated with high 
mtDNA levels. This is in keeping with the idea that a higher inflammatory 
burden is associated with higher mtDNA levels. A larger cohort may reveal 
further factors, which in turn could suggest further avenues of investigation.  
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Pre- and post-colectomy data 
Patients who underwent colectomy had post-colectomy mtDNA levels that 
were significantly lower than pre-colectomy levels. All patients were resampled 
in clinic at a variable number of days post colectomy (median Δ107 days, IQR 
89-189), and were in clinical remission with the diseased colon removed. This 
data is consistent with a possible role for mtDNA in monitoring disease activity 
over time. Furthermore, it is consistent with the hypothesis that mtDNA in the 
circulation arises from the inflamed gut in IBD (Chapter 4). Further studies with 
measurement of mtDNA at multiple time points would be useful to further 
define how mtDNA levels change post-colectomy. 
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3.4.4 Implications of findings 
 
In this thesis, I have gone some way to helping identify mtDNA as a potential 
novel biomarker. It is important to emphasise the exploratory nature of this 
work. Further investigation is required, initially for validation of these findings, 
and subsequently to explore potential clinical or research applications. 
Nevertheless, I have shown that in some patients, plasma mtDNA levels 
correlate with disease activity and severity, and find mtDNA (and mitochondrial 
DAMPs more generally) to be a potential mechanistic biomarker in IBD.  
 
Earlier, I highlighted the importance of such functional biomarkers to identify 
sub-mechanisms that drive the heterogenous clinical presentations and 
disease progression in IBD, where specific therapeutic interventions can be 
stratified accordingly (Section 3.4.1). However, several challenges exist to 
adoption of mtDNA as a biomarker. These include the variation in the 
methodology in which mtDNA is measured and reported in the literature (e.g. 
serum vs plasma, mtDNA specific PCR primers, plasma processing protocol). 
Standardisation of these protocols, including identification of ‘normal’ and 
‘abnormal’ ranges, will be important prior to clinical use. Furthermore, further 
studies reporting clinically relevant predictive statistics in a variety of 
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Data presented in chapters 2 and 3 show elevated plasma levels of mtDNA in 
patients with IBD, with a potential role as a biomarker. A pertinent question is 
whether this observation is simply an epiphenomenon in IBD, or whether these 
mitochondrial DAMPs play a role in instigating and/or perpetuating 
inflammation. To investigate the precise contribution of mtDNA to IBD related 
inflammation would entail a substantial body of work in itself, beyond the time 
and funding constraints of this project. 
 
As discussed earlier, a pro-inflammatory milieu of DAMPs along with mucosal 
oxidative stress and deregulation of homeostatic pathways after initial non-
apoptotic cell death may promote further and ongoing intestinal damage 
(Boyapati, Rossi, et al., 2016). I hypothesised that if mitochondrial DAMPs had 
a pathogenic role in the inflammation seen in IBD, they would be released at 
the level of the inflamed gut. In this chapter, I pursue multiple lines of evidence 
to investigate this hypothesis.  
 
Firstly, mtDNA analysis of stool samples was performed to test the hypothesis 
that raised levels would be found in patients with IBD due to mitochondrial 
DAMP release into the faeces. This is conceptually similar to the DAMP 
S100A/9 (calprotectin) which is measured in the stool to test for gut 
inflammation. Secondly, transmission electron microscopy (TEM) of colonic 
epithelium from IBD patients was used to assess the presence of damaged 
mitochondria. Thirdly, expression of the downstream target of mtDNA (TLR9) 
was assessed in IBD vs non-IBD colonic specimens.  




4.2.1 Stool mtDNA analysis 
 
Stool collection 
Stool was collected using a Sterilin Polystyrene 30mL container 
(ThermoFisher) and immediately stored at 4oC. Within 4 hours, the sample 
was transferred to -80oC until further use. 
 
Isolation of DNA from stool 
DNA was isolated using the QIAamp DNA Stool Mini Kit as per manufacturer’s 
instructions. At Step 2, ASL buffer is used in the protocol; samples were 
processed in duplicate with one using the ASL buffer and one using phosphate 
buffered saline (PBS; to minimise processing-related liberation of DAMPs). 
PBS data is presented for mtDNA quantification. 
 
200 mg of stool was placed in a 2mL microcentrifuge tube and placed on ice. 
1.6mL of PBS or ASL buffer (see above) was added to each stool sample and 
then pulse-vortexed continuously until the stool sample was thoroughly 
homogenised (at least 1 minute). This was then centrifuged at 20,000g to pellet 
the stool particles. 1.4mL of the supernatant was then transferred to a new 
2mL tube and the pellet was discarded. 1 InhibitEX Tablet (Qiagen) was added 
to the sample and vortexed immediately and continuously for 1 minute (until 
the tablet was completely suspended). The suspension was then incubated for 
1 minute at room temperature (15-25oC) to allow inhibitors to adsorb to the 
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InhibitEX matrix. The sample was then centrifuged at full speed for 3 minutes 
to pellet stool particles and inhibitors bound to InhibitEX matrix. Immediately 
post centrifugation, the supernatant was transferred to a new 1.5mL 
microcentrifuge tube and the pellet was discarded. The sample was 
centrifuged at 20,000g for 3 minutes.  
 
25µL proteinase K was added to a new 2mL microcentrifuge tube and 600µL 
of supernatant from the sample was added. 600µL of Buffer AL was added and 
vortexed for 15 seconds. This was then incubated at 70oC for 10 minutes and 
then 600µL of ethanol (96-100%) was added to the lysate, and then mixed by 
vortexing. 
 
600µL of the lysate was then applied to the a QIAamp (Qiagen) spin column 
and centrifuged at 20,000g for 1 minute. The spin column was placed in a new 
collection tube and the filtrate was discarded. A second aliquot of 600µL lysate 
was applied to the spin column and centrifuged at 20,000g for 1 minute. The 
spin column was placed in a new collection tube and the filtrate was discarded. 
A third aliquot of 600µL lysate was applied to the spin column and centrifuged 
at 20,000g for 1 minute. The spin column was placed in a new collection tube 
and the filtrate was discarded.  
 
500µL of Buffer AW1 was then added to the spin column and centrifuged at 
20,000g for 1 minute. The spin column was placed in a new collection tube 
and the filtrate was discarded. 500µL of Buffer AW2 was then added to the 
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spin column and centrifuged at 20,000g for 3 minutes. The spin column was 
placed in a new collection tube and the filtrate was discarded. This was then 
centrifuged at 20,000g for a further 1 minute to help eliminate the chance of 
possible Buffer AW2 carryover. 
 
The spin column was transferred to a new 1.5mL microcentrifuge tube and 
200µL of Buffer AE was applied directly onto the QIAamp membrane. This was 
incubated for 1 minute at room temperature and then centrifuged at full speed 
for 1 minute to elute the DNA, with the elute stored at -20°C until analysed. 
 
qPCR for absolute quantification of mtDNA in stool 
The method previously described (Section 2.2.7) was used to quantify mtDNA 
in stool samples.  
 
4.2.2 Transmission Electron Microscopy 
 
Colonic pinch biopsies from IBD and non-IBD controls were obtained from 
distal colon during colonoscopy, briefly washed with sterile PBS and 
immediately transferred into 3% electron microscopy grade glutaraldehyde 
solution in 0.1M Sodium Cacodylate buffer, pH 7.3, for 2 hours before further 
processing (details available on request). For mouse studies, colons were 
flushed with PBS before transfer into electron microscopy solution as above. 
All TEMs were carried out at Electron Microscopy Unit, King’s Building, 
University of Edinburgh. 
 




Parrafin-embedded gut sections of healthy individuals, and individuals with 
IBD were provided by the Western General pathology department (via Dr 
Joseph Loane) using the Scottish Tissue Bank via Scottish Academic Health 
Sciences Collaboration (SAHSC) SR493. All IBD samples were coded and 
matched (sex, age and tissue location) with a non-IBD control group. 
 
I am grateful to Dr Arina Tambrowska who optimised the protocol and 
performed the immunohistochemistry described below. The IHC protocol was 
optimised by testing various antigen retrieval protocols and primary antibody 
concentrations.  
 
The sections were deparaffinised in xylene, rehydrated and retrieved using 
Tris-EDTA buffer. The endogenous peroxidase activity was quenched with 3% 
hydrogen peroxide. The sections were immunostained with polyclonal anti-
TLR9 antibody (ab52967, Abcam) using Vectastatin Elite ABC Kit (Vector 
Laboratories) and diaminobenzidine. The sections were counterstained, 
cover-slipped and imaged with Zeiss Axiovert200 microscope using AxioVision 









4.3.1 Higher faecal mtDNA levels in ASUC 
 
4.3.1.1 Processing methodology 
In step 2 of the QIAamp DNA stool mini kit protocol, ASL buffer is used for lysis 
of stool samples. 6 samples were processed in duplicate with a single 
difference: ASL was substituted with PBS. The samples processed with ASL 
had significantly higher levels of mtDNA detected compared to matched PBS 
samples (1027 copies/nL [IQR 11.75-374] vs 171 copies/nL [193.2-2631], 
p=0.03, Wilcoxon), likely due to processing related liberation of mtDNA with 
ASL (Figure 4.1).  
 
Figure 4.1: Comparison of matched samples with PBS and ASL used for step 
2 of the QIAamp DNA stool mini protocol. 
 
Herein, data from the PBS method is presented. 
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4.3.1.2 Faecal mtDNA is significantly elevated in ASUC 
12 individuals with ASUC and 12 healthy controls were prospectively recruited 
to provide stool samples. 
 
Significantly higher mtDNA levels (p<0.0001) were found in ASUC compared 
to non-IBD controls (222 copies/nL [IQR 19-313] vs. 1 copy/nL [IQR 0-7]) 
(Figure 4.2).  
 
Figure 4.2: Faecal mtDNA (copy/nL) in active UC and non-IBD controls 
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4.3.2 Matched stool vs plasma mtDNA  
 
Of the 12 faecal samples analysed for mtDNA levels, 8 had matched (same 
day) plasma mtDNA data available for analysis (figure 4.3). There was no 











Figure 4.3: Faecal mtDNA (copy/nL) with matched plasma mtDNA (copy/mL) 
in active UC (n=8). 
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4.3.3 Active IBD is associated with mucosal 
mitochondrial damage 
 
6 individuals with active UC and 6 non-IBD controls were prospectively 
recruited for pinch biopsies collected from the affected colon at time of 
colonoscopy. Patient characteristics are listed in Table 4.1.  
 
Case Age / Sex Clinical Description 
UC 1 23 years, Female Active proctitis (UC), Mayo 2 
UC 2 44 years; Male Active left sided UC, Mayo 1 
UC 3 41 years, Female Active pan-UC, Mayo 2 
UC 4 20 years, Male  Active left sided UC, Mayo 2 
UC 5 33 years, Male Active severe UC, to point of insertion 
(descending), Mayo 3 
UC 6 49 years, Female Active proctitis (UC), Mayo 1 
HC 1 56 years; Male Investigated for abdominal pain and weight 
loss; normal 
HC 2 45 years; Female Investigated for iron deficiency anaemia; 
internal haemorrhoids only 
HC 3 62 years, Male Investigated for PR bleeding; sigmoid 
diverticular disease found otherwise normal 
HC 4 55 years, Male Investigated for altered bowel habit and 
family history bowel cancer; normal 
HC 5 39 years, Female Investigated for iron deficiency anaemia; 
normal 
HC 6 71 years, Male Surveillance scope post polypectomy 2 
years ago; left sided diverticular disease 
otherwise normal 
Table 4.1: Clinical characteristics of individuals for transmission electron 
microscopy studies of distal colon. Mayo score refers to endoscopic 
classification (Appendix F) 
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Transmission electron microscopy (TEM) of the colon showed evidence of 
mitochondrial damage (with loss of inner cristae structure, increased lucency 
with swollen rounded appearances) in areas of cellular injury and were also 
extravasated within sub-epithelium in affected UC.  
 
Representative images are shown in Figure 4.4 and images from participants 
are shown in Figure 4.5.  
 















Figure 4.4: Representative transmission electron microscopy of distal colonic epithelium from active UC vs. non-IBD controls (n= 6/group; 
bar = 5µm). Annotated image: Purple – damage mitochondria (DM), Blue – healthy mitochondria (HM) and yellow – lipid droplets (LD). 
Black scale bar 2µm. Yellow insert – Damaged and healthy mitochondria from UC and controls respectively (Orange bar 0.5 µm). 




Figure 4.5: Representative colonic TEM images of 6 UC vs. 6 non-IBD individuals. 
Panel A – UC; Panel B – Non-IBD controls. Black bar - 2µm. Red arrows denote 
damaged mitochondria. 




Colonic resection specimens from 14 IBD (7 UC and 7 CD) and 14 non-IBD 
controls were obtained for analysis.  
 
We analysed TLR9 protein expression in human IBD colonic resection 
specimens and found increased frequency of lamina propria TLR9+ve cells in 
active UC and CD. Representative IHC is presented in Figure 4.6 and cell 







Figure 4.6: Immunohistochemistry for anti-TLR9 in human IBD colon (UC and 
CD; n=7/group vs. non-IBD control; n=14). Red arrows – TLR9 positive cells. 
Black scale bar 100 µm. 
  











Figure 4.7: TLR9+ve cell counts in lamina propria (LP) of human IBD colon 
















The main finding of this thesis is that mitochondrial DAMPs can be found in 
the circulation of patients with active IBD (Chapter 2). Given that DAMPs are 
released during times of cellular stress and necrosis, this release is likely to 
occur at the gut mucosal level (Boyapati, Rossi, et al., 2016). Local release of 
mtDNA at the site of inflammation would be in keeping with findings of higher 
mtDNA levels in the cerebrospinal fluid of patients with subarachnoid 
haemorrhage (Wang et al., 2013), traumatic brain injury (Walko  3rd et al., 
2014) and multiple sclerosis (Varhaug et al., 2016). More specifically to IBD, 
local release fits conceptually with the clinically useful finding of higher levels 
of another DAMP (calprotectin) in the stool in patients with gut inflammation. 
 
The results in this chapter help support the hypothesis that mtDNA found in 
the circulation of IBD patients is released locally at the sites of inflammation in 
the gut. However, the functional consequence of mtDNA in IBD remains 
unclear. Significant further research, including in vivo studies, are required 
before this is demonstrated and any potential for therapeutic targets may be 
pursued (discussed further in Chapter 5). Time and resource restraints meant 
that a definitive exploration of mitochondrial DAMP release from inflamed 
mucosa and the functional consequence on this was thought to be 
unachievable.  
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I hypothesise that when present in overwhelming concentrations at the gut 
mucosal level, mtDNA may help instigate or propagate this inflammation. Prior 
to discussing the major findings in this chapter (Section 4.4.4), I present the 
current understanding of the cellular mechanisms of mtDNA as an 
inflammatory mediator including its release, clearance and manner in which 
mtDNA is thought to promote inflammation. 
 
4.4.2 mtDNA release and clearance 
 
4.4.2.1 Mechanisms of mtDNA release 
Two levels of mtDNA release, cytosolic and then extracellular, are critically 
important steps. In the former, the mechanism of release of mtDNA from 
mitochondria relies on the opening of mitochondrial permeability transition 
pores in the inner mitochondrial membrane (Patrushev et al., 2004). Inhibition 
of pore opening with cyclosporine A resulted in lower mtDNA in the cytosol 
after stimulation with LPS and ATP (Nakahira et al., 2011). Ding et al. showed 
that the induction of ROS using ox-LDL increased mtDNA leakage into the 
cytosol in a dose dependent manner, and this effect was ameliorated with 
blockade of the ox-LDL receptor or a ROS inhibitor (Ding et al., 2013).  
 
In terms of extracellular release, cellular stress and necrosis are primary 
factors in the non-discriminant liberation of a host of mitochondrial components 
such as mtDNA, N-formyl peptides, ATP, TFAM and mitochondrial lipids. 
These mitochondrial constituents also exert their respective effects, which is 
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wide-ranging on key inflammatory pathways (extensively reviewed by 
Nakahira et al. (Nakahira, Hisata and Choi, 2015)). Aside from this non-
selective release after uncontrolled cell death, several studies have suggested 
additional mechanisms such as necroptosis (or programmed necrosis) 
(Kaczmarek, Vandenabeele and Krysko, 2013). Blood transfusion induced 
endothelial necroptosis was recently found to increase extracellular mtDNA as 
a potential mechanism to explain transfusion related lung injury (Mangalmurti 
et al., 2016). A recent study suggested that during necroptosis, mitochondria 
were released before plasma membrane rupture and they are then 
phagocytosed by monocyte-derived macrophages or dendritic cells triggering 
an inflammatory response as evidenced by cytokine production and cell 
maturation respectively (Maeda and Fadeel, 2014). Thus, ingestion of intact 
mitochondria may represent a distinct uptake mechanism following 
necroptosis.  
 
In a separate study, platelets were also found to be a source for free 
extracellular mitochondria release and they then act as an endogenous 
substrate for bactericidal secreted phospholipase A2IIA (sPLA2-IIA) leading to 
mitochondrial membrane hydrolysis, loss of mitochondrial structural integrity 
and mtDNA release (Boudreau et al., 2014). Intriguingly, Xin et al. found lower 
levels of mitochondria-derived ROS (mtROS) production when metformin was 
added to activated platelets and this was associated with decreased 
extracellular mtDNA release (Xin et al., 2016). The authors found lower 
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complex I activity of the platelet mitochondrial respiratory chain, and suggested 
this as a mechanism for the observed suppressed mitochondrial dysfunction.  
 
Whether there is an active element in mtDNA release is an interesting point of 
consideration. Active cellular transfer of mitochondria from stromal cells to 
rescue stricken lung alveoli cells in acute lung injury has been demonstrated 
(Islam et al., 2012). Extracellular vesicles are important modes of intercellular 
communication and comprise of exosomes (endosomal) and microvesicles 
(plasma membrane derived), and is directed by exocytosis. Both chromosomal 
DNA (Balaj et al., 2011; Waldenström et al., 2012) and mtDNA have been 
observed in extracellular vesicles (Guescini, Genedani, et al., 2010; Guescini, 
Guidolin, et al., 2010; Ye et al., 2017). In non-alcoholic steatohepatitis patients 
(NASH), a greater percentage of mitochondria were found inside extracellular 
microparticles and a higher percentage of microparticles contained 
mitochondria compared with lean subjects (Garcia-Martinez et al., 2016). 
Additionally, a recent study found genomic DNA and mtDNA to be mainly 
detected in microvesicles, with only low levels found in exosomes (Cai et al., 
2017). 
 
Further clarification is required on the concentration and significance of mtDNA 
in extracellular vesicles, and whether this has different immunostimulatory 
effects compared to cell-free or surface bound mtDNA. A recent study in 
chronic heart failure patients found plasma-derived exosomal-bound mtDNA 
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triggered an inflammatory response which could be blocked by chloroquine (a 
TLR9 inhibitor) (Ye et al., 2017)..  
 
As previously mentioned, the pro-inflammatory effects of mtDNA is dependent 
on its oxidisation (Shimada et al., 2012; Pazmandi et al., 2014). The highly 
oxidative extracellular milieu at sites of tissue inflammation in patients with 
chronic inflammatory disease may overwhelm anti-oxidant systems, further 
potentiating the inflammatory potential of DAMPs such as mtDNA (Boyapati, 
Rossi, et al., 2016). 
 
4.4.2.2 MtDNA degradation & clearance 
Several well-described clearance mechanisms limit the pro-inflammatory 
nature of mtDNA. Autophagy, as discussed earlier, is important (Oka et al., 
2012) and defective autophagy is strongly linked to IBD. A proportion of 
circulating DNA in the bloodstream appears to cross the kidney barrier and be 
excreted in the urine (Botezatu et al., 2000). Indeed, mtDNA has been detected 
in the urine at elevated levels in patients with progressive acute kidney injury 
(Whitaker et al., 2015). This may be due to inflammatory state associated with 
this condition, the increased clearance with a disturbed kidney barrier or both.  
 
Another possible mechanism of mtDNA clearance is phagocytosis by 
macrophages in a similar manner to the ingestion of the structurally similar 
bacterial DNA (Stacey, Sweet and Hume, 1996). As described earlier, the 
outcome of phagocytosis of intact mitochondria may be pro-, rather than anti-
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inflammatory; these divergent effects may also be dependent on the 
phenotype of the phagocytosing cells (e.g. inflammatory vs. pro-resolution 
macrophages/monocytes, neutrophils and red blood cells) (Maeda and 
Fadeel, 2014; Mangalmurti et al., 2016).  
 
In general, non-host DNA in the circulation is digested in part by circulating 
nucleases, and mtDNA may be affected by a similar mechanism (Lo et al., 
1999). Intracellularly, DNases found in the autophagolysosome play a vital role 
to degrade mtDNA (Okabe et al., 2005; Oka et al., 2012). Oka et al. showed 
that cardiac-specific deletion of DNAse II resulted in mtDNA accumulation in 
cardiomyocytes and the development of heart failure (Oka et al., 2012). In 
human umbilical vein endothelial cells (HUVECs), lysosomal DNases protect 
cells against inflammation from mtDNA damage induced by ox-LDL (Ding et 
al., 2013). Here, siRNA knock down of DNAase II amplifies mtDNA-TLR9 
mediated inflammatory response (Ding et al., 2013).  
 
It is unclear whether nucleases have a similar action on mtDNA in the 
extracellular space or is relevant in the physiological setting, especially when 
mtDNA are present in microvesicles or housed within intact mitochondria, 
which protect against DNase II. Intriguingly, DNase pre-treatment abolished 
renal mitochondrial injury that was observed after injection of mitochondrial 
debris (including mtDNA) in mice (Tsuji et al., 2015). The precise role of DNase 
and its effect on the immunostimulatory effects of mtDNA is likely to be more 
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complex, however, as illustrated by a recent study which showed DNase II was 
required for TLR9 activation by bacterial genomic DNA (Chan et al., 2015).    
 
4.4.3 MtDNA inflammatory pathways  
 
Current evidence shows that mtDNA-mediated inflammation is predominantly 
driven by the TLR9-, inflammasome- and more recently, STING pathways. 
 
4.4.3.1 Toll-like receptor (TLR9) 
TLR9 is located in the ER of various immune cells and translocates to the 
endosome upon sensing of hypomethylated DNA with CpG motifs, such as 
bacterial DNA (Latz et al., 2004; Leifer et al., 2004). Given its high frequency 
of unmethylated CpG dinucleotide repeats, it is postulated that mtDNA 
mediates inflammation dependent on the TLR9 pathway and potentially exerts 
a similar effect to bacterial CpG. TLR9 recognises a variety of types of 
oligodeoxynucleotides (ODNs) – for example, class A ODNs preferentially 
activate plasmacytoid dendritic cells whilst class B CpG ODNs activate B cells 
(Moseman et al., 2004). Some of our understanding of how mtDNA may 
interact with TLR9 is extrapolated from work with class A ODNs, although they 
do not necessarily have the same effect. After activation of TLR9 by CpG DNA, 
inflammatory cytokine induction and Th1 immune responses occur (Hemmi et 
al., 2000) and TLR9 is necessary in CpG DNA driven responses (Bauer et al., 
2001). TLR9 ligands can preferentially activate downstream pathways 
including pro-inflammatory NFKB, and NLRP3 inflammasomes; and IRF-7 
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dependent type 1-IFN that can upregulate IL-1 receptor antagonist (Sasai, 
Linehan and Iwasaki, 2010; Petrasek et al., 2011).  
 
Most tissue injury models show better outcomes when tlr9 gene is deleted. 
Wei et al. recently observed tlr9-/- mice have improved survival outcome in a 
necrotic lung model of cationic nanocarrier induced necrosis and mtDNA 
release in vivo (Wei et al., 2015). Furthermore, the pulmonary inflammation 
seen post injection of mtDNA, was significantly reduced in tlr9-/- and MyD88-/- 
mice, underlining the importance of TLR9-MyD88 pathway (Wei et al., 2015). 
Intravenous injection of mitochondrial debris with substantial amounts of 
mtDNA into mice induced a systemic inflammatory response in wild type mice 
which was significantly attenuated in tlr9-/- mice (Tsuji et al., 2015). Tlr9-/- mice 
also have better survival compared to wild-type counterparts in severe renal 
ischaemia reperfusion injury with associated decreased circulating mtDNA 
(Bakker et al., 2015). A similar protective effect is also seen in tlr9-/- mice with 
acute acetaminophen overdose with observed lower serum mtDNA and an 
absence of lung inflammation in contrast to the findings of wild type mice 
(Marques et al., 2012). Nevertheless, the reduction in mtDNA in tlr9-/- mice is 
intriguing and could be explained by the reduced inflammation with lower 
resultant cellular necrosis.  
 
Alternatively, it is possible that TLR9 is somehow involved in mtDNA release 
into the extracellular circulation. In a recent study using a murine model of non-
alcoholic steatohepatitis (NASH), mtDNA from NASH hepatocytes resulted in 
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greater activation of TLR9 than mtDNA from control livers (Garcia-Martinez et 
al., 2016). This suggests that mtDNA that is selectively modified during 
pathologic disease processes can augment the ensuing inflammatory 
response. Similarly, the level of TLR9 expression (due to various factors) 
appears to be important. In those with high mtDNA levels, higher TLR9 
expression is associated with increased mortality in ICU as earlier discussed 
(Arnalich et al., 2012).  
 
Neutrophils have received the most attention in studies on mtDNA-TLR9 
signalling in several different inflammatory settings. Zhang et al. found that 
mtDNA activates neutrophil p38 mitogen activated protein kinase (MAPK) 
through TLR9 with release of MMP8 (matrix metalloproteinase) and MMP9 
(Zhang et al., 2010; Zhang, Itagaki and Hauser, 2010), a finding confirmed in 
another study where phosphorylated p38 and MMP9 increased after mtDNA 
treatment of neutrophils (Sudakov et al., 2015). A separate study reported 
similar findings where pre-treatment with TLR9 inhibitor ODN2088 inhibited 
activation of p38 MAPK and release of MMP-8 (Wei et al., 2015). Gu et al. also 
found intratracheal administration of mtDNA provokes lung inflammation 
through TLR9-p38 MAPK (Gu et al., 2015). Hip fracture in rats resulted in 
mtDNA release into circulation as well as higher TLR9 and NF-KB p65 
activation and subsequent lung injury (Gan et al., 2015). The role of other 
MAPKs such as extracellular signal-regulated kinases (ERK) and c-Jun N-
terminal kinases (JNK) remain unclear, and to our knowledge unexamined in 
this context. These data suggest a pathway where mtDNA activates 
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neutrophils through TLR9 binding and activation of the MAPK pathway with 
subsequent MMP8 and MMP9 release. 
 
In considering mtDNA vis-à-vis the site and location of TLR9 receptor, mtDNA 
must be either displaced from whole mitochondria and moved into the cytosol 
or when extracellular, internalised by some mechanism(s) to act on endosomal 
TLR9. The endosomal location of TLR9 is most likely a mechanism to avoid 
unwanted activation (Barton and Kagan, 2009). It is unclear how extracellular 
mtDNA are internalised but possibilities include endocytosis, transmembrane 
diffusion, phagocytosis and receptor mediated endocytosis (Ziello, Huang and 
Jovin, 2010). Transmembrane diffusion is unlikely due to the highly 
(negatively) charged nature of DNA, which makes it difficult to pass through 
the cellular membrane. A recent study found that monocyte derived 
macrophages can take up whole mitochondria released from necroptosis 
suggesting that phagocytosis could be a relevant mechanism (Maeda and 
Fadeel, 2014). Given that the macrophage also has a clear role in resolving 
inflammation by clearing up cellular debris and apoptotic bodies, inadequate 
clearance of mitochondria following non-apoptotic cell death may lead to 
cellular corpses with mtDNA still abundantly present, being internalised by 
phagocytosis.  
 
Typically, apoptotic corpses can suppress the transcription of pro-inflammatory 
cytokine genes, promote the secretion anti-inflammatory cytokines by 
phagocytes, and cause antigen-presenting cells to present dead cell antigen 
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in a manner that promotes immunological tolerance (reviewed by Zitvogel et 
al. (Zitvogel, Kepp and Kroemer, 2010)). It will be of interest to consider the 
fate of mtDNA when macrophages or dendritic cells phagocytose cellular 
corpses with mtDNA. Does this clear the mtDNA or does it regulate 
subsequent functions (e.g. immune responsiveness) in these cell types? This 
has yet to be studied in detail. It is also possible that binding to additional 
cofactors may facilitate the internalisation into immune cells and in this 
instance, HMGB1 and RAGE have been implicated (Tian et al., 2007). In this 
study, HMGB1-CpG (class A) complexes resulted in TLR9/RAGE association 
and recruitment of MyD88 in B cells (Tian et al., 2007). Here, RAGE was 
visualised as associating with the DNA and was internalised with some 
sequestered in endosome-like structures. However, this possible mechanism 
requires further investigation. It has also been proposed that activation of 
autoreactive B cells by CpG DNA occurs after B cell receptor engagement 
leading to delivery of CpG DNA to endosomal TLR9 (Viglianti et al., 2003).  
 
Although nucleic acid-sensing TLRs on immune cells are mainly found within 
cells, cell surface expression has also been described. Using flow cytometry, 
TLR9 has been detected on surface of resting B lymphocytes (Dasari et al., 
2005; Baiyee et al., 2006) and peripheral blood mononuclear cells (Eaton-
Bassiri et al., 2004; Saikh et al., 2004). One functional ex vivo study found 
primary human and mouse TLR9 surface expression in neutrophils which are 
upregulated by a variety of stimuli including TLR9 agonists (Lindau et al., 
2013). However, it remains unclear whether TLR9 can signal from the cell 
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surface. In other cell types, TLR9 is also expressed on the cell surface. For 
example, TLR9 is expressed on both the apical and basolateral membrane of 
intestinal epithelial cells although NFKB is activated only via basolateral 
stimulation of CpG ligands (Ewaschuk et al., 2007; Lee et al., 2007). This is 
relevant at the gut mucosal interphase as this limits the extent of TLR9 
activation at the apical surface, which is in contact with a luminal milieu rich 
with bacterial DNA. Hence, compromised intestinal barrier integrity and 
translocation of bacterial CpG from the lumen during gut pathology will lead to 
basolateral stimulation in this context. Whether mtDNA has a different 
propensity compared to bacterial CpG to trigger TLR9 depending on epithelial 
site has not been studied.  
 
4.4.3.2 The inflammasome 
The inflammasomes are targets of mtDNA leading to cleavage and activation 
of caspase-1 and downstream maturation of interleukin-1β (IL-1β) and IL-18 
(Gurung, Lukens and Kanneganti, 2015). Here, it is cytosolic release of mtDNA 
that exerts the dominant effect on inflammasome activation. Of the several 
inflammasomes described, the NLRP3 inflammasome is the best 
characterised in this regard. Nakahira and colleagues showed that depletion 
of mtDNA reduced IL-1β secretion in macrophages following treatment with 
known inflammasome triggers, LPS and ATP (Nakahira et al., 2011). Of 
interest, mtROS is a further key mediator in this process. Pharmacologic 
induction of mtROS correlates with higher secretion of active IL-1β in a NLRP3 
and caspase-1-dependent manner and treatment with mtROS scavengers 
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suppresses this effect (Zhou et al., 2011). The requirement for mtROS in 
NLRP3 activation has also been confirmed by other studies (Nakahira et al., 
2011; Shimada et al., 2012; Zhang et al., 2013; Won et al., 2015) and may be 
explained by its oxidising effects on mtDNA. mtROS not only enhances the 
oxidative process, but also the cytosolic translocation of oxidised mtDNA that 
then binds directly to NLRP3 (Shimada et al., 2012). Non-oxidised mtDNA is 
insufficient to activate the NLRP3 inflammasome, although it may stimulate IL-
1β production via other inflammasomes such as AIM2 (Dombrowski et al., 
2012). Interestingly, genetic deletion of NLRP3 and caspase-1 results in less 
mtDNA release (Nakahira et al., 2011; Won et al., 2015). This suggests a 
positive-feedback loop, in which activation of the NLRP3 inflammasome by 
oxidised mtDNA further promotes mtDNA release. The overwhelming and/or 
persisting ROS production by inflammatory cells, for example, is known to 
damage macromolecules (DNA, as well as RNA, lipids, carbohydrates and 
proteins) of the surrounding cells. Activated neutrophils produce large amounts 
of ROS as part of their essential role in host defence (Holmstrom and Finkel, 
2014). Hence this is a likely major contributory factor to mtDNA damage once 
the inflammatory process is triggered. 
 
Other factors controlling mitochondria-mediated NLRP3 activation are also 
relevant. For example, defective autophagy increases caspase-1 activation, 
IL-1β and IL-18 production and cytosolic mtDNA translocation in LPS and ATP 
primed macrophages (Zhang et al., 2013). Pharmacological inhibition of 
mitophagy/autophagy in human macrophages results in accumulation of 
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damaged mitochondria, ROS generation and IL-1β secretion (Zhou et al., 
2011) and increased NLRP3 expression in the presence of LPS (Ding et al., 
2014). Hence, defective autophagy leads to inadequate clearance of damaged 
mitochondria, priming the internal cellular environment for NLRP3 activation. 
It is noteworthy that given the diversity of NLRP3 activators, current literature 
suggest that the precise mechanism of NLRP3 activation is still under debate 
(Nakahira, Hisata and Choi, 2015).  Although the role of the inflammasome is 
considered separate to TLR9 here, there is evidence that TLR/NFKB activation 
is a necessary priming step leading to NLRP3 upgregulation and subsequent 
downstream signalling. NF-κB-activating stimulus is required for cells to 
express pro-IL-1β and NLRP3 (Bauernfeind et al., 2009). Imeada et al. showed 
that stimulation of TLR9 by DNA fragments during early acetaminophen-
induced cell death can lead to the transcriptional activation of the IL-1β gene 
resulting in the formation of pro-IL-1β (Imaeda et al., 2009). Using the 
acetaminophen hepatotoxicity model, they showed that NLRP3-deletion (and 
related inflammasome components ASC and Caspase-1) were protective 
against induced liver failure (Imaeda et al., 2009). A further study however, did 
not show any effect of NLRP3-deletion on the outcomes of acetaminophen-
induced liver failure (Williams et al., 2011). Hence in the context of liver 
necrosis, the role for NLRP3 inflammasome remains controversial. 
 
4.4.3.3 STING pathway 
The role of mtDNA in innate immunity through the stimulator of interferon 
genes (STING) pathway has also been a focus of recent studies. STING is a 
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cytosolic protein anchored to the ER (Ishikawa and Barber, 2008). STING can 
be activated either by direct association with double-stranded (dsDNA) or by 
cyclic dinucleotides, which can be derived from intracellular bacteria or viruses, 
or produced by a DNA sensor, cyclic GMP-AMP (cGAMP) synthetase (cGAS) 
(Barber, 2014). This in turn, activates interferon regulatory factor 3 (IRF3) 
which ultimately translocates to the nucleus and transcribes type I interferon 
(IFN) genes and also NFKB pathway (Ishikawa and Barber, 2008).  
 
Two independent groups recently discovered that STING-mediated IFN 
response can also be activated by mtDNA (Rongvaux et al., 2014; White et al., 
2014).  They first observed that deficiency of apoptotic caspases (3, 7 and 9) 
resulted in upregulation of type I IFN genes. This response was dependent on 
Bak/Bax, pro-apoptotic proteins responsible for mitochondrial outer membrane 
permeabilisation leading to mtDNA release; and the release of cytochrome C 
that activates the intrinsic apoptotic pathway. Typically, apoptosis is 
considered immunologic silent e.g. it does not trigger an inflammatory 
response. However, these studies demonstrated that when caspases (9, 3/7) 
responsible for the completion of apoptotic process are inhibited or deleted, 
cytosolic mtDNA go on to activate cGAS/STING-mediated type I IFN signalling 
(Rongvaux et al., 2014; White et al., 2014). Hence, these caspases serve as 
a ‘brake’ on mtDNA-inflammatory effect during cell death. MtDNA released 
during cell death has been previously reported to provide a second signal that 
cooperates with an additional inflammatory signal (e.g., LPS) to activate the 
NLRP3 inflammasome and induce IL-1β production in murine macrophages 
(Shimada et al., 2012). Further evidence of mtDNA role in STING-mediated 
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IFN responses comes from West et al. (West et al., 2015). Here, partial 
deficiency of mtDNA binding protein TFAM was associated with increased 
concentrations of cytosolic mtDNA and enhanced type I IFN response, which 
was attenuated by knockdown of components of the STING pathway.  
 
Aberrant mtDNA-STING signalling has been also implicated in human 
inflammatory diseases, such as SLE. As earlier discussed, Lood et al. showed 
that treatment of human neutrophils with SLE-abundant ribonucleoprotein 
immune complexes induces mtROS, mtDNA oxidisation and translocation of 
the mitochondria to the plasma membrane (Lood et al., 2016). Oxidised 
mtDNA is then released extracellularly as a component of neutrophil 
extracellular traps (NETs). Transfection of NETs-derived mtDNA results in 
expression of IFN-β in human peripheral mononuclear cells. Systemic injection 
of oxidised mtDNA increases interferon-stimulated genes expression in spleen 
of wild type, but not STING deficient mice. Similar to inflammasomes, 
uncontrolled mtROS production promoting cytosolic mtDNA release is 
important in the STING activation and potentially in the case of autoimmunity. 
These studies highlight the importance of the innate cellular functions to 
handle the mtDNA release during the initiation of cell death, which ultimately 
will decide if the ensuing fate will be that of a silent or inflammatory outcome. 
  
4.  MtDNA release in IBD  186 
 
4.4.4 Local release of mtDNA in IBD 
 
4.4.4.1 Abnormal mitochondria seen at the intestinal 
epithelial level 
Our group recently found loss of mitochondrial protective mechanisms at the 
intestinal mucosal level rendered the mitochondria susceptible to damage, and 
triggered the onset of colitis in multidrug resistant-1 (mdr1) deficient mice (Ho 
et al., 2018). Other relevant IBD mice models with primary autophagy (Irgm 
and Atg16l1)(Adolph et al., 2013; Liu et al., 2013); including those with 
secondary autophagy impairments due to defective ER-stress (Kaser et al., 
2008) and NLRP6 inflammasome activity (Elinav et al., 2011) all exhibited 
similar accumulations of damaged mitochondria within the gut epithelium as 
seen in mdr1-deficient mice. In addition, genome-wide association data sets 
show around 5% of IBD susceptibility genes have direct roles in regulating 
mitochondrial homeostasis (Ho et al., 2018). These findings implicate defective 
mitochondria as a novel pathological mechanism in IBD.  
 
In this thesis, TEM of the colon showed evidence of mitochondrial damage 
(with loss of inner cristae structure, increased lucency with swollen rounded 
appearances) in areas of cellular injury. These damaged mitochondria were 
also extravasated within sub-epithelium in affected UC. The nature of TEM did 
not allow more detailed discrimination of whether specific enterocyte or 
inflammatory cell types displayed a predilection towards mitochondrial 
damage. Further limitations of the TEM data described in this chapter include 
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the lack of blinding, and the data was observational only with no quantification 
of mitochondrial damage performed to compare UC and healthy controls. 
 
Our findings of damaged mitochondria in areas of cellular injury on TEM are in 
keeping with studies in CD which found increased mitochondrial size and 
disrupted cristae (Soderholm et al., 2002; Nazli et al., 2004). In UC, 
mitochondrial abnormalities have been found on TEM even prior to any light 
microscopic changes (Delpre et al., 1989; Hsieh et al., 2006). Reduction in the 
mitochondrial electron transport complex activity has also been found in UC, 
and mitochondrial dysfunction has been found early in the development of 
DSS colitis in mice (Santhanam et al., 2012).  
 
4.4.4.2 Higher levels of mtDNA in the faeces 
Stool testing provides a non-invasive method of intestinal assessment and has 
been used to test for inflammation (stool calprotectin) and gut microbiota (16S 
ribosomal DNA sequencing). Although not as accurate as assessment at the 
mucosal level (e.g. with endoscopy and histology), it is far more practical and 
less invasive. 
 
I hypothesised that the widespread cellular disruption at the intestinal epithelial 
level would lead to local release of DAMPs (including mitochondrial DAMPs) 
into the faeces, and that these would be detectable. I find for the first time that 
mtDNA levels are significantly elevated in the stool of patients with UC 
compared to healthy controls. Using prospectively sampled stool, significantly 
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higher mtDNA levels were found in individuals with ASUC compared to non-
IBD controls. Faecal mtDNA was significantly higher than plasma levels 
(~1000-fold) which may be explained by inherent nature of the different 
biological material.  
 
These findings are in keeping with other DAMPs that have been detected as 
raised in the faeces of patients with IBD. In addition to calprotectin, lactoferrin 
(a marker of neutrophil degranulation that acts as an alarmin) is also detectable 
in the stool and can be used to differentiate IBD from functional disorders 
(Lewis, 2011). High levels of faecal S100A12 is found in active IBD, although 
existing studies are limited by size and most relate to the paediatric cohort (De 
Jong, Leach and Day, 2006; Kaiser et al., 2007; Sidler, Leach and Day, 2008). 
Similarly, faecal HMGB1 is raised in intestinal inflammation associated with 
IBD (Vitali et al., 2011; Palone et al., 2014). 
 
Samples of stool and plasma from the same patient on the same day did not 
show a statistically significant correlation. This may be due to multiple factors. 
This was a small dataset (n=8), so the analysis may have suffered from type 
II error. Furthermore, the stool mtDNA method is novel and requires validation 
(see below).   
 
This is the first time mtDNA has been measured in stool. A widely used 
commercial kit was used to extract DNA from the stool samples (QIAamp DNA 
Stool Mini, Qiagen). A change to the protocol was made in order to reduce the 
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amount of cellular lysis (and thus minimise post processing liberation of 
DAMPs). This theory was supported with data presented showing when the 
manufacturer’s lysis buffer (ASL) was used in matched specimens, mtDNA 
levels were dramatically higher than when PBS was used. The protocol 
includes an absorption resin to help remove PCR inhibitors. Despite this, there 
is a risk that the substitution of ASL to PBS led to incomplete removal of PCR 
inhibitors from the samples. Further work needs to be performed to optimise 
mtDNA detection in the stool. 
 
4.4.4.3 Higher levels of TLR9 expression in active IBD 
mtDNA has many similarities to bacterial DNA, particularly the high frequency 
of unmethylated CpG dinucleotide repeats. Once liberated from mitochondrial 
membranes, mtDNA can induce inflammation through three main pathways: 
TLR9, inflammasome and STING (Boyapati et al., 2017) of which mtDNA-
TLR9 is best characterised. TLR9 is expressed in many immune cells including 
dendritic cells, B-cells as well as in the cytoplasm and on the apical and 
basolateral surfaces of intestinal epithelial cells (Pedersen et al., 2005). We 
hypothesised that if there was local release of mtDNA, TLR9 would be 
expressed in epithelial cells and in lamina propria immune cells. 
 
The findings presented in this chapter confirms TLR9 expression in human 
intestinal epithelial cells and in lamina propria immune cells. TLR9 was 
expressed in the cytoplasm of the epithelial cells (similarly in the surface and 
in the crypt bases). We also noted cytoplasmic TLR9 expression in the immune 
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cells in the lamina propria. Moreover, we found that TLR9+ lamina propria cells 
were significantly more abundant in gut resection specimens of active IBD 
compared to non-IBD controls.  
 
These data are in keeping with findings of strong TLR9 expression in the 
cytoplasm of epithelial cells from patients with UC compared to those from 
normal controls (Fan and Liu, 2015). This study also found TLR9 mRNA 
expression to be significantly higher in UC. However, our findings are in 
contrast to another study in which TLR9 mRNA expression was found to be 
reduced in inflamed IBD gut sections (Pedersen et al., 2005).  
 
In this thesis, we have showed that TLR9 expression is increased in IBD 
patients and that mtDNA is elevated in these patients. The data is associative 
and does not definitively show mtDNA dependent downstream function. It is 
possible that other ligands for TLR9 are raised in active IBD, leading to the 
higher expression seen. Further work should focus on demonstrating that 
mtDNA directly activates TLR9, and that this contributes to the inflammation 

















5. Conclusions and further research  192 
 
Chapter 5 Contents 
 
5.1 Preamble .......................................................................................... 192 
5.2 Mitochondrial DNA as a biomarker ................................................... 193 
5.3 Defining the effect of mtDNA in IBD ................................................. 195 
5.4 mtDNA as a therapeutic target in IBD .............................................. 201 
5.5 Model for mitochondrial dysfunction in IBD ...................................... 203 
 
  




A detailed discussion of the results are presented within each chapter 
(Sections 2.4, 3.4 and 4.4). This final chapter will discuss the overall 
implications of the thesis and focus on how future research could extend this 
exploratory work.  
 
5.2 Mitochondrial DNA as a biomarker 
 
DAMPs offer great potential as biomarkers in disease diagnosis, prediction of 
outcome, monitoring of progression and response to treatment. The role of 
calprotectin as an established IBD biomarker has been discussed, as have the 
numerous other DAMPs found in high levels in serum, faeces or at the mucosal 
level in IBD (Section 2.4.6.4, Table 2.3).  At a broader level, investigating 
whether respective IBD sub-phenotypes have specific DAMP-signatures offers 
an opportunity to stratify patients for therapy and clinical trials.  
 
MtDNA is becoming increasingly appreciated as a highly potent DAMP and 
relevant in the inflammatory cascade of human inflammatory diseases. In this 
thesis, I show for the first time that mtDNA is present at high levels in IBD, 
levels correlate with disease activity in some patient groups, and that mtDNA 
has the potential to be a novel biomarker.  
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MtDNA’s potential as a biomarker offers a unique opportunity to stratify and 
identify individuals that may benefit from specific therapeutic targeting of 
downstream inflammation pathways (e.g. TLR9, NLRP3 or STING pathways). 
As discussed earlier, there are numerous studies in sepsis, trauma and acute 
single organ injury which have already demonstrated individuals with high 
mtDNA levels and TLR9 expression have worse prognosis. Therefore, there 
are clear groups in which stratification is useful.  
 
However, several challenges exist to its implementation as a clinically useful 
biomarker as evidenced by numerous potentially promising biomarkers failing 
to be incorporated into IBD clinical practice. Further work should initially focus 
on validating mtDNA as a biomarker in different and larger cohorts, with 
prospective correlation to endoscopic and/or histologic activity as a surrogate 
for longer term outcomes. Other more fundamental issues exist such as 
variations in the method of quantification. Standardisation of these protocols, 
including identification of ‘normal’ and ‘abnormal’ ranges will be necessary.  
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5.3 Defining the effect of mtDNA in IBD 
 
The main findings presented in this thesis of raised mtDNA in the circulation of 
patients with active IBD raises numerous questions. Foremost among these is 
whether the observation of elevated mtDNA (and mitochondrial DAMPs more 
generally) contribute to, or are simply a consequence of, inflammation in IBD. 
Indeed, the finding of raised mtDNA levels is not isolated to IBD, suggesting 
that its effect is unlikely to be IBD-specific (Section 1.3.5). Furthermore, 
numerous other DAMPs have been found to be elevated in IBD and 
experimental colitis including calprotectin, S100A12 and HMGB1 (Section 
2.4.6.4) raising the question as to the relative significance of mtDNA compared 
to other DAMPs in IBD. 
 
Although extensive further research is required, there are many reasons to 
believe that mtDNA may be a highly relevant functional DAMP in IBD. There 
is an increasing understanding of the functional role of mtDNA in other 
inflammatory diseases as well as IBD-specific factors which support its 
proposed status as an active player. In this section, I discuss the evidence 
implicating mtDNA as a functional mediator in inflammatory disease in general 
and IBD specifically, and further avenues of investigation to help define its 
possible functional role in IBD.  
 
mtDNA contributes to the inflammatory response 
Collins et al., first reported the inflammatory potential of mtDNA in 2004, when 
they found that mtDNA (and not nuclear DNA) induced TNFα and caused 
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inflammatory arthritis when injected into the joints of the mice (Collins et al., 
2003). There are now numerous studies utilising in vivo injection of mtDNA to 
provoke local and/or systemic inflammation (Zhang, Itagaki and Hauser, 2010; 
Gan et al., 2015; Hu et al., 2015; Tsuji et al., 2015; Xie et al., 2017).  
 
Moreover, there are now several in vivo studies to show that genetic deletion 
or pharmacologic interference of these pathways reduce the inflammatory 
effect of mtDNA. MtDNA’s role as a TLR9 agonist has received most attention 
where many inflammatory models show better outcomes when TLR9-
signalling is abolished. Tlr9–deletion is protective against SIRS following 
systemic administration of mitochondrial DAMPs (Tsuji et al., 2015); and in 
lung (Wei et al., 2015), liver (Marques et al., 2012) and kidney (Bakker et al., 
2015) injury models characterised by high mtDNA release. Blocking TLR9 
using inhibitory ligands has been shown to improve mtDNA-driven mouse 
models of cardiac failure (Oka et al., 2012) and NASH (Garcia-Martinez et al., 
2016).  
 
Collectively, these studies support the role of mtDNA as a direct contributor to 
inflammatory disease and not simply an epiphenomenon.  
 
mtDNA-TLR9 in IBD 
The role of mtDNA-TLR9 in IBD and intestinal inflammation however, is more 
complex. TLR9 is expressed both in the intestinal epithelium and, in resident 
and recruited lamina propria immune cells. Whereas NFKB-activation is 
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prototypically pro-inflammatory (Zhang, Lenardo and Baltimore, 2017), 
intestinal epithelial NFKB-activation is cytoprotective and important to maintain 
barrier integrity (Nenci et al., 2007). Hence in tlr9-deficiency, the intestinal 
epithelium is postulated to have lower protective NFKB-activation and is more 
susceptible to injury. Along these lines, CpG oligonucleotide treatment in 
mouse studies using low dose DSS colitis showed either no difference or a 
protective role with the beneficial effects seen before the induction of colitis 
(Rachmilewitz et al., 2004; Lee et al., 2006; Rose, Sakamoto and Leifer, 2012). 
In contrast, CpG oligonucleotide treatment given during colitis worsened 
inflammation (Obermeier et al., 2005).  Similarly, our group has showed that 
tlr9-deletion was protective in 2% DSS colitis (a higher concentration than 
previously studied) with less weight loss, milder histology score and preserved 
colon length (unpublished).  
 
It is likely, therefore, that the effect of TLR9 activation is dependent on the 
stage of inflammation, severity of colitis (and thus extent of mtDNA release) 
and the cellular context of where TLR9 is blocked. In health, TLR-NFKB 
activation from PAMPs (ligands from commensal microflora) promotes 
cytoprotective factors. However, if epithelial barrier integrity is breached, or 
cytoprotective factors overwhelmed in active or severe disease, TLR9 
activation may augment colitis, potentially driven by extracellular mtDNA in 
IBD. This may help explain why a recent clinical study of a TLR9-agonist in 
moderate-to-severe UC failed to show overall clinical improvement (Atreya et 
al., 2016).  
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This area is ripe for further investigation. In active intestinal inflammation, the 
local environment is enriched with various DAMPs and microbial ligands for 
TLR9 – a key avenue of investigation will be to clarify the relative effect of 
mtDNA in this context. There should be a focus on how this varies with disease 
severity, duration and extent, and the ultimate cellular target of mtDNA (e.g. 
intestinal epithelial cells vs. lamina propria immune cells).  
 
Oxidised mtDNA and relevance to IBD 
MtDNA in disease may have higher inflammatory potential than from healthy 
controls. Two  recent  studies  in  human  disease  (NASH  and  SLE)  
demonstrate  that  equivalent  respective  mtDNA concentrations have higher 
inflammatory potential compared to mtDNA from healthy controls likely due to 
differences in oxidisation (Caielli et al., 2016; Garcia-Martinez et al., 2016).   
 
It is pertinent that the inflamed gut environment is associated with 
mitochondrial damage, which leads to increased mtROS production (Brookes, 
2004; Ho et al., 2018). MtROS potentiates the oxidisation of mtDNA, critical to 
its role as an inflammasome agonist (Shimada et al., 2012; Novak and Mollen, 
2015). Excessive mtROS also inhibits autophagy, necessary for the clearance 
of damaged mitochondria. Hence, defective autophagy (Oka et al., 2012; 
Caielli et al., 2016) as seen in IBD further influences mtDNA’s inflammatory 
capacity prior to its release.  
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Beyond simply a secondary phenomenon following uncontrolled cell death, 
recent studies in SLE show that neutrophils with impaired mitophagy can 
actively extrude mtDNA which upon oxidisation becomes a potent activator of 
plasmacytoid dendritic cells (Caielli et al., 2016). Furthermore, oxidised mtDNA 
can become bound to neutrophil extracellular traps (NET) following NETosis, 
a cell death pathway characterised by extrusion of chromatin bound to 
cytosolic and granular content, which can further enhance and maintain its 
inflammatory potential (Lood et al., 2016).   
 
Further investigation should aim to clarify several areas including a) how 
oxidisation of mtDNA differs in IBD compared to health and other inflammatory 
conditions; b) whether mtDNA associated with IBD has a higher 
proinflammatory potential; and c) the extent of NET-bound oxidised mtDNA 
and its precise effects in IBD.  
 
mtDNA release in IBD 
Uncontrolled cell death and increased necrosis of inflammatory and intestinal 
epithelial cells are necessary preceding events for mtDNA (and DAMP) 
release into the extracellular milieu, and these are hallmark features of active 
IBD (Günther et al., 2011). In this thesis, indirect evidence is presented to 
support local mtDNA release at the level of the inflamed gut in IBD. Damaged 
mitochondria were present in the colonic epithelium of active IBD compared to 
non-IBD patients on TEM. It is known that damaged and dysfunctional 
mitochondria produce increased levels of ROS, and excessive mtROS has 
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multiple effects including oxidisation of mtDNA (Brookes, 2004). Furthermore, 
faecal levels of mtDNA were significantly raised in active IBD compared to non-
IBD samples, as was TLR9 expression in colonic resection specimens. Further 
work is required to extend these associative data and interrogate the 
mechanisms behind local mtDNA release in IBD. A number of areas require 
exploration, including direct evidence of TLR9 activation by mtDNA locally; 
how the manner of cell death (e.g. necroptosis vs. necrosis) in IBD affects 
mtDNA release; the role of cytosolic mtDNA in IBD; and the contribution of 
DNases on mtDNA in the circulation. 
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5.4 mtDNA as a therapeutic target in IBD 
 
The role of DAMPs as functionally active mediators of inflammation makes this 
class a highly novel and exciting therapeutic target in IBD. This approach in 
related inflammatory diseases has already shown promise in animal models 
(Boyapati, Rossi, et al., 2016). At present, most potential DAMP therapeutics 
have yet to be studied in human clinical trials. Many challenges exist, and 
these include: understanding complex disease-specific DAMP biology with 
their diverse often competing effects; how to localize therapeutic effects to the 
site of inflammation; deciphering DAMP-PRR and DAMP-DAMP interactions; 
understanding the triggers for DAMP release; and how DAMP mediated 
signalling varies depending on context. 
 
The current evidence offers a rich ream of translational opportunities to target 
mtDNA-mediated inflammation. There are many plausible approaches which 
include targeting cytosolic mtDNA release (e.g. directly at MPT using 
cyclosporine or by specific mitochondrial anti-oxidant strategies e.g. MitoQ10 
to reduce mtROS), augmenting clearance (e.g. using autophagy activators or 
correcting factors leading to impaired autophagy), diverting the cellular 
response following mitochondrial damage (e.g. induction of pro-apoptotic 
caspases) and reducing the inflammatory potential of mtDNA (e.g. DNAses to 
digest NET-bound mtDNA and reducing oxidisation of mtDNA), augmenting 
damaged mitochondrial clearance mechanisms (e.g. mitophagy activation), 
interfering with mtDNA-TLR9 activation (using inhibitory CpG ligands) and 
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targeting downstream NFKB- and MAPK-pathways in the relevant 
inflammatory cell groups (e.g. neutrophils).  
 
Similarly, much is known about the biological effects of N-formylated peptides 
and its cognate receptors (FPR1, 2 and 3). Activation of FPR1 drives neutrophil 
chemotaxis and stimulates a variety of antimicrobial responses, including 
degranulation, ROS production and cytokine release. Both FPR1 gene-
deletion and pharmacologic inhibition are protective in inflammatory lung 
disease (Dorward et al., 2015, 2017). There are other DAMPs such as 
calprotectin (s100a8/9), HMGB1 and IL-33 with known pro-inflammatory 
mechanisms found in active IBD (Boyapati, Rossi, et al., 2016). The relative 
importance of these DAMPs is not yet clarified but offers multiple avenues of 
investigation. 
 
The aim of this thesis was not to determine whether mtDNA was a therapeutic 
target, although this question is naturally raised in the investigation of 
mechanistic biomarkers. Significant work in precisely defining mtDNA’s role in 
IBD in different conditions and on different cell types is required prior to work 
in this regard. However, once a framework is established, there is significant 
translational potential to investigate how existing novel therapies can modulate 
these pathways. If direct evidence is found suggesting blockade of 
mitochondrial DAMPs can reduce inflammation in the gut, novel therapies can 
be envisaged. These projects would require significant investment and 
partnerships from research councils or industry. 
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5.5 Model for mitochondrial dysfunction in IBD 
 
In this thesis, I have shown that mitochondrial DAMPs are released in IBD and 
correlate with disease activity. Supportive evidence suggests that release is at 
the level of cellular damage in the gut and that they may be measured as a 
novel biomarker in the circulation and stool for some patients with IBD. Given 
that many lines of evidence implicate mtDNA as a functional pro-inflammatory 
mediator, these findings have direct translational importance.  
 
The colonic epithelial mitochondria, uniquely juxtaposed with the austere 
luminal environment are particularly susceptible to damage. Overall, I propose 
a model whereby epithelial mitochondrial dysfunction in IBD leads to the 
accumulation of damaged mitochondria, increased mtROS which can either 
directly activate inflammatory signalling (e.g. through the inflammasome) or 
lead to a vicious cycle of further mitochondrial dysfunction (Figure 5.1). This 
accumulation is potentiated by defective homeostatic mechanisms such as 
autophagy. Non-apoptotic cell death can lead to release of these mitochondrial 
DAMPs into the extracellular milieu which can then activate innate 
inflammatory pathways.  
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Figure 5.1: Proposed model for contribution of mitochondria as a 
proinflammatory source in IBD 
 
More broadly, our findings open avenues to explore a new mechanistic layer 
which may further expand the current model of IBD pathogenesis to 
incorporate the ‘danger’ model. Indeed, one of the strengths of this work is the 
novelty associated with addressing this relatively unexplored area in IBD. 
Hence DAMPs as ‘enemies within’, may represent a potential major player in 
addition to established data implicating genetic susceptibility, and exogenous 
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Appendix A – Clinical disease activity indices in IBD 
 
Variable Variable Description 
General well-being Score 0 = very well 
Score 1 = slightly below par 
Score 2 = poor 
Score 3 = very poor 
Score 4 = terrible 
Abdominal pain Score 0 = none 
Score 1 = mild 
Score 2 = moderate 
Score 3 = severe 
Number of liquid stools / day Score 1 point for each liquid stool 
Abdominal mass Score 0 = none 
Score 1 = dubious 
Score 2 = definite 
Score 3 = definite and tender 









Remission < 5; mild disease 5-7; moderate disease 8-16; severe disease > 16 
Table A1: Harvey Bradshaw Index (HBI) for clinical assessment of disease 
activity in CD 
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Variable Variable Description 
Bowel frequency (day) Score 0 = 0-3 
Score 1 = 4-6 
Score 2 = 7-9 
Score 3 = >9 
Bowel frequency (night) Score 0 = 0 
Score 1 = 1-3 
Score 2 = 4-6 
Urgency of defecation Score 0 = None 
Score 1 = Hurry 
Score 2 = Immediately 
Score 3 = Incontinence 
Blood in stool Score 0 = None 
Score 1 = Trace 
Score 2 = Occasionally frank 
Score 3 = Usually frank 
General well-being Score 0 = Very well 
Score 1 = Slightly below par 
Score 2 = Poor 
Score 3 = Very poor 
Score 4 = Terrible 





Remission <=2, clinical activity > 2 
Table A2: Simple Clinical Colitis Activity Index (SCCAI) for clinical assessment 
of disease activity in UC 
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Bloody diarrhoea ≥ 6 bloody stools per day 
and at least one of:  
Temperature > 37.8 degrees Celsius 
Pulse rate > 90 beats per minute 
Haemoglobin < 105 g/L 
ESR > 30 mm/h 
 
Table A3: Modified Truelove & Witts’ criteria for diagnosis of ASUC 
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Appendix B – Patient Questionnaire 
 
Patient Questionnaire 
To be completed by research clinician  
Patient ID      Date of completion 
   
 
Gender                 M / F        please circle  
Ethnic origin 
1. Which of the following best describes your ethnic origin? 
White European  
Jewish   Ashkenazi    Sephardic    
South Asian    (Bangladesh/India/Pakistan) 
South East Asian  
Hispanic  
Afro-Caribbean  
African American  
Pacific Islander    Native Hawaiian       
Native American    Native Alaskan         
Other     Please specify  
Mixed     Please specify 
   
Country of birth 
2. Where were you born (town and country)? 
..………………………......................................... 
3. Where did you spend the majority of your childhood (town and 
country)? …………………. 
4. Was this location  Urban / Rural ?    please circle 
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5. Where were your biological parents born (town and country)? 
Mother …………………………………….        
Father………………………………………. 
 
Social History and Environmental factors 
Education 
6. Number of years of education at recruitment (primary, secondary and 
further education).  
 
Smoking 
7. Do you currently smoke every day?      
(If no skip to Q 10) 
    Yes 
    No 
8. If yes, what do you smoke? 
    Cigarettes 
    Cigars 
    Pipe 
    Roll-ups 
9. How many do you smoke per day? 
   
10. If you only smoke socially, how many do you smoke per month?  
(If no skip to Q 12) 
   
11. When did you start smoking? (Year) 
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Have you ever smoked?    Yes (If no skip to Q 17) 
     No 
   
12. If yes, what did you smoke?   Cigarettes 
    Cigars 
    Pipe 
    Roll-ups 
13. When did you start smoking? (Year) 
     
14.  When did you stop smoking? (Year) 
   
15. How many did you smoke per day? 
   
16. Does your partner smoke? 
    Yes 
    No 
17. Did anyone smoke in the house while you were growing up? 
 
    Yes 
    No 
18. Smoking status at diagnosis of IBD 
    Smoker 
    Non-smoker 
    Ex-smoker 
    Unsure 
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Alcohol 
19. Do you consume alcohol?               Yes 
   Never 
   
If yes, how often?  Most days       Once or 
twice a week 
   At weekends only      
Once or twice a month 
   Once or twice a year   
   
20. If yes, how many drinks per day?    
    0-1    
    2-3 
    More than 3  
21. If more than 3, how many usually? …………………………………….. 
22. What do you usually drink?   Beer   Cider 
 Wine  Spirits    
Childhood exposure 
23.  Did you have a pet in the house as a child?   
 Yes     No  …………..…………………… ……… 
(type of pet) 
24.  Did you receive all your recommended vaccinations? 
  Yes     No    Unsure 
25. Did you require frequent antibiotics as a child? 
  Yes     No    Unsure 
26. If yes, what were these mainly required for? 
………………………………………….. 
27. Were there any concerns over poor growth in childhood?          
Or delayed puberty?     
Please ask if you have any queries about any of the 
questions above. 
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The following sections should be completed with the aid of a 
doctor or nurse. 
Family and Medical History 
28. In total, how many biological brothers and sisters do you have?   
29. How many biological children do you have?     
30. Is there a family history of IBD?  
  Yes     No (skip to Q.32) 








Father      
Mother      
Siblings   number  number  number  
Children   number  number  number  
 























      
      
      
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31. Have you or anyone in your family had any of the following conditions? 
 Personal History Family History (if yes, please 
specify relation) 
Multiple Sclerosis   No     Yes   No     Yes   Relation 
Psoriasis   No     Yes   No     Yes   Relation 
Coeliac Disease   No     Yes   No     Yes   Relation 
Ankylosing 
Spondylitis 
  No     Yes   No     Yes   Relation 
 
Colorectal Cancer 
  No     Yes 
Age at diagnosis 
  No     Yes   Relation 
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Present Diagnosis 
  Crohn’s disease   Ulcerative Colitis   IBD unspecified    Unknown  
33. When did your symptoms start (month and year)  
 ………………………… 
34. What symptoms did you have? (Tick all that apply) 
 growth failure    diarrhoea   blood in stool    abdominal pain   
 fatigue/tiredness 
 fistula/abscess  nausea  vomiting  none  other 
If “none” please specify the clinical history that led to diagnosis of IBD. 
………………………………………………………………………………………… 
If “other” please specify what other symptoms you had. 
………………………………………………………………………………………… 
35. Have you lost any weight since the onset of your symptoms? 
  Yes   No 
36. If yes, how much?       …………....................... 
37. When were you diagnosed (month and year)?   ………………………… 
38. What was your weight at diagnosis?  ………………       
and your height?  ……...……… 
39. How many times have you been admitted to hospital for your IBD (other than 
for planned   investigations)?   
 ………………………………………………………………………………… 
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41. Do you currently have an   
 ileoanal pouch  ileostomy   colostomy ? 
42. Have you had your tonsils removed?    
If yes, what year?  ………………………….. 
43. Have you had your appendix removed?  
If yes, what year?  …………………………… 





Medication Treated with Tolerated On now 
Oral 5-ASA    
Rectal 5-ASA    
Sulphasalazine    
Oral steroid    
Rectal steroid    
Azathioprine    
6-Mercaptopurine    
Methotrexate    
Ciclosporin    
Infliximab    
Adalimumab    
Certolizumab    
Natalizumab    
Antibiotics for IBD    
Elemental diet    
 
Other IBD therapies?...................................................................................... 
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45. Oral contraceptive status    Current   Never  Ex 
46. Have you taken any NSAIDS ( eg.ibuprofen, diclofenac, naproxen) in the last  
6 months? 
       Yes    No 
47. If yes, how often?      Seldom          
Frequently   
48. Have you taken any aspirin in the last 6 months?   Yes               No 
49. If yes, how often?     Seldom        Frequently 
50. Have you taken any paracetamol in the last 6 months?   Yes        No 
51. If yes, how often?     Seldom        Frequently 
52. What was your usual diet during the 6 months to a year prior to diagnosis? 
 Mixed meat/fish/veg  No red meat  Vegetarian  Vegan
  Pescetarian  Gluten free  Dairy free    Lactose free 
 Diabetic  High fibre       Low residue     Low FODMAP 




53. Have you been pregnant since you were diagnosed with IBD? 
  Yes    No 
 
 
End of questionnaire 
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Appendix C – Clinical Activity Form 
  
  Sample Collection       Clinic Assessment (please tick) 
To be completed by research clinician 
Patient 
ID 
 Date of 
sample/clinic 
 Temp / Pulse  
Current weight 
(kg) 
 Usual weight (kg)  Unwanted weight 
loss(kg) 
 
Time to weight 
loss(months) 
 Height (metres)  BMI  
Fasting state   fasted   non-fasted 
 
Type of bowel prep   
List all current meds including non-IBD drugs. Please 





   
Have you had any courses of antibiotics in the last 6 months?(Please specify - what for, 
which antibiotic(s), when taken and how long for) 
 
 
Smoking status  never  current, cigs =   ex, stop date = 
SCCAI / HBI 
Please describe the following for the day and night prior to taking bowel prep 
(or previous day if none taken). 
 
General well-being    Very well     Slightly below par     Poor     Very poor     
Terrible 
Bowel frequency during day            no of formed stools =                   no of liquid stools = 
Bowel frequency during night         no of formed stools =                   no of liquid stools = 
Description of bowel movements 
 
Urgency of defecation       None      Hurry      Immediate      Incontinence 
 
Blood in stool        None      Trace      Occasionally frank      Usually frank 
 
Abdominal pain           None      Mild       Moderate      Severe 
 
Abdominal mass            None      Possible   Definite       Tender 
 
EIMS         Arthralgia     Uveitis     Erythema Nodosum   Pyoderma Gangrenosum 
 
                  Anal fissure  New fistula    Abscess     Aphthous ulcers 
 










 Mixed meat/fish/veg    No red meat     Vegetarian  Vegan 
 
 Pescetarian  Gluten free  Dairy free  Lactose free 
 
 Diabetic  High fibre  Low residue  Low FODMAP 
  
 Polymeric diet  Elemental diet  Clear fluid diet 
 









Do you consume alcohol? 
 
 Yes   Never 
 
 Most days  At weekends  only     Once or twice a week 
 
 Once or twice a month      Once or twice a year 
    
How many drinks per day? 
 
 0-1  2-3  More than 3  If more than 3, how many? 
……………………… 
 
What do you usually drink? 
 






Clinician’s assessment of patient’s health status :  
0 is worst, 10 is best (perfect health) 
 
Please circle one number below 
 
0 1 2 3 4 5 6 7 8 9 10 
 
Each recruiting centre should specify the units used locally for each test below 
Blood test Date Result Stool test Date Result 
Haemoglobin   Calprotectin   
WCC   Stool culture   





Lymphocytes   
Platelets   
ESR   C.diff toxin   
Albumin   CMV(specify test 
below) 
  
CRP      
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Appendix D – Primer sequences used for quantification of mtDNA by qPCR 
 
Name Forward Reverse Ref 
Cytochrome C oxidase subunit III (COXIII) 5’-ATGACCCACCAATCACATGC-3’ 5’-ATCACATGGCTAGGCCGGAG-3’ (Zhang et al., 
2010) 
NADH-dehydrogenase 2 (ND2) 5’- CACAGAAGCTGCCATCAAGTA-3’ 5’- CCGGAGAGTATATTGTTGAAGAG-3’ (Lu et al., 2010) 
Table A4: Primer sequences used for quantification of mtDNA by qPCR 
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Appendix E – N-terminal hexapeptide sequences 
of mitochondrial formylated peptides* 
 
Formylated peptide N terminus Uniprot number  
NADH 1 Formyl-MPMANL P03886  
NADH 2 Formyl-MNPLAQ P03891  
NADH 3 Formyl-MNFALI P03897 
NADH 4L Formyl-MPLIYM P03901 
NADH 4 Formyl-MLKLIV P03905 
NADH 5 Formyl-MTMHTT P03915 
NADH 6 Formyl-MMYALF P03923 
COX I Formyl-MFADRW P00395 
COX II Formyl-MAHAAQ P00403 
COX III Formyl-MTHQSH P00414 
Cytochrome b Formyl-MTPMRK P00156 
ATP synthase subunit 6 Formyl-MNENLF P00846 
ATP synthase subunit 8 Formyl-MPQLNT P03928 
 
*As described in (Rabiet, Huet and Boulay, 2005) 
Table A5: N-terminal hexapeptide sequences of mitochondrial formylated 
peptides.  
  
Appendices  250 
 
Appendix F – Mayo endoscopic classification of 
UC severity 
 
Mayo Score Description Detailed description 
0 Normal No friability or granularity 
Intact vascular pattern 
1 Mildly active Erythema 
Decreased vascular pattern 
Mild friability 
2 Moderately active Marked erythema 
Absent vascular pattern 
Friability 
Erosions 
3 Severely active Marked erythema 





Table A6: Mayo endoscopic classification of UC severity (Schroeder, 
Tremaine and Ilstrup, 1987) 
 
 
